



US007033590B1

(12) **United States Patent**
Scheifflinger et al.(10) **Patent No.:** US 7,033,590 B1
(45) **Date of Patent:** Apr. 25, 2006(54) **FACTOR IX/FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES**(75) Inventors: **Friedrich Scheifflinger**, Vienna (AT); **Randolf Kerschbaumer**, Vienna (AT); **Falko-Guenter Falkner**, Orth/Donau (AT); **Friedrich Dorner**, Vienna (AT); **Hans-Peter Schwarz**, Vienna (AT)(73) Assignee: **Baxter Aktiengesellschaft**, Vienna (AT)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 462 days.

(21) Appl. No.: 09/661,992

(22) Filed: Sep. 14, 2000

(30) **Foreign Application Priority Data**

Sep. 14, 1999 (AT) 1576/99

(51) **Int. Cl.**

A61K 39/395	(2006.01)
A61K 38/04	(2006.01)
C12N 5/20	(2006.01)
C07K 16/00	(2006.01)
C07K 16/34	(2006.01)

(52) **U.S. Cl.** 424/145.1; 435/326; 530/388.25; 530/387.1; 530/327; 530/328; 530/389.3(58) **Field of Classification Search** 530/387.3, 530/388.25, 389.3, 327, 328; 424/133.1, 424/145.1; 435/326

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,395,396 A	7/1983	Eibl et al.
4,873,316 A	10/1989	Meade et al.
5,932,706 A	8/1999	Mertens et al.
6,391,299 B1 *	5/2002	Blackburn et al.
6,632,927 B1 *	10/2003	Adair et al.

FOREIGN PATENT DOCUMENTS

WO	WO95/13300	5/1995
WO	WO97/26010	7/1997
WO	WO99/01476	1/1999

OTHER PUBLICATIONS

Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. 85(9):3080–3084, 1988.*

Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. 79(6):1979–1983, 1982.*

Ames, R.S. et al., Conversion of Murine Fab Isolated From a Combinatorial Phage Display Library to Full Length Immunoglobulins, J. Immunol. Methods, pp. 177–186 (1995).

Bajaj, S.P. et al., A Monoclonal Antibody to Factor IX That Inhibits the Factor VIII:Ca Potentiation of Factor X Activation, The Journal of Biological Chemistry, 260(21), pp. 11574–11580 (1985).

Bessos, H., et al., The Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor IX, Thrombosis Research, 40, pp. 863–867 (1985).

Cao, Y. et al., Bispecific Antibodies as Novel Bioconjugates, Bioconjugate Chemistry, 9(6); pp. 635–644 (1998).

Cohen, F.E., et al., The Combinatorial Approach, Protein Structure Prediction—A Practical Approach (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 9, pp. 207–227 (1996).

Engelhardt, O., et al., Two Step Cloning of Antibody Variable Domains in a Phage Display Vector, Biotechniques, 17, p. 44–46 (1994).

Esser, C., et al., Immunoglobulin Class Switching: Molecular and Cellular Analysis, Annu. Rev. Immunol., 8, p. 717–735 (1990).

Evan, G.I., et al., Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product, Mol. Cell. Biol., 5(12), p. 3610–3616 (1985).

Fay, P.J., et al., Factor Villa A2 Subunit Residues 558–565 Represent a Factor IXa Interactive Site, Journal of Biological Chemistry, 269(32), p. 20522–20527 (1994).

Frazier, D., et al., Mapping of Monoclonal Antibodies to Human Factor IX, Blood, 74(3), p. 971–977 (1989).

Gao, C., et al., Making Artificial Antibodies: A Format for Phage Display of Combinatorial Heterodimeric Arrays, Proc. Natl. Acad. Sci., 96, p. 6025–6030 (1999).

Grassy, G., et al., Computer-Assisted Rational Design of Immunosuppressive Compounds, Nature Biotechnology, 16, p. 748–752 (1998).

Greer, J., et al., Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design, Journal of Medicinal Chemistry, 37(8), p. 1035–1054 (1994).

Harlow, E., et al., 2. Antibody Molecules, Antibodies—A Laboratory Manual; pp. 7–22 (1988).

Harlow, E., et al., 3. Antibody–Antigen Interactions, Antibodies—A Laboratory Manual; p. 23–35 (1988).

Harlow, E., et al., 6. Monoclonal Antibodies, Antibodies—A Laboratory Manual; p. 139–243 (1988).

Hochuli, E., et al., Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent, Biotechnology, 6, p. 1321–1325 (1988).

Huston, J.S., et al., Medical Applications of Single-Chain Antibodies, Intern. Rev. Immunol., 10, p. 195–217 (1993).

(Continued)

Primary Examiner—Christina Chan

Assistant Examiner—Maher Haddad

(74) Attorney, Agent, or Firm—Townsend and Townsend and Crew LLP

(57)


ABSTRACT


An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.


OTHER PUBLICATIONS


- Jones, D.T., et al., *Protein Folds and Their Recognition from Sequence, Protein Structure Prediction—A Practical Approach* (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 8, p. 174–206 (1996).
- Jones, P.T., et al., *Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse*, *Nature*, 321, p. 522–525 (1986).
- Jorquerá, J.I., et al., *Synthetic Peptides Derived from Residues 698 to 710 of Factor VIII Inhibit Factor IXa Activity*, *Circulation*, 86, Abstract No. 2725, p. I–685 (1992).
- Karpen, M.E., et al., *Modelling Protein Conformation by Molecular Mechanics and Dynamics, Protein Structure Prediction—A Practical Approach* (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 10, p. 229–261 (1996).
- Kemp, D.S., *Peptidomimetics and the Template Approach to Nucleation of B-sheets and a-helices in Peptides*, *TIBTECH*8, p. 249–255 (1990).
- Kerschbaumer, R.J., et al., *pDAP2: A Vector for Construction of Alkaline Phosphatase Fusion-Proteins*, *Immunotechnology*, 2, p. 145–150 (1996).
- Kerschbaumer, R.J. et al., *Single-Chain Fv Fusion Proteins Suitable as Coating and Detecting Reagents in a Double Antibody Sandwich Enzyme-Linked Immunosorbent Assay*, *Analytical Biochemistry*, 249, p. 219–227 (1997).
- Lane, R.D., *A Short-Duration Polyethylene Glycol Fusion Technique for Increasing Production of Monoclonal Antibody-Secreting Hybridomas*, *Journal of Immunological Methods*, 81, p. 223–227 (1985).
- Lenting, P.J., et al., *The Sequence Glu¹⁸¹¹–Lys¹⁸¹⁸ of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX*, *Journal of Biological Chemistry*, 271(4), p. 1935–1940 (1996).
- Liles, D.K., et al., *The Factor VIII Peptide Consisting of Amino Acids 698 to 712 Enhances Factor IXa Cleavage of Factor X*, *Blood*, 90(1), Abstract No. 2054, p. 463a (1997).
- Lin, H-F., et al., *A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B*, *Blood*, 90(10), p. 3962–3966 (1997).
- Malik, P., et al., *Multiple Display of Foreign Peptide Epitopes on Filamentous Bacteriophage Virions*, *Phage Display of Peptides and Proteins* (Ed. B. K. Kay et al.), Academic Press, p. 127–139 (1996).
- Mann, K.G., et al., *Surface-Dependent Reactions of the Vitamin K-Dependent Enzyme Complexes*, *Blood*, 76(1), p. 1–16 (1990).
- Mikaelsson, M., et al., *Standardization of VIII:C Assays: A Manufacturer's View*, *Scandinavian Journal of Haematology* (Ed. Nilsson et al.), 33, p. 79–86 (1984).
- Nilsson, I.M. et al., *Induction of Split Tolerance and Clinical Cure in High-Responding Hemophiliacs with Factor IX Antibodies*, *Proc. Natl. Acad. Sci. USA*, 83, p. 9169–9173 (1986).
- Persic, L., et al., *An Integrated Vector System For The Eukaryotic Expression of Antibodies of Their Fragments After Selection From Phase Display Libraries, Genes*, p. 9–18 (1997).
- Pluckthun, A., et al., *New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments*, *Immunotechnology*, 3, p. 83–105 (1997).
- Raag, R., et al., *Single-Chain Fvs*, *FASEB Journal*, 9(1), pp. 73–80 (1995).
- Rees, A.R., et al., *Antibody Combining Sites: Structure and Prediction*, *Protein Structure Prediction—A Practical Approach* (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 7, p. 141–172 (1996).
- Roitt, I.M., et al., *Molecules which Recognize Antigen*, *Immunology*, 2nd Edition, p. 5.1–5.11 (1989).
- Sadler, J.E., et al., *Hemophilia A, Hemophilia B, and von Willebrand's Disease, The Molecular Basis of Blood Diseases* (Ed. G. Stamatoyannopoulos et al.), p. 575–630 (1987).
- Vaughan, T.J., et al., *Human Antibodies By Design*, *Nature Biotechnology*, p. 535–539 (1998).
- Winter, G., et al., *Making Antibodies by Phage Display Technology*, *Annu. Rev. Immunol.*, 12, p. 433–455 (1994).
- Zhong, D., et al., *Some Human Inhibitor Antibodies Interface with Factor VIII Binding to Factor IX*, *Blood*, 92(1), p. 136–142 (1998).

* cited by examiner

**FIG. 1**

**FIG. 2**



**FIG. 4**





FIG. 5

**FIG. 6A**





FIG. 6B

**FIG. 7A**




FIG. 7B




FIG. 8A









FIG. 8B

**FIG. 8C**

**FIG. 9**

**FIG. 10A**

**FIG. 10B**

**FIG. 11**

Mouse V_H back primers (containing SfiI-site) :

VH1BACK-SfII	5' C ATG CCA TGA CTC GCG GCC CAG CCG GCC ATG GCC SAG GTS MAR CTG CAG SAG TCW GG 3' (SEQ.ID.NO. 50)
VH1BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTG CAG CTT CAG GAG TCA GG 3' (SEQ.ID.NO. 51)
VH2BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAT GTG CAG CTT CAG GAG TCR GG 3' (SEQ.ID.NO. 52)
VH3BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTG CAG CTG AAG SAG TCA GG 3' (SEQ.ID.NO. 53)
VH4/6BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTY CAG CTG CAR CAR TCT GG 3' (SEQ.ID.NO. 54)
VH5/9BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTY CAR CTG CAG CAG YCT GG 3' (SEQ.ID.NO. 55)
VH7BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAR GTG AAG CTG GTG GAR TCT GG 3' (SEQ.ID.NO. 56)
VH8BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTT CAG CTT CAG CAG TCT GG 3' (SEQ.ID.NO. 57)
VH10BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAA GTG CAG CTG KTG GAG WCT GG 3' (SEQ.ID.NO. 58)
VH11BACKSfI	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG ATC CAG TTG CTG CAG TCT GG 3' (SEQ.ID.NO. 59)

FIG. 12-1

Mouse J_H forward primers (containing 1/2 linker-sequence and Ascl-site) :

VH1FOR2LiAsc	5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CC 3' (SEQ.ID.NO. 60)
JH1FORLiAsc	5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC GGT GAC CGT GGT CCC 3' (SEQ.ID.NO. 61)
JH2FORLiAsc	5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC TGT GAG AGT GGT GCC 3' (SEQ.ID.NO. 62)
JH3FORLiAsc	5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGC AGA GAC AGT GAC CAG AGT CCC 3' (SEQ.ID.NO. 63)
JH4FORLiAsc	5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC GGT GAC TGA GGT TCC 3' (SEQ.ID.NO. 64)

IUPAC-Code: M=A/C, W=A/T, R=A/G, Y=C/T, S=C/G, K=G/T, H=A/C/T, D=A/G/T, V=A/C/G, B=T/C/G.

FIG. 12-2

**Primers for cloning mouse V_k genes
Mouse V_k back primers (containing AscI-site and 1/2 linker-sequence):**

VK2BACK-LiAscI	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GAG CTC ACC CAG TCT CCA 3' (SEQ.ID.NO. 65)
VK1BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GTG ATG WCA CAG TCT CC 3' (SEQ.ID.NO. 66)
VK2BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAT GTT KTG ATG ACC CAA ACT CC 3' (SEQ.ID.NO. 67)
VK3BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAT ATT GTG ATR ACB CAG GCW GC 3' (SEQ.ID.NO. 68)
VK4BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GTG CTG ACM CAR TCT GC 3' (SEQ.ID.NO. 69)
VK5BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG SAA AWT GTK CTC ACC CAG TCT CC 3' (SEQ.ID.NO. 70)
VK6BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAY ATY VNG ATG ACM CAG WCT CC 3' (SEQ.ID.NO. 71)
VK7BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG CAA ATT GTT CTC ACC CAG TCT CC 3' (SEQ.ID.NO. 72)
VK8BACKLi Asc	5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG TCA TTA TTG CAG GTG CTT GTG GG 3' (SEQ.ID.NO. 73)

FIG. 13-1

Mouse J_K forward primers (containing NotI-site):

JK1NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT GAT TTC CAG CTT GGT GCC 3'
(SEQ.ID.NO. 74)

JK2NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT TAT TTC CAG CTT GGT CCC 3'
(SEQ.ID.NO. 75)

JK3NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT TAT TTC CAG TCT GGT CCC 3'
(SEQ.ID.NO. 76)

JK4NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT TAT TTC CAA CTT TGT CCC 3'
(SEQ.ID.NO. 77)

JK5NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT CAG CTC CAG CTT GGT CCC 3'
(SEQ.ID.NO. 78)

IUPAC-Code : K=G/T, M=A/C, W=A/T, R=A/G, Y=C/T, S=C/G, H=A/C/T, D=A/G/T, V=A/C/G, B=T/C/G.

FIG. 13-2

VH

+1 E V K L V E S G P E L K K P G
 1 GAG GTG AAG CTG GTG GAG TCT GGA CCT GAG CTG AAG AAG CCT GGA
 +1 E T V K I S C K A S G . Y I F T
 46 GAG ACA GTC AAG ATC TCC TGC AAG GCT TCT GGG TAT ATC TTC ACA
 +1 N Y G M N W V K Q A P G K G L
 91 AAC TAT GGA ATG AAC TGG GTG AAG CAG GCT CCA CGA AAG GGT TTA
 +1 K W M G W I N T Y T G E P T Y
 136 AAG TGG ATG GCC TGG ATA AAC ACC TAC ACT GGA GAG CCA ACA TAT
 +1 A D D F K G R F A F S L E T S
 181 GCT GAT GAC TTC AAG GGA CGG TTT GCC TTC TCT TTG GAA ACC ACC TCT
 +1 A S T A Y L Q I N N L K N E D
 226 GCC AGC ACT GCC TAT TTG CAG ATC AAC AAC CTC AAA AAT GAG GAC
 +1 T A T Y F C A L Y G N S P K G
 271 ACG GCT ACA TAT TTC TGT GCA TTA TAT GGT AAC TCC CCT AAG GGG

linker

+1 F A Y W G Q G T L V T V S A G
 316 TTT GCT TAC TGG GGC CAA GGG ACT CTG GTC ACT GTC TCT GCA GGT

VL

+1 G G G S G G R A S G G G S D
 361 GGA GGC GGT TCA GGT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAT
 +1 I Q M T Q S P K F L L V S A G
 406 ATT CAG ATG ACA CAG TCT CCC AAA TTC CTG CTT GTA TCA GCA GGA

FIG. 14-1

+1 D R V T I T C K A S Q S V S N
451 GAC AGG GTT ACC ATA ACC TGC AAG GCC AGT CAG AGT GTG AGT AAT

+1 D V A W Y Q Q K P G Q S P K L
496 GAT GTA GCT TGG TAC CAA CAG AAG CCG GGG CAG TCT CCT AAA CTA

+1 L M Y Y A S N R Y T G V P D R
541 CTG ATG TAC TAT GCA TCC AAT CGC TAC ACT GGA GTC CCT GAT CGC

+1 F T G S G Y G T D F T F T I S
586 TTC ACT GGC AGT GGA TAT GGG ACG GAT TTC ACT TTC ACC ATC AGC

+1 T V Q A E D L A V Y F C Q Q D
631 ACT GTG CAG GCT GAA GAC CTG GCA GTT TAT TTC TGT CAG CAG GAT

+1 Y G S P P T F G G G T K L E I
676 TAT GGC TCT CCT CCC ACG TTC GGA GGG GGC ACC AAG CTG GAA ATT

+1 K R
721 AAA CGG

FIG. 14-2

VH

+1 E V Q L V E S G G G L V K P G
 1 GAA GTG CAG CTG GTG GAG TCT GGG GGA GGC CTA GTG AAG CCT GGA

+1 G S L K L S C A A S G F T F S
 46 GGG TCC CTG AAA CTC TCC TGT GCA GCC TCT GGA TTC ACT TTC AGT

+1 T Y T M S W V R Q T P E K R L
 91 ACC TAT ACC ATG TCT TGG GTT CGC CAG ACT CCG GAG AAG AGG CTG

+1 E W V A T I S S G G S Y T Y Y
 136 GAG TGG GTC GCA ACC ATT AGT AGT GGT GGT AGT TAC ACC TAC TAT

+1 P D S V R G R F T I S R D N A
 181 CCA GAC AGT GTG AGG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC

+1 K N T L Y L Q M S S L K S E D
 226 AAG AAC ACC CTG TAC CTG CAA ATG AGC AGT CTG AAG TCT GAG GAC

+1 T A M Y Y C T R D G G H G Y G
 271 ACA GCC ATG TAT TAC TGT ACA AGA GAT GGG GGA CAC GGG TAC GGT

+1 S S F D Y W G Q G T T L T V S
 316 AGT AGC TTT GAC TAC TGG GGC CAA GGC ACC ACT CTC ACA GTC TCC

linker

+1 S G G G G S G G R A S G G G
 361 TCA GGT GGA GGC GGT TCA GGT GGG CGC GCC TCT GGC GGT GGC GGA

VL

+1 S Q I V L T Q S P L S L P V S
 406 TCG CAA ATT GTG CTC ACC CAG TCT CCA CTC TCC CTG CCT GTC AGT

FIG. 15-1

+1 L G D Q A S I S C R S S Q S I
451 CTT GGA GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC ATT

+1 V H S N G N T Y L E W Y L Q K
496 GTA CAT AGT AAT GGA AAC ACC TAT TTA GAA TGG TAC CTG CAG AAA

+1 P G Q S P K L L I Y K V S N R
541 CCA GGC CAG TCT CCA AAG CTC CTG ATC TAC AAA GTT TCC AAC CGA

+1 F S G V P D K F S G S G S G T
586 TTT TCT GGG GTC CCA GAC AAA TTC AGT GGC AGT GGA TCA GGG ACA

+1 D F T L K I S R V E A E D L G
631 GAT TTC ACA CTC AAG ATC AGC AGA GTG GAG GCT GAG GAT CTG GGA

+1 V Y Y C F Q G S H V P W T F G
676 GTT TAT TAC TGC TTT CAA GGT TCA CAT GTT CCG TGG ACG TTC GGT

+1 G G T K L E I K R
721 GGA GGC ACC AAG CTG GAA ATC AAA CGG

FIG. 15-2

+1 E V Q L Q E S G G G L V K P G
 1 GAG GTG CAG CTT CAG GAG TCA GGG GGA GGC TTA GTG AAG CCT GGA

 +1 G S L K L S C A A S G F T F S
 46 GGG TCC CTG AAA CTC TCC TGT GCA GCC TCT GGA TTC ACT TTC AGT

 +1 S Y T M S W V R Q T P E K R L
 91 AGC TAT ACC ATG TCT TGG GTT CGC CAG ACT CCG GAG AAG AGG CTG

 +1 E W V A T I S S G G S S T Y Y
 136 GAG TGG GTC GCA ACC ATT AGT AGT GGT GGT AGT TCC ACC TAC TAT

 +1 P D S V K G R F T I S R D N A
 181 CCA GAC AGT GTG AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC

 +1 K N T L Y L Q M S S L R S E D
 226 AAG AAC ACC CTG TAC CTG CAA ATG AGC AGT CTG AGG TCT GAG GAC

 +1 T A M Y Y C T R E G G G F T V
 271 ACA GCC ATG TAT TAC TGT ACA AGA GAG GGG GGT GGT TTC ACC GTC

 +1 N W Y F D V W G A G T L V T V
 316 AAC TGG TAC TTC GAT GTC TGG GGC GCA GGG ACT CTG GTC ACT GTC

linker
 +1 S A G G G G G S G G R A S G G G
 361 TCT GCA GGT GGA GGC GGT TCA GGT GGG CGC GCC TCT GGC GGT GGC

 VL
 +1 G S E N V L T Q S P A S L A V
 406 GGA TCG GAA AAT GTG CTC ACC CAG TCT CCA GCT TCT TTG GCT GTG

FIG. 16-1

+1 S L G Q R A T I S C R A S E S
451 TCT CTA GGG CAG AGG GCC ACC ATA TCC TGC AGA GCC AGT GAA AGT

+1 V D S Y G Y N F M H W Y Q Q I
496 GTT GAT AGT TAT GGC TAT AAT TTT ATG CAC TGG TAT CAG CAG ATA

+1 P G Q P P K L L I Y R A S N L
541 CCA GGA CAG CCA CCC AAA CTC CTC ATC TAT CGT GCA TCC AAC CTA

+1 E S G I P A R F S G S G S R T
586 GAG TCT GGG ATC CCT GCC AGG TTC AGT GGC AGT GGG TCT AGG ACA

+1 D F T L T I N P V E A D D V A
631 GAC TTC ACC CTC ACC ATT AAT CCT GTG GAG GCT GAT GAT GTT GCA

+1 T Y Y C Q Q S N E D P L T F G
676 ACC TAT TAC TGT CAG CAA AGT AAT GAG GAT CCG CTC ACG TTC GGT

+1 T G T R L E I K R
721 ACT GGG ACC AGA CTG GAA ATA AAA CGG

FIG. 16-2

VH

+1 E V Q L Q E S G G L V K P G G S L K L
 1 GAG GTG CAG CCT CAG GAG TCA GGG GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC
 CTC CAC GTC GAA GTC CTC AGT CCC CCT CCG AAT CAC TTC GGA CCT CCC AGG GAC TTT GAG

+1 S C A A S G F I F S S Y T M S W V R Q T
 61 TCC TGT GCA GCC TCT GGA TTC ATT TTT AGT AGT TAT ACC ATG TCT TGG GTT CGC CAG ACT
 AGG ACA CGT CGG AGA CCT AAG TAA AAA TCA TCA ATA TGG TAC AGA ACC CAA GCG GTC TGA

+1 P E K R L E W V A T I S S G G S S T Y Y
 121 CCG GAG AAG AGG CTG GAG TGG GTC GCA ACC ATT AGT AGT GGT AGT TCC ACC TAC TAT
 GGC CTC TTC TCC GAC CTC ACC CAG CGT TGG TAA TCA TCA CCA TCA AGG TGG ATG ATA

+1 P D S V K G R F T I S R D N A K N T L Y
 181 CCA GAC AGT GTG AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC
 GGT CTG TCA CAC TTC CCG GCT AAG TGG TAG AGG TCT CTG TTA CGG TTC TTG TGG GAC ATG

+1 L Q M S S L K S E D T A M Y H C T R E G
 241 CTG CAA ATG AGC AGT CTG AAG TCC GAG GAC ACA GCC ATG TAT CAC TGT ACA AGA GAG GGG
 GAC GTT TAC TCG TCA GAC TTC AGA CTC CTG TGT CGG TAC ATA GTG ACA TGT TCT CTC CCC

+1 G G Y Y V N W Y F D V W G A G T T L T V
 301 GGT GGT TAT TAC GTC AAC TGG TAC TTC GAT GTC TGG GCA GGC ACC ACT CTC ACA GTC
 CCA CCA ATA ATG CAG TTG ACC ATG AAG CTA CAG ACC CCG CGT CCG TGG TGA GAG TGT CAG

linker


+1 S S G G G S G R A S G G G S D I E
 361 TCC TCA GGT GGA GGC GGT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GAG
 AGG AGT CCA CCT CCG CCA AGT CCA CCC GCG CGG AGA CCG CCA CCG CCT AGC CTG TAA CTC

+1 L T Q S P A S L A V S L G Q R A T I S C
 421 CTC ACN CAG TCT CCA GCT TCT TTG GCT GTG TCT CTA GGG CAG AGG GCC ACC ATA TCC TGC
 GAG TGN GTC AGA GGT CGA AGA AAC CGA CAC AGA GAT CCC GTC TCC CGG TGG TAT AGG ACG

FIG. 17-1

	R	A	S	E	S	V	D	S	Y	G	K	S	F	M	H	W	Y	Q	Q	K
481	AGA	GCC	AGT	GAA	AGT	GAT	AGT	TAT	GGC	AAG	AGT	TTT	ATG	CAC	TGG	TAC	CAG	CAG	AAA	
	TCT	CGG	TCA	CTT	TCA	CAA	CTA	TCA	ATA	CCG	TTC	TCA	AAA	TAC	GTG	ACC	ATG	GTC	GTC	TTT
	P	G	Q	P	P	K	L	I	Y	R	A	S	N	L	E	S	G	I	P	
+1	CCA	GGG	CAG	CCA	CCC	AAA	CTC	CTC	ATC	TAT	CGT	GCA	TCC	AAC	CTA	GAA	TCT	GGG	ATC	CCT
541	GGT	CCC	GTC	GGT	GGG	TTT	GAG	GAG	TAG	ATA	GCA	CGT	AGG	TTG	GAT	CTT	AGA	CCC	TAG	GGG
	A	R	F	S	G	S	G	S	R	T	D	F	T	L	T	I	N	P	V	
+1	GCC	AGG	TTC	AGT	GGC	AGT	GGG	TCT	AGG	ACA	GAC	TTC	ACC	CTC	ACC	ATT	AAT	CCT	GTG	GAG
601	CGG	TCC	AAG	TCA	CCG	TCA	CCC	AGA	TCC	TGT	CTG	AAG	TGG	GAG	TGG	TAA	TTA	GGA	CAC	CTC
	A	D	D	V	A	T	Y	Y	C	Q	Q	S	N	E	D	P	L	T	F	G
+1	GCT	GAT	GAT	GTT	GCN	ACC	TAT	TAC	TGT	CAG	CAA	AGT	AAT	GAG	GAT	CCC	CTC	ACG	TTC	GGT
661	CGA	CTA	CTA	CAA	CGN	TGG	ATA	ATG	ACA	GTC	GTT	TCA	TTA	CTC	CTA	GGG	GAG	TGC	AAG	CCA
	A	G	T	R	L	E	I	K	R											
+1	GCT	GGG	ACC	AGA	CTG	GAA	ATA	AAA	CGG											
721	CGA	CCC	TGG	TCT	GAC	CTT	TAT	TTT	GCC											

FIG. 17-2

**FIG. 18**









FIG. 19


**FIG. 20**

**FIG. 21**

**FIG. 22**

**FIG. 23**

**FIG. 24A**

**FIG. 24B**




FIG. 25

PelB-Leader

+1 M K Y L L P T A A A G L L L
 1 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA
 TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT

VH

+1 L A A Q P A M A E V K L V E
 43 CTC GCG GCC CAG CCG GCC ATG GCG GAG GTG AAG CTG GTG GAG
 GAG CGC CGG GTC GGC CGG TAC CGC CTC CAC TTC GAC CAC CTC

+1 S G G G L V K P G G S L K L
 85 TCT GGG GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC
 AGA CCC CCT CCG AAT CAC TTC GGA CCT CCC AGG GAC TTT GAG

+1 S C A A S G F T F S S Y T M
 127 TCC TGT GCA GCC TCT GGA TTC ACT TTC AGT AGC TAT ACC ATG
 AGG ACA CGT CGG AGA CCT AAG TGA AAG TCA TCG ATA TGG TAC

+1 S W V R Q T P E K R L E W V
 169 TCT TGG GTT CGC CAG ACT CCG GAG AAG AGG CTG GAG TGG GTC
 AGA ACC CAA GCG GTC TGA GGC CTC TTC TCC GAC CTC ACC CAG

+1 A T I S S G G S S T Y Y P D
 211 GCA ACC ATT AGT AGT GGN GGT AGT TCC ACC TAC TAT CCA GAC
 CGT TGG TAA TCA TCA CCN CCA TCA AGG TGG ATG ATA GGT CTG

+1 S V K G R F T I S R D N A K
 253 AGT GTG AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC AAG
 TCA CAC TTC CCG GCT AAG TGG TAG AGG TCT CTG TTA CGG TTC

+1 N T L Y L Q M S S L R S E D
 295 AAC ACC CTG TAC CTG CAA ATG AGC AGT CTG AGG TCT GAG GAC
 TTG TGG GAC ATG GAC GTT TAC TCG TCA GAC TCC AGA CTC CTG

+1 T A M Y Y C T R E G G G F T
 337 ACA GCC ATG TAT TAC TGT ACA AGA GAG GGG GGT GGT TTC ACC
 TGT CGG TAC ATA ATG ACA TGT TCT CTC CCC CCA CCA AAG TGG

+1 V N W Y F D V W G A G T S V
 379 GTC AAC TGG TAC TTC GAT GTC TGG GGC GCA GGA ACC TCA GTC
 CAG TTG ACC ATG AAG CTA CAG ACC CCG CGT CCT TGG AGT CAG

linker

+1 T V S S G G G G S G G R A S
 421 ACC GTC TCC TCA GGT GGA GGC GGT TCA GGT GGG CGC GCC TCT
 TGG CAG AGG AGT CCA CCT CCG CCA AGT CCA CCC GCG CGG AGA

FIG. 26-1

	VL +1 G G G G S D I V L T Q S P A 463 GGC GGT GGC GGA TCG GAC ATT GTG CTG ACA CAG TCT CCA GCT CCG CCA CCG CCT AGC CTG TAA CAC GAC TGT GTC AGA GGT CGA		
	+1 S L A V S L G Q R A T I S C 505 TCT TTG GCT GTG TCT CTA GGG CAG AGG GCC ACC ATA TCC TGC AGA AAC CGA CAC AGA GAT CCC GTC TCC CGG TGG TAT AGG ACG		
	+1 R A S E S V D S Y G Y N F M 547 AGA GCC AGT GAA AGT GTT GAT AGT TAT GGC TAT AAT TTT ATG TCT CGG TCA CTT TCA CAA CTA TCA ATA CCG ATA TTA AAA TAC		
	+1 H W Y Q Q I P G Q P P K L L 589 CAC TGG TAT CAG CAG ATA CCA GGA CAG CCA CCC AAA CTC CTC GTG ACC ATA GTC GTC TAT GGT CCT GTC GGT GGG TTT GAG GAG		
	+1 I Y R A S N L E S G I P A R 631 ATC TAT CGT GCA TCC AAC CTA GAG TCT GGG ATC CCT GCC AGG TAG ATA GCA CGT AGG TTG GAT CTC AGA CCC TAG GGA CGG TCC		
	+1 F S G S G S R T D F T L T I 673 TTC AGT GGC AGT GGG TCT AGG ACA GAC TTC ACC CTC ACC ATT AAG TCA CCG TCA CCC AGA TCC TGT CTG AAG TGG GAG TGG TAA		
	+1 N P V E A D D V A T Y Y C Q 715 AAT CCT GTG GAG GCT GAT GAT GTT GCA ACC TAT TAC TGT CAG TTA GGA CAC CTC CGA CTA CAA CGT TGG ATA ATG ACA GTC		
	+1 Q S N E D P L T F G T G T R 757 CAA AGT AAT GAG GAT CCG CTC ACG TTC GGT ACT GGG ACC AGA GTT TCA TTA CTC CTA GGC GAG TGC AAG CCA TGA CCC TGG TCT		
	Spacer Alkaline phosphatase +1 L E I K R A A A A R A P E M 799 CTG GAA ATA AAA CGG GCG GCC GCA GCC CGG GCA CCA GAA ATG GAC CTT TAT TTT GCC CGC CGG CGT CGG GCC CGT GGT CTT TAC		
	+1 P V L E N R A A Q G D I T A 841 CCT GTT CTG GAA AAC CGG GCT GCT CAG GGC GAT ATT ACT GCA GGA CAA GAC CTT TTG GCC CGA CGA GTC CCG CTA TAA TGA CGT		
	+1 P G G A R R L T G D Q T A A 883 CCC GGC GGT GCT CGC CGT TTA ACG GGT GAT CAG ACT GCC GCT GGG CCG CCA CGA GCG GCA AAT TGC CCA CTA GTC TGA CGG CGA		
	+1 L R D S L S D K P A K N I I 925 CTG CGT GAT TCT CTT AGC GAT AAA CCT GCA AAA AAT ATT ATT GAC GCA CTA AGA GAA TCG CTA TTT GGA CGT TTT TTA TAA TAA		

FIG. 26-2

+1 L L I G D G M G D S E I T A
 463 TTG CTG ATT GGC GAT GGG ATG GGG GAC TCG GAA ATT ACT GCC
 AAC GAC TAA CCG CTA CCC TAC CCC CTG AGC CTT TAA TGA CGG

+1 A R N Y A E G A G G F F K G
 505 GCA CGT AAT TAT GCC GAA GGT GCG GGC GGC TTT TTT AAA GGT
 CGT GCA TTA ATA CGG CTT CCA CGC CCG CCG AAA AAA TTT CCA

+1 I D A L P L T G Q Y T H Y A
 1051 ATA GAT GCC TTA CCG CTT ACC GGG CAA TAC ACT CAC TAT GCG
 TAT CTA CGG AAT GGC GAA TGG CCC GTT ATG TGA GTG ATA CGC

+1 L N K K T G K P D Y V T D S
 1093 CTG AAT AAA AAA ACC GGC AAA CCG GAC TAC GTC ACC GAC TCG
 GAC TTA TTT TGG CCG TTT GGC CTG ATG CAG TGG CTG AGC

+1 A A S A T A W S T G V K T Y
 1135 GCT GCA TCA GCA ACC GCC TGG TCA ACC GGT GTC AAA ACC TAT
 CGA CGT AGT CGT TGG CGG ACC AGT TGG CCA CAG TTT TGG ATA

+1 N G A L G V D I H E K D H P
 1177 AAC GGC GCG CTG GGC GTC GAT ATT CAC GAA AAA GAT CAC CCA
 TTG CCG CGC GAC CCG CAG CTA TAA GTG CTT TTT CTA GTG GGT

+1 T I L E M A K A A G L A T G
 1219 ACG ATT CTG GAA ATG GCA AAA GCC GCA GGT CTG GCG ACC GGT
 TGC TAA GAC CTT TAC CGT TTT CGG CGT CCA GAC CGC TGG CCA

+1 N V S T A E L Q D A T P A A
 1261 AAC GTT TCT ACC GCA GAG TTG CAG GAT GCC ACG CCC GCT GCG
 TTG CAA AGA TGG CGT CTC AAC GTC CTA CGG TGC GGG CGA CGC

+1 L V A H V T S R K C Y G P S
 1303 CTG GTG GCA CAT GTG ACC TCG CGC AAA TGC TAC GGT CCG AGC
 GAC CAC CGT GTA CAC TGG AGC GCG TTT ACG ATG CCA GGC TCG

+1 A T S E K C P G N A L E K G
 1345 GCG ACC AGT GAA AAA TGT CCG GGT AAC GCT CTG GAA AAA GGC
 CGC TGG TCA CTT TTT ACA GGC CCA TTG CGA GAC CTT TTT CCG

+1 G K G S I T E Q L L N A R A
 1387 GGA AAA GGA TCG ATT ACC GAA CAG CTG CTT AAC GCT CGT GCC
 CCT TTT CCT AGC TAA TGG CTT GTC GAC GAA TTG CGA GCA CGG

+1 D V T L G G G A K T F A E T
 1429 GAC GTT ACG CTT GGC GGC GGC GCA AAA ACC TTT GCT GAA ACG
 CTG CAA TGC GAA CCG CCG CGT TTT TGG AAA CGA CTT TGC

FIG. 26-3

+1 A T A G E W Q G K T L R E Q
 1471 GCA ACC GCT GGT GAA TGG CAG GGA AAA ACG CTG CGT GAA CAG
 CGT TGG CGA CCA CTT ACC GTC CCT TTT TGC GAC GCA CTT GTC

+1 A Q A R G Y Q L V S D A A S
 1513 GCA CAG GCG CGT GGT TAT CAG TTG GTG AGC GAT GCT GCC TCA
 CGT GTC CGC GCA CCA ATA GTC AAC CAC TCG CTA CGA CGG AGT

+1 L N S V T E A N Q Q K P L L
 1555 CTG AAT TCG GTG ACG GAA GCG AAT CAG CAA AAA CCC CTG CTT
 GAC TTA AGC CAC TGC CTT CGC TTA GTC GTT TTT GGG GAC GAA

+1 G L F A D G N M P V R W L G
 1577 GGC CTG TTT GCT GAC GGC AAT ATG CCA GTG CGC TGG CTA GGA
 CCG GAC AAA CGA CTG CCG TTA TAC GGT CAC GCG ACC GAT CCT

+1 P K A T Y H G N I D K P A V
 1639 CCG AAA GCA ACG TAC CAT GGC AAT ATC GAT AAG CCC GCA GTC
 GGC TTT CGT TGC ATG GTA CCG TTA TAG CTA TTC GGG CGT CAG

+1 T C T P N P Q R N D S V P T
 1681 ACC TGT ACG CCA AAT CCG CAA CGT AAT GAC AGT GTA CCA ACC
 TGG ACA TGC GGT TTA GGC GTT GCA TTA CTG TCA CAT GGT TGG

+1 L A Q M T D K A I E L L S K
 1723 CTG GCG CAG ATG ACC GAC AAA GCC ATT GAA TTG TTG AGT AAA
 GAC CGC GTC TAC TGG CTG TTT CGG TAA CTT AAC AAC TCA TTT

+1 N E K G F F L Q V E G A S I
 1765 AAT GAG AAA GGC TTT TTC CTG CAA GTT GAA GGT GCG TCA ATC
 TTA CTC TTT CCG AAA AAG GAC GTT CAA CTT CCA CGC AGT TAG

+1 D K Q D H A A N P C G Q I G
 1807 GAT AAA CAG GAT CAT GCT GCG AAT CCT TGT GGG CAA ATT GGC
 CTA TTT GTC CTA GTA CGA CGC TTA GGA ACA CCC GTT TAA CCG

+1 E T V D L D E A V Q R A L E
 1849 GAG ACG GTC GAT CTC GAT GAA GCC GTA CAA CGG GCG CTG GAA
 CTC TGC CAG CTA GAG CTA CTT CGG CAT GTT GCC CGC GAC CTT

+1 F A K K E G N T L V I V T A
 1891 TTC GCT AAA AAG GAG GGT AAC ACG CTG GTC ATA GTC ACC GCT
 AAG CGA TTT TTC CTC CCA TTG TGC GAC CAG TAT CAG TGG CGA

+1 D H A H A S Q I V A P D T K
 1933 GAT CAC GCC CAC GCC AGC CAG ATT GTT GCG CCG GAT ACC AAA
 CTA GTG CGG GTG CGG TCG GTC TAA CAA CGC GGC CTA TGG TTT

+1 A P G L T Q A L N T K D G A
 1975 GCT CCG GGC CTC ACC CAG GCG CTA AAT ACC AAA GAT GGC GCA
 CGA GGC CCG GAG TGG GTC CGC GAT TTA TGG TTT CTA CCG CGT

+1 V M V M S Y G N S E E D S Q
2017 GTG ATG GTG ATG AGT TAC GGG AAC TCC GAA GAG GAT TCA CAA
CAC TAC CAC TAC TCA ATG CCC TTG AGG CTT CTC CTA AGT GTT

+1 E H T G S Q L R I A A Y G P
2059 GAA CAT ACC GGC AGT CAG TTG CGT ATT GCG GCG TAT GGC CCG
CTT GTA TGG CCG TCA GTC AAC GCA TAA CGC CGC ATA CCG GGC

+1 H A A N V V G L T D Q T D L
2101 CAT GCC GCC AAT GTT GTT GGA CTG ACC GAC CAG ACC GAT CTC
GTA CGG CGG TTA CAA CAA CCT GAC TGG CTG GTC TGG CTA GAG

+1 F Y T M K A A L G D I | A H H
2143 TTC TAC ACC ATG AAA GCC GCT CTG GGG GAT ATC | GCA CAC CAT
AAG ATG TGG TAC TTT CGG CGA GAC CCC CTA TAG | CGT GTG GTA

+1 H H H H *
2185 CAC CAT CAC CAT TAA
GTG GTA GTG GTA ATT

FIG. 26-5




FIG. 27

PelB-Leader

+1 M K Y L L P T A A A G L L L L
 1 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
 TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT GAG

+1 A A Q P A M A E V K L V E S G
 46 GCG GCC CAG CCG GCC ATG GCG GAG GTG AAG CTG GTG GAG TCT GGG
 CGC CGG GTC GGC CGG TAC CGC CTC CAC TTC GAC CAC CTC AGA CCC

+1 G G L V K P G G S L K L S C A
 91 GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC TCC TGT GCA
 CCT CCG AAT CAC TTC GGA CCT CCC AGG GAC TTT GAG AGG ACA CGT

+1 A S G F T F S S Y T M S W V R
 136 GCC TCT GGA TTC ACT TTC AGT AGC TAT ACC ATG TCT TGG GTT CGC
 CGG AGA CCT AAG TGA AAG TCA TCG ATA TGG TAC AGA ACC CAA GCG

+1 Q T P E K R L E W V A T I S S
 181 CAG ACT CCG GAG AAG AGG CTG GAG TGG GTC GCA ACC ATT AGT AGT
 GTC TGA GGC CTC TTC TCC GAC CTC ACC CAG CGT TGG TAA TCA TCA

+1 G G S S T Y Y P D S V K G R F
 226 GGN GGT AGT TCC ACC TAC TAT CCA GAC AGT GTG AAG GGC CGA TTC
 CCN CCA TCA AGG TGG ATG ATA GGT CTG TCA CAC TTC CCG GCT AAG

+1 T I S R D N A K N T L Y L Q M
 271 ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC CTG CAA ATG
 TGG TAG AGG TCT CTG TTA CGG TTC TTG TGG GAC ATG GAC GTT TAC

+1 S S L R S E D T A M Y Y C T R
 316 AGC AGT CTG AGG TCT GAG GAC ACA GCC ATG TAT TAC TGT ACA AGA
 TCG TCA GAC TCC AGA CTC CTG TGT CGG TAC ATA ATG ACA TGT TCT

+1 E G G F T V N W Y F D V W G
 361 GAG GGG GGT GGT TTC ACC GTC AAC TGG TAC TTC GAT GTC TGG GGC
 CTC CCC CCA CCA AAG TGG CAG TTG ACC ATG AAG CTA CAG ACC CCG

Linker

+1 A G T S V T V S S G G G G S G
 406 GCA GGA ACC TCA GTC ACC GTC TCC TCA GGT GGA GGC GGT TCA GGT
 CGT CCT TGG AGT CAG TGG CAG AGG AGT CCA CCT CCG CCA AGT CCA

VL

+1 G R A S G G G G S D I V L T Q
 451 GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GTG CTG ACA CAG
 CCC GCG CGG AGA CCG CCA CGG CCT AGC CTG TAA CAC GAC TGT GTC

+1	X	P	A	S	L	A	V	S	L	G	Q	R	A	T	I
496	TNT	CCA	GCT	TCT	TTG	GCT	GTG	TCT	CTA	GGG	CAG	AGG	GCC	ACC	ATA
	ANA	GGT	CGA	AGA	AAC	CGA	CAC	AGA	GAT	CCC	GTC	TCC	CGG	TGG	TAT

+1	S	C	R	A	S	E	S	V	D	S	Y	G	Y	N	F
541	TCN	TGC	AGA	GCC	AGT	GAA	AGT	GTT	GAT	AGT	TAT	GGC	TAT	AAT	TTT
	AGN	ACG	TCT	CGG	TCA	CTT	TCA	CAA	CTA	TCA	ATA	CCG	ATA	TTA	AAA

+1	M	H	W	Y	Q	Q	I	P	G	Q	P	P	K	L	L
586	ATG	CAC	TGG	TAT	CAG	CAG	ATA	CCA	GGA	CAG	CCA	CCC	AAA	CTC	CTC
	TAC	GTG	ACC	ATA	GTC	GTC	TAT	GGT	CCT	GTC	GGT	GGG	TTT	GAG	GAG

+1	I	Y	R	A	S	N	L	E	S	G	I	P	A	R	F
631	ATC	TAT	CGT	GCA	TCC	AAC	CTA	GAG	TCT	GGG	ATC	CCT	GCC	AGG	TTC
	TAG	ATA	GCA	CGT	AGG	TTG	GAT	CTC	AGA	CCC	TAG	GGA	CGG	TCC	AAG

+1	S	G	S	G	S	R	T	D	F	T	L	T	I	N	P
676	AGT	GGC	AGT	GGG	TCT	AGG	ACA	GAC	TTC	ACC	CTC	ACC	ATT	AAT	CCT
	TCA	CCG	TCA	CCC	AGA	TCC	TGT	CTG	AAG	TGG	GAG	TGG	TAA	TTA	GGA

+1	V	E	A	D	D	V	A	T	Y	Y	C	Q	Q	S	N
721	GTG	GAG	GCT	GAT	GAT	GTT	GCA	ACC	TAT	TAC	TGT	CAG	CAA	AGT	AAT
	CAC	CTC	CGA	CTA	CTA	CAA	CGT	TGG	ATA	ATG	ACA	GTC	GTT	TCA	TTA

+1	E	D	P	L	T	F	G	T	G	T	R	L	E	I	K
766	GAG	GAT	CCG	CTC	ACG	TTC	GGT	ACT	GGG	ACC	AGA	CTG	GAA	ATA	AAA
	CTC	CTA	GGC	GAG	TGC	AAG	CCA	TGA	CCC	TGG	TCT	GAC	CTT	TAT	TTT

Spacer Hinge

Helix

+1	R	A	A	A	P	K	P	S	T	P	P	G	S	S	R
811	CGG	GCG	GCC	GCA	CCG	AAG	CCT	TCC	ACT	CCG	CCC	GGG	TCT	TCC	CGT
	GCC	CGC	CGG	CGT	GGC	TTC	GGA	AGG	TGA	GGC	GGG	CCC	AGA	AGG	GCA

+1	M	K	Q	L	E	D	K	V	E	E	L	L	S	K	N
856	ATG	AAA	CAG	CTG	GAA	GAC	AAA	GTA	GAG	GAG	CTC	CTT	AGC	AAG	AAC
	TAC	TTT	GTC	GAC	CTT	CTG	TTT	CAT	CTC	CTC	GAG	GAA	TCG	TTC	TTG

+1	Y	H	L	E	N	E	V	A	R	L	K	K	L	V	G
901	TAC	CAT	CTA	GAA	AAC	GAG	GTA	GCT	CGT	CTG	AAA	AAG	CTT	GTT	GGT
	ATG	GTA	GAT	CTT	TTG	CTC	CAT	CGA	GCA	GAC	TTT	TTC	GAA	CAA	CCA

Spacer His-tag

R G G H H H

946 GAA CGT GGT GGT CAC CAT CAC CAT CAC CAT TAA
CTT GCA CCA CCA GTG GTA GTG GTA GTG GTA ATT

FIG. 28-2

PelB-Leader

+1 M K Y L L P T A A A G L L L
 1 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA
 TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT

+1 L A A Q P A M A | VH E V Q L Q Q
 43 CTC GCG GCC CAG CCG GCC ATG GCC | GAG GTT CAG CTT CAG CAG
 GAG CGC CGG GTC GGC CGG TAC CGG | CTC CAA GTC GAA GTC GTC

+1 S G P E L V K P G A S V K I
 85 TCT GGA CCT GAG CTG GTG AAG CCC GGG GCC TCA GTG AAG ATT
 AGA CCT GGA CTC GAC CAC TTC GGG CCC CGG AGT CAC TTC TAA

+1 S C K A S G Y A F S S S W M
 127 TCC TGC AAA GCT TCT GGC TAC GCA TTC AGT AGC TCT TGG ATG
 AGG ACG TTT CGA AGA CCG ATG CGT AAG TCA TCG AGA ACC TAC

+1 N W V K Q R P G Q G L E W I
 169 AAC TGG GTG AAG CAG AGG CCT GGA CAG GGT CTT GAG TGG ATT
 TTG ACC CAC TTC GTC TCC GGA CCT GTC CCA GAA CTC ACC TAA

+1 G R I Y P G N G D T N Y N G
 211 GGA CGG ATT TAT CCT GGA AAT GGA GAT ACT AAC TAC AAT GGG
 CCT GCC TAA ATA GGA CCT TTA CCT CTA TGA TTG ATG TTA CCC

+1 K F K G K A T L T A D K S S
 253 AAG TTC AAG GGC AAG GCC ACA CTG ACT GCA GAC AAA TCC TCC
 TTC AAG TTC CCG TTC CGG TGT GAC TGA CGT CTG TTT AGG AGG

+1 S T A Y M Q L S S L T S V D
 295 AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACC TCT GTG GAC
 TCG TGT CGG ATG TAC GTC GAG TCG TCG GAC TGG AGA CAC CTG

+1 S A V Y F C A D G N V Y Y Y
 337 TCT GCG GTC TAT TTC TGT GCA GAT GGT AAC GTA TAT TAC TAT
 AGA CGC CAG ATA AAG ACA CGT CTA CCA TTG CAT ATA ATG ATA

+1 A M D Y W G Q G T S V T V S
 379 GCT ATG GAC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC
 CGA TAC CTG ATG ACC CCA GTT CCT TGG AGT CAG TGG CAG AGG

Linker

+1 S | G G G G S G G R A S G G G
 421 TCA | GGT GGA GGC GGT TCA GGT GGG CGC GCC TCT GGC GGT GGC
 AGT CCA CCT CCG CCA AGT CCA CCC GCG CGG AGA CCG CCA CCG

+1 G S | VL
 463 GGA TCG | CAA ATT GTT CTC ACC CAG TCT CCT GCT TCC TTA GCT
 CCT AGC | GTT TAA CAA GAG TGG GTC AGA GGA CGA AGG AAT CGA

+1 V S L G Q R A T I S C R A S
 505 GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA TGC AGG GCC AGC
 CAT AGA GAC CCC GTC TCC CGG TGG TAG AGT ACG TCC CGG TCG

+1 K S V S T S G Y S Y M H W Y
 547 AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG TAC
 TTT TCA CAG TCA TGT AGA CCG ATA TCA ATA TAC GTG ACC ATG

+1 Q Q K P G Q P P K L L I Y L
 589 CAA CAG AAA CCA GGA CAG CCA CCC AAA CTC CTC ATC TAT CTT
 GTT GTC TTT GGT CCT GTC GGT GGG TTT GAG GAG TAG ATA GAA

+1 A S N L E S G V P A R F S G
 631 GCA TCC AAC CTA GAA TCT GGG GTC CCT GCC AGG TTC AGT GGC
 CGT AGG TTG GAT CTT AGA CCC CAG GGA CGG TCC AAG TCA CCG

+1 S G S G T D F T L N I H P V
 679 AGT GGG TCT GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG
 TCA CCC AGA CCC TGT CTG AAG TGG GAG TTG TAG GTA GGA CAC

+1 E E E D A A T Y Y C Q H S R
 715 GAG GAG GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC AGT AGG
 CTC CTC CTC CTA CGA CGT TGG ATA ATG ACA GTC GTG TCA TCC

+1 E L P R T F G G G T K L E I
 757 GAG CTT CCT CGG ACG TTC GGT GGA GGC ACC AAG CTG GAA ATC
 CTC GAA GGA GCC TGC AAG CCA CCT CCG TGG TTC GAC CTT TAG

	Spacer				Alkaline phosphatase									
+1	K	R	A	A	A	A	R	A	P	E	M	P	V	L
799	AAA	CGG	GCG	GCC	GCA	GCC	CGG	GCA	CCA	GAA	ATG	CCT	GTT	CTG
	TTC	CGC	CGG	CGT	CGG	CGG	GCC	CGT	GGT	CTT	TAC	GGG	CAC	GAC

+1 E N R A A Q G D I T A P G G
 841 GAA AAC CGG GCT GCT CAG GGC GAT ATT ACT GCA CCC GGC GGT
 CTT TTG GCC CGA CGA GTC CCG CTA TAA TGA CGT GGG CCG CCA

+1 A R R L T G D Q T A A L R D
 883 GCT CGC CGT TTA ACG GGT GAT CAG ACT GCC GCT CTG CGT GAT
 CGA GCG GCA AAT TGC CCA CTA GTC TGA CGG CGA GAC GCA CTA

+1 S L S D K P A K N I I L L I
 925 TCT CTT AGC GAT AAA CCT GCA AAA AAT ATT ATT TTG CTG ATT
 AGA GAA TCG CTA TTT GGA CGT TTT TTA TAA TAA AAC GAC TAA

+1 G D G M G D S E I T A A R N
 967 GGC GAT GGG ATG GGG GAC TCG GAA ATT ACT GCC GCA CGT AAT
 CCG CTA CCC TAC CCC CTG AGC CTT TAA TGA CGG CGT GCA TTA

+1 Y A E G A G G F F K G I D A
 1009 TAT GCC GAA GGT GCG GGC GGC TTT TTT AAA GGT ATA GAT GCC
 ATA CGG CTT CCA CGC CCG CCG AAA AAA TTT CCA TAT CTA CGG

+1 L P L T G Q Y T H Y A L N K
 1051 TTA CCG CTT ACC GGG CAA TAC ACT CAC TAT GCG CTG AAT AAA
 AAT GGC GAA TGG CCC GTT ATG TGA GTG ATA CGC GAC TTA TTT

+1 K T G K P D Y V T D S A A S
 1093 AAA ACC GGC AAA CCG GAC TAC GTC ACC GAC TCG GCT GCA TCA
 TTT TGG CCG TTT GGC CTG ATG CAG TGG CTG AGC CGA CGT AGT

+1 A T A W S T G V K T Y N G A
 1135 GCA ACC GCC TGG TCA ACC GGT GTC AAA ACC TAT AAC GGC GCG
 CGT TGG CGG ACC AGT TGG CCA CAG TTT TGG ATA TTG CCG CGC

+1 L G V D I H E K D H P T I L
 1177 CTG GGC GTC GAT ATT CAC GAA AAA GAT CAC CCA ACG ATT CTG
 GAC CCG CAG CTA TAA GTG CTT TTT CTA GTG GGT TGC TAA GAC

+1 E M A K A A G L A T G N V S
 1219 GAA ATG GCA AAA GCC GCA GGT CTG GCG ACC GGT AAC GTT TCT
 CTT TAC CGT TTT CGG CGT CCA GAC CGC TGG CCA TTG CAA AGA

+1 T A E L Q D A T P A A L V A
 1261 ACC GCA GAG TTG CAG GAT GCC ACG CCC GCT GCG CTG GTG GCA
 TGG CGT CTC AAC GTC CTA CGG TGC GGG CGA CGC GAC CAC CGT

+1 H V T S R K C Y G P S A T S
 1303 CAT GTG ACC TCG CGC AAA TGC TAC GGT CCG AGC GCG ACC AGT
 GTA CAC TGG AGC GCG TTT ACG ATG CCA GGC TCG CGC TGG TCA

+1 E K C P G N A L E K G G K G
 1345 GAA AAA TGT CCG GGT AAC GCT CTG GAA AAA GGC GGA AAA GGA
 CTT TTT ACA GGC CCA TTG CGA GAC CTT TTT CCG CCT TTT CCT

+1 S I T E Q L L N A R A D V T
 1387 TCG ATT ACC GAA CAG CTG CTT AAC GCT CGT GCC GAC GTT ACG
 AGC TAA TGG CTT GTC GAC GAA TTG CGA GCA CGG CTG CAA TGC

+1 L G G G A K T F A E T A T A
 1429 CTT GGC GGC GGC GCA AAA ACC TTT GCT GAA ACG GCA ACC GCT
 GAA CCG CCG CGT TTT TGG AAA CGA CTT TGC CGT TGG CGA

+1 G E W Q G K T L R E Q A Q A
 1471 GGT GAA TGG CAG GGA AAA ACG CTG CGT GAA CAG GCA CAG GCG
 CCA CTT ACC GTC CCT TTT TGC GAC GCA CTT GTC CGT GTC CGC

FIG. 29-3

+1 R G Y Q L V S D A A S L N S
 1513 CGT GGT TAT CAG TTG GTG AGC GAT GCT GCC TCA CTG AAT TCG
 GCA CCA ATA GTC AAC CAC TCG CTA CGA CGG AGT GAC TTA AGC

+1 V T E A N Q Q K P L L G L F
 1555 GTG ACG GAA GCG AAT CAG CAA AAA CCC CTG CTT GGC CTG TTT
 CAC TGC CTT CGC TTA GTC GTT TTT GGG GAC GAA CCG GAC AAA

+1 A D G N M P V R W L G P K A
 1597 GCT GAC GGC AAT ATG CCA GTG CGC TGG CTA GGA CCG AAA GCA
 CGA CTG CCG TTA TAC GGT CAC GCG ACC GAT CCT GGC TTT CGT

+1 T Y H G N I D K P A V T C T
 1639 ACG TAC CAT GGC AAT ATC GAT AAG CCC GCA GTC ACC TGT ACG
 TGC ATG GTA CCG TTA TAG CTA TTC GGG CGT CAG TGG ACA TGC

+1 P N P Q R N D S V P T L A Q
 1681 CCA AAT CCG CAA CGT AAT GAC AGT GTA CCA ACC CTG GCG CAG
 GGT TTA GGC GTT GCA TTA CTG TCA CAT GGT TGG GAC CGC GTC

+1 M T D K A I E L L S K N E K
 1723 ATG ACC GAC AAA GCC ATT GAA TTG TTG AGT AAA AAT GAG AAA
 TAC TGG CTG TTT CGG TAA CTT AAC AAC TCA TTT TTA CTC TTT

+1 G F F L Q V E G A S I D K Q
 1765 GGC TTT TTC CTG CAA GTT GAA GGT GCG TCA ATC GAT AAA CAG
 CCG AAA AAG GAC GTT CAA CTT CCA CGC AGT TAG CTA TTT GTC

+1 D H A A N P C G Q I G E T V
 1807 GAT CAT GCT GCG AAT CCT TGT GGG CAA ATT GGC GAG ACG GTC
 CTA GTA CGA CGC TTA GGA ACA CCC GTT TAA CCG CTC TGC CAG

+1 D L D E A V Q R A L E F A K
 1849 GAT CTC GAT GAA GCC GTA CAA CGG GCG CTG GAA TTC GCT AAA
 CTA GAG CTA CTT CGG CAT GTT GCC CGC GAC CTT AAG CGA TTT

+1 K E G N T L V I V T A D H A
 1891 AAG GAG GGT AAC ACG CTG GTC ATA GTC ACC GCT GAT CAC GCC
 TTC CTC CCA TTG TGC GAC CAG TAT CAG TGG CGA CTA GTG CGG

+1 H A S Q I V A P D T K A P G
 1933 CAC GCC AGC CAG ATT GTT GCG CCG GAT ACC AAA GCT CCG GGC
 GTG CGG TCG GTC TAA CAA CGC GGC CTA TGG TTT CGA GGC CCG

+1 L T Q A L N T K D G A V M V
 1975 CTC ACC CAG GCG CTA AAT ACC AAA GAT GGC GCA GTG ATG GTG
 GAG TGG GTC CGC GAT TTA TGG TTT CTA CCG CGT CAC TAC CAC

FIG. 29-4

+1 M S Y G N S E E D S Q E H T
2017 ATG AGT TAC GGG AAC TCC GAA GAG GAT TCA CAA GAA CAT ACC
TAC TCA ATG CCC TTG AGG CTT CTC CTA AGT GTT CTT GTA TGG

+1 G S Q L R I A A Y G P H A A
2059 GGC AGT CAG TTG CGT ATT GCG GCG TAT GGC CCG CAT GCC GCC
CCG TCA GTC AAC GCA TAA CGC CGC ATA CCG GGC GTA CGG CGG

+1 N V V G L T D Q T D L F Y T
2101 AAT GTT GTT GGA CTG ACC GAC CAG ACC GAT CTC TTC TAC ACC
TTA CAA CAA CCT GAC TGG CTG GTC TGG CTA GAG AAG ATG TGG

+1 M K A A L G D I A | His tag
2143 ATG AAA GCC GCT CTG GGG GAT ATC GCA | H H H H H
TAC TTT CGG CGA GAC CCC CTA TAG CGT | CAC CAT CAC CAT CAC
GTG GTA GTG GTA GTG

+1 H *
2185 CAT TAA
GTA ATT

FIG. 29-5

PelB-Leader

+1 M K Y L L P T A A A G L L L L
 1 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
 TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT GAG

VH

+1 A A Q P A M A E V Q L Q Q S G
46 GCG GCC CAG CCG GCC ATG GCG GAG GTT CAG CTT CAG CAG TCT GGA
CGC CGG GTC GGC CGG TAC CGC CTC CAA GTC GAA GTC GTC AGA CCT

+1 P E L V K P G A S V K I S C K
 91 CCT GAG CTG GTG AAG CCC GGG GCC TCA GTG AAG ATT TCC TGC AAA
 GGA CTC GAC CAC TTC GGG CCC CGG AGT CAC TTC TAA AGG ACG TTT

+1 A S G Y A F S S S W M N W V K
 136 GCT TCT GGC TAC GCA TTC AGT AGC TCT TGG ATG AAC TGG GTG AAG
 CGA AGA CCG ATG CGT AAG TCA TCG AGA ACC TAC TTG ACC CAC TTC

+1 Q R P G Q G L E W I G R I Y P
 181 CAG AGG CCT GGA CAG GGT CTT GAG TGG ATT GGA CGG ATT TAT CCT
 GTC TCC GGA CCT GTC CCA GAA CTC ACC TAA CCT GCC TAA ATA GGA

+1 G N G D T N Y N G K F K G K A
 226 GGA AAT GGA GAT ACT AAC TAC AAT GGG AAG TTC AAG GGC AAG GCC
 CCT TTA CCT CTA TGA TTG ATG TTA CCC TTC AAG TTC CCG TTC CGG

+1 T L T A D K S S S T A Y M Q L
 271 ACA CTG ACT GCA GAC AAA TCC TCC AGC ACA GCC TAC ATG CAG CTC
 TGT GAC TGA CGT CTG TTT AGG AGG TCG TGT CGG ATG TAC GTC GAG

+1 S S L T S V D S A V Y F C A D
 316 AGC AGC CTG ACC TCT GTG GAC TCT GCG GTC TAT TTC TGT GCA GAT
 TCG TCG GAC TGG AGA CAC CTG AGA CGC CAG ATA AAG ACA CGT CTA

+1 G N V Y Y Y A M D Y W G Q G T
 361 GGT AAC GTA TAT TAC TAT GCT ATG GAC TAC TGG GGT CAA GGA ACC
 CCA TTG CAT ATA ATG ATA CGA TAC CTG ATG ACC CCA GTT CCT TGG

Linker

+1 S V T V S S G G G G S G G R A
406 TCA GTC ACC GTC TCC TCA GGT GGA GGC GGT TCA GGT GGG CGC GCC
AGT CAG TGG CAG AGT CCA CCT CCG CCA AGT CCA CCC GCG CGG

FIG. 30-1

VL

+1 S G G G G S | Q I V L T Q S P A
 451 TCT GGC GGT GGC GGA TCG | CAA ATT GTT CTC ACC CAG TCT CCT GCT
 AGA CCG CCA CCG CCT AGC | GTT TAA CAA GAG TGG GTC AGA GGA CGA

+1 S L A V S L G Q R A T I S C R
 496 TCC TTA GCT GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA TGC AGG
 AGG AAT CGA CAT AGA GAC CCC GTC TCC CGG TGG TAG AGT ACG TCC

+1 A S K S V S T S G Y S Y M H W
 541 GCC AGC AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG
 CGG TCG TTT TCA CAG TCA TGT AGA CCG ATA TCA ATA TAC GTG ACC

+1 Y Q Q K P G Q P P K L L I Y L
 586 TAC CAA CAG AAA CCA GGA CAG CCA CCC AAA CTC CTC ATC TAT CTT
 ATG GTT GTC TTT GGT CCT GTC GGT TTT GAG GAG TAG ATA GAA

+1 A S N L E S G V P A R F S G S
 631 GCA TCC AAC CTA GAA TCT GGG GTC CCT GCC AGG TTC AGT GGC AGT
 CGT AGG TTG GAT CTT AGA CCC CAG GGA CGG TCC AAG TCA CCG TCA

+1 G S G T D F T L N I H P V E E
 676 GGG TCT GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG GAG GAG
 CCC AGA CCC TGT CTG AAG TGG GAG TTG TAG GTA GGA CAC CTC CTC

+1 E D A A T Y Y C Q H S R E L P
 721 GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC AGT AGG GAG CTT CCT
 CTC CTA CGA CGT TGG ATA ATG ACA GTC GTG TCA TCC CTC GAA GGA

Spacer

+1 R T F G G G T K L E I K R A A
 766 CGG ACG TTC GGT GGA GGC ACC AAG CTG GAA ATC AAA CGG GCG GCC
 GCC TGC AAG CCA CCT CCG TGG TTC GAC CTT TAG TTT GCC CGC CGG

Hinge

+1 A P K P S T P P G S S | R M K Q
 811 GCA CCG AAG CCT TCC ACT CCG CCC GGG TCT TCC | CGT ATG AAA CAG
 CGT CGC TTC GGA AGG TGA GGC GGG CCC AGA AGG GCA TAC TTT GTC

Helix


+1 L E D K V E E L L S K N Y H L
 856 CTG GAA GAC AAA GTA GAG GAG CTC CTT AGC AAG AAC TAC CAT CTA
 GAC CTT CTG TTT CAT CTC CTC GAG GAA TCG TTC TTG ATG GTA GAT

+1 E N E V A R L K K L V G E R G
 901 GAA AAC GAG GTA GCT CGT CTG AAA AAG CTT GTT GGT GAA CGT GGT
 CTT TTG CTC CAT CGA GCA GAC TTT TTC GAA CAA CCA CTT GCA CCA

FIG. 30-2

	Spacer	His-tag						
+1	G	H	H	H	H	H	H	*
946	GGT	CAC	CAT	CAC	CAT	CAC	CAT	TAA
	CCA	GTG	GTA	GTG	GTA	GTG	GTA	ATT

FIG. 30-3

**FIG. 31**




FIG. 32

HindIII

2206 CAG GAA ACA GCT ATG ACC ATG ATT ACG CC^A^TGC^TT^C CAT GAA AAT
GTC CTT TGT CGA TAC TGG TAC TAA TGC GGT TCG AAG GTA CTT TTA

PelB-Leader

	M	K	Y	L	L	P	T
--	---	---	---	---	---	---	---

2251 TCT ATT TCA AGG AGA CAG TCA TAA TGA AAT ACC TAT TGC CTA CGG
AGA TAA AGT TCC TCT GTC AGT ATT ACT TTA TGG ATA ACG GAT GCC

A	A	A	G	L	L	L	A	A	Q	P	A	M	A
---	---	---	---	---	---	---	---	---	---	---	---	---	---

SfiI

2296 CAG CCG CTG GAT TGT TAT TAC TCG CG^G^TCC^TAG^C^TGG^TCA TGG CCC
GTC GGC GAC CTA ACA ATA ATG AGC GCC GGG TCG GCC GGT ACC GGG

Polylinker

Q	V	Q	L	Q	A	R	L	Q	V	D	L	E	I	K
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

AscI

2341 AGG TGC AGC TGC A^G^TGG^C^TGC^A^T TGC AGG TCG ACC TCG AGA TCA AAC
TCC ACG TCG ACG TCC GCG CGG ACG TCC AGC TGG AGC TCT AGT TTG

R	Spacer			Myc-tag									
	A	A	A	E	Q	K	L	I	S	E	E	D	L

NotI

2386 GG^G^TGG^C^TGG^A^TAG AAC AAA AAC TCA TCT CAG AAG AGG ATC TGA ATG
CCC GCC GGC GTC TTG TTT TTG AGT AGA GTC TTC TCC TAG ACT TAC

G	Spacer			His tag									
	A	A	H	H	H	H	H	*	*				

ECORI

2431 GGG CGG CAC ATC ACC ATC ACC ATC ACT AAT AAG AAT TCA CTG GCC
CCC GCC GTG TAG TGG TAG TGG TAG TGA TTA TTC TTA AGT GAC CGG

FIG. 33

PelB-leader

+1 M K Y L L P T A A A G L L L L
 1 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
 TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT GAG

VH

+1 A A Q P A M A | E V K L V E S G
 46 GCG GCC CAG CCG GCC ATG GCC | GAG GTG AAG CTG GTG GAG TCT GGG
 CGC CGG GTC GGC CGG TAC CGG | CTC CAC TTC GAC CAC CTC AGA CCC

+1 G G L V K P G G S L K L S C A
 91 GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC TCC TGT GCA
 CCT CCG AAT CAC TTC GGA CCT CCC AGG GAC TTT GAG AGG ACA CGT

+1 A S G F T F S S Y T M S W V R
 136 GCC TCT GGA TTC ACT TTC AGT AGC TAT ACC ATG TCT TGG GTT CGC
 CGG AGA CCT AAG TGA AAG TCA TCG ATA TGG TAC AGA ACC CAA GCG

+1 Q T P E K R L E W V A T I S S
 181 CAG ACT CCG GAG AAG AGG CTG GAG TGG GTC GCA ACC ATT AGT AGT
 GTC TGA GGC CTC TTC TCC GAC CTC ACC CAG CGT TGG TAA TCA TCA

+1 G G S S T Y Y P D S V K G R F
 226 GGN GGT AGT TCC ACC TAC TAT CCA GAC AGT GTG AAG GGC CGA TTC
 CCN CCA TCA AGG TGG ATG ATA GGT CTG TCA CAC TTC CCG GCT AAG

+1 T I S R D N A K N T L Y L Q M
 271 ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC CTG CAA ATG
 TGG TAG AGG TCT | CTG TTA CGG TTC TTG TGG GAC ATG GAC GTT TAC

+1 S S L R S E D T A M Y Y C T R
 316 AGC AGT CTG AGG TCT GAG GAC ACA GCC ATG TAT TAC TGT ACA AGA
 TCG TCA GAC TCC AGA CTC CTG TGT CGG TAC ATA ATG ACA TGT TCT

+1 E G G F T V N W Y F D V W G
 361 GAG GGG GGT GGT TTC ACC GTC AAC TGG TAC TTC GAT GTC TGG GGC
 CTC CCC CCA CCA AAG TGG CAG TTG ACC ATG AAG CTA CAG ACC CCG

Leader

+1 A G T S V T V S S | G G G G S G
 406 GCA GGA ACC TCA GTC ACC GTC TCC TCA | GGT GGA GGC GGT TCA GGT
 CGT CCT TGG AGT CAG TGG CAG AGG AGT | CCA CCT CCG CCA AGT CCA

FIG. 34-1

VK

+1	G	R	A	S	G	G	G	S	D	I	V	L	T	Q	
451	GGG	CGC	GCC	TCT	GGC	GGT	GGC	GGA	TCG	GAC	ATT	GTG	CTG	ACA	CAG
	CCC	GCG	CGG	AGA	CCG	CCA	CCG	CCT	AGC	CTG	TAA	CAC	GAC	TGT	GTC

+1	S	P	A	S	L	A	V	S	L	G	Q	R	A	T	I
496	TCT	CCA	GCT	TCT	TTG	GCT	GTG	TCT	CTA	GGG	CAG	AGG	GCC	ACC	ATA
	AGA	GGT	CGA	AGA	AAC	CGA	CAC	AGA	GAT	CCC	GTC	TCC	CGG	TGG	TAT

+1	S	C	R	A	S	E	S	V	D	S	Y	G	Y	N	F
541	TCC	TGC	AGA	GCC	AGT	GAA	AGT	GTT	GAT	AGT	TAT	GGC	TAT	AAT	TTT
	AGG	ACG	TCT	CGG	TCA	CTT	TCA	CAA	CTA	TCA	ATA	CCG	ATA	TTA	AAA

+1	M	H	W	Y	Q	Q	I	P	G	Q	P	P	K	L	L
586	ATG	CAC	TGG	TAT	CAG	CAG	ATA	CCA	GGA	CAG	CCA	CCC	AAA	CTC	CTC
	TAC	GTG	ACC	ATA	GTC	GTC	TAT	GGT	CCT	GTC	GGT	GGG	TTT	GAG	GAG

+1	I	Y	R	A	S	N	L	E	S	G	I	P	A	R	F
631	ATC	TAT	CGT	GCA	TCC	AAC	CTA	GAG	TCT	GGG	ATC	CCT	GCC	AGG	TTC
	TAG	ATA	GCA	CGT	AGG	TTG	GAT	CTC	AGA	CCC	TAG	GGA	CGG	TCC	AAG

+1	S	G	S	G	S	R	T	D	F	T	L	T	I	N	P
676	AGT	GGC	AGT	GGG	TCT	AGG	ACA	GAC	TTC	ACC	CTC	ACC	ATT	AAT	CCT
	TCA	CCG	TCA	CCC	AGA	TCC	TGT	CTG	AAG	TGG	GAG	TGG	TAA	TTA	GGA

+1	V	E	A	D	D	V	A	T	Y	Y	C	Q	Q	S	N
721	GTG	GAG	GCT	GAT	GAT	GTT	GCA	ACC	TAT	TAC	TGT	CAG	CAA	AGT	AAT
	CAC	CTC	CGA	CTA	CAA	CGT	TGG	ATA	ATG	ACA	GTC	GTT	TCA	TTA	

+1	E	D	P	L	T	F	G	T	G	T	R	L	E	I	K
766	GAG	GAT	CCG	CTC	ACG	TTC	GGT	ACT	GGG	ACC	AGA	CTG	GAA	ATA	AAA
	CTC	CTA	GGC	GAG	TGC	AAG	CCA	TGA	CCC	TGG	TCT	GAC	CTT	TAT	TTT

Spacer				Myc-tag											
+1	R	A	A	A	E	Q	K	L	I	S	E	E	D	L	N
811	CGG	GGC	GCC	GCA	GAA	CAA	AAA	CTC	ATC	TCA	GAA	GAG	GAT	CTG	AAT
	GCC	CGC	CGG	CGT	CTT	GTT	TTT	GAG	TAG	AGT	CTT	CTC	CTA	GAC	TTA

Spacer				His tag											
+1	G	A	A	H	H	H	H	H	*	*					
856	GGG	GCG	GCA	CAT	CAC	CAT	CAC	CAT	CAC	TAA	TAA				
	CCC	CGC	CGT	GTA	GTG	GTA	GTG	GTA	GTG	ATT	ATT				

FIG. 34-2

Pel-leader

+1 M K Y L L P T A A A G L L L L
 1 ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
 TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT GAG

VH

+1 A A Q P A M A | E V Q L Q Q S G
 46 GCG GCC CAG CCG GCC ATG GCC | GAG GTT CAG CTT CAG CAG TCT GGA
 CGC CGG GTC GGC CGG TAC CGG | CTC CAA GTC GAA GTC GTC AGA CCT

+1 P E L V K P G A S V K I S C K
 91 CCT GAG CTG GTG AAG CCC GGG GCC TCA GTG AAG ATT TCC TGC AAA
 GGA CTC GAC CAC TTC GGG CCC CGG AGT CAC TTC TAA AGG ACG TTT

+1 A S G Y A F S S S W M N W V K
 136 GCT TCT GGC TAC GCA TTC AGT AGC TCT TGG ATG AAC TGG GTG AAG
 CGA AGA CCG ATG CGT AAG TCA TCG AGA ACC TAC TTG ACC CAC TTC

+1 Q R P G Q G L E W I G R I Y P
 181 CAG AGG CCT GGA CAG GGT CTT GAG TGG ATT GGA CGG ATT TAT CCT
 GTC TCC GGA CCT GTC CCA GAA CTC ACC TAA CCT GCC TAA ATA GGA

+1 G N G D T N Y N G K F K G K A
 226 GGA AAT GGA GAT ACT AAC TAC AAT GGG AAG TTC AAG GGC AAG GCC
 CCT TTA CCT CTA TGA TTG ATG TTA CCC TTC AAG TTC CCG TTC CGG

+1 T L T A D K S S S T A Y M Q L
 271 ACA CTG ACT GCA GAC AAA TCC TCC AGC ACA GCC TAC ATG CAG CTC
 TGT GAC TGA CGT CTG TTT AGG AGG TCG TGT CGG ATG TAC GTC GAG

+1 S S L T S V D S A V Y F C A D
 316 AGC AGC CTG ACC TCT GTG GAC TCT GCG GTC TAT TTC TGT GCA GAT
 TCG TCG GAC TGG AGA CAC CTG AGA CGC CAG ATA AAG ACA CGT CTA

+1 G N V Y Y Y A M D Y W G Q G T
 361 GGT AAC GTA TAT TAC TAT GCT ATG GAC TAC TGG GGT CAA GGA ACC
 CCA TTG CAT ATA ATG ATA CGA TAC CTG ATG ACC CCA GTT CCT TGG

Leader

+1 S V T V S S | G G G G S G G R A
 406 TCA GTC ACC GTC TCC TCA | GGT GGA GGC GGT TCA GGT GGG CGC GCC
 AGT CAG TGG CAG AGG AGT CCA CCT CCG CCA AGT CCA CCC GCG CGG

VL

+1 S G G G S | Q I V L T Q S P A
 451 TCT GGC GGT GGC GGA TCG | CAA ATT GTT CTC ACC CAG TCT CCT GCT
 AGA CCG CCA CCG CCT AGC | GTT TAA CAA GAG TGG GTC AGA GGA CGA

+1 S L A V S L G Q R A T I S C R
 496 TCC TTA GCT GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA TGC AGG
 AGG AAT CGA CAT AGA GAC CCC GTC TCC CGG TGG TAG AGT ACG TCC

+1 A S K S V S T S G Y S Y M H W
 541 GCC AGC AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG
 CGG TCG TTT TCA CAG TCA TGT AGA CCG ATA TCA ATA TAC GTG ACC

+1 Y Q Q K P G Q P P K L L I Y L
 586 TAC CAA CAG AAA CCA GGA CAG CCA CCC AAA CTC CTC ATC TAT CTT
 ATG GTT GTC TTT GGT CCT GTC GGT GGG TTT GAG GAG TAG ATA GAA

+1 A S N L E S G V P A R F S G S
 631 GCA TCC AAC CTA GAA TCT GGG GTC CCT GCC AGG TTC AGT GGC AGT
 CGT AGG TTG GAT CTT AGA CCC CAG GGA CGG TCC AAG TCA CCG TCA

+1 G S G T D F T L N I H P V E E
 676 GGG TCT GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG GAG GAG
 CCC AGA CCC TGT CTG AAG TGG GAG TTG TAG GTA GGA CAC CTC CTC

+1 E D A A T Y Y C Q H S R E L P
 721 GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC AGT AGG GAG CTT CCT
 CTC CTA CGA CGT TGG ATA ATG ACA GTC GTG TCA TCC CTC GAA GGA

Spacer

+1 R T F G G G T K L E I K R A A
 766 CGG ACG TTC GGT GGA GGC ACC AAG CTG GAA ATC AAA CGG GGG GCC
 GCC TGC AAG CCA CCT CCG TGG TTC GAC CTT TAG TTT GCC CGC CGG

Myc-tag Spacer

+1 A | E Q K L I S E E D L N G | A A
 811 GCA | GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT GGG GCG GCA
 CGT | CTT GTT TTT GAG TAG AGT CTT CTC CTA GAC TTA CCC CGC CGT

His tag

+1 H H H H H H *
 856 CAT CAC CAT CAC CAT CAC TAA
 GTA GTG GTA GTG GTA GTG ATT

FIG. 35-2




FIG. 36

1

**FACTOR IX/FACTOR IXA ACTIVATING
ANTIBODIES AND ANTIBODY
DERIVATIVES**

The present invention relates to factor IX/factor IXa-antibodies and antibody derivatives.

Blood clots (thrombi) are formed by a series of zymogen activations referred to as the coagulation cascade. In the course of this enzymatic cascade, the activated form of each of such zymogens (referred to as factors) catalyzes the activation of the next one. Thrombi are deposits of blood components on the surface of a blood vessel wall and mainly consist of aggregated blood platelets and insoluble, cross-linked fibrin. Fibrin formation is effected by means of thrombin by limited proteolysis of fibrinogen. Thrombin is the final product of the coagulation cascade, (K. G. Mann, Blood, 1990, Vol. 76, pp. 1-16).

Activation of factor X by the complex of activated factor IX (FIXa) and activated factor VIII (FVIIIa) is a key step in coagulation. The absence of the components of this complex or a disturbance of their function is associated with the blood coagulation disorder called hemophilia (J. E. Sadler & E. W. Davie: Hemophilia A, Hemophilia B and von Willebrand's disease, in G. Stamatoyannopoulos et al. (Eds.): The molecular basis of blood diseases. W. B. Saunders Co., Philadelphia, 1987, pp. 576-602). Hemophilia A denotes a (functional) absence of factor VIII activity, while Hemophilia B is characterized by the absence of factor IX activity. At present, treatment of Hemophilia A is effected via a substitution therapy by administering factor VIII concentrates. However, approximately 20-30% of Hemophilia A patients develop factor VIII inhibitors (i.e. antibodies against factor VIII), whereby the effect of administered factor VIII preparations is inhibited. Treatment of factor VIII inhibitor patients is very difficult and involves risks, and so far there exist only a limited number of treatments for these patients.

In the case of patients having a low FVIII inhibitor level, it is possible, though expensive, to administer high doses of factor VIII to such patients and thus to neutralize the antibodies against factor VIII. The amount of factor VIII beyond that needed to neutralize the inhibitor antibodies then has hemostatic action. In many cases, desensitization can be effected, whereupon it is then possible again to apply standard factor VIII treatments. Such high dose factor VIII treatments require, however, large amounts of factor VIII, are time-consuming and may involve severe anaphylactic side reactions. Alternatively, the treatment may be carried out with porcine factor VIII molecules.

A further high-cost method involves removing factor VIII inhibitors through extra corporeal immunoadsorption on lectins which bind to immunoglobulins (protein A, protein G) or to immobilized factor VIII. Since the patient must be connected to an apheresis machine during this treatment, the treatment also constitutes a great burden on the patient. It is also not possible to treat an acute hemorrhage in this way.

At present, the therapy of choice is to administer activated prothrombin complex concentrates (APCC), such as FEIBA® and AUTOPLEX®, which are suitable for the treatment of acute hemorrhages even in patients having a high inhibitor titer (DE 31 27 318).

In the intravascular system of blood coagulation, the last step is the activation of factor X. This reaction is stimulated by the binding of factor VIIIa to factor IXa and the formation of a "tenase"-complex consisting of the factors IXa, VIIIa, X and phospholipid. Without the binding of FVIIIa, FIXa exhibits no or only a very slight enzymatic activity relative to FX.

2

Over the last several years, a number of possible binding sites for factor VIIIa to factor IXa have been characterized, and it has been shown that antibodies or peptides which bind to these regions inhibit the activity of FIXa (Fay et al., J. Biol. Chem., 1994, Vol. 269, pp. 20522-20527, Lenting et al., J. Biol. Chem., 1996, Vol. 271, pp. 1935-1940, Jorquera et al., Circulation, 1992, Vol. 86, Abstract 2725). The inhibition of coagulation factors, such as factor IX, has also been achieved through the use of monoclonal antibodies with the aim of preventing thrombosis formation (WO 97/26010).

The opposite effect, i.e. an increase in the factor IXa mediated activation of factor X, has been described by Liles D. K. et al., (Blood, 1997, Vol. 90, suppl. 1, 2054) through the binding of a factor VIII peptide (amino acids 698-712) to factor IX. Yet, this effect only occurs in the absence of factor VIIIa, while in the presence of factor VIIIa the factor IXa/factor VIIIa-mediated cleavage of factor X is inhibited by this peptide.

SUMMARY OF THE INVENTION

With a view to the possible risks and side effects which may occur in the treatment of hemophilia patients, there is a need for a therapy which allows for the effective treatment of FVIII inhibitor patients. Therefore, it is an object of the present invention to provide a preparation for the treatment of blood coagulation disorders which has particular advantages for factor VIII inhibitor patients.

According to the present invention, this object is achieved through the use of antibodies or antibody derivatives against factor IX/factor IXa which have factor VIIIa-cofactor activity or factor IXa-activating activity and lead to an increase in the procoagulant activity of factor IXa. Surprisingly, the action of these inventive factor IX/factor IXa-activating antibodies and antibody derivatives is not negatively affected by the presence of inhibitors, such as inhibitors against factor VIII/factor VIIIa, but instead the procoagulant activity of factor IXa in this case also is increased.

A further advantage of this invention is that the administration of the preparation according to the invention allows for rapid blood coagulation even in the absence of factor VIII or factor VIIIa, even in the case of FVIII inhibitor patients. Surprisingly, these agents are also effective in the presence of factor VIIIa.

The antibodies and antibody derivatives according to the present invention thus have a FVIII-cofactor-like activity which, in a FVIII assay (e.g. a COATEST® assay or Immunochrom test) after 2 hours of incubation exhibits a ratio of background (basic noise) to measured value of at least 3. Calculation of this ratio may, e.g., be effected according to the following scheme:

$$\frac{\text{Antibody measurement (OD 405) - blank value from reagent}}{\text{Mouse-IgG-measurement (OD 405) - blank value from reagent}} \geq 3$$

after two hours of incubation.

The antibodies according to the invention preferably have an *in vivo* half life of at least 5 days, more preferably at least 10 days, though it is more preferred to have a half life of at least 20 days.

A further aspect of this invention is a preparation comprising antibodies and/or antibody derivatives against factor IX/factor IXa and a pharmaceutically acceptable carrier substance. Furthermore, the preparation according to the invention may additionally comprise factor IX and/or factor IXa.

A further aspect of the invention is the use of the antibodies or antibody derivatives to increase the amidolytic activity of factor IXa.

FIG. 1 shows the results of a screening of supernatants from hybridoma cell cultures for FVIII-like activity. Pre-selected clones from fusion experiments, #193, #195 and #196, were tested in a chromogenic assay.

FIG. 2 shows the results of screening for IgG-mediated factor VIII-like activity in supernatants of a hybridoma cell culture of a master plate.

FIG. 3 shows the subcloning of clone 193/C0, namely the results of the first cloning round.

FIG. 4 shows a comparison of the chromogenic FVIII-like activity and factor IX-ELISA-reactivity of hybridoma cultures derived from the starting clone 193/C0.

FIG. 5 shows the results of the measurement of the chromogenic activity of some master clones and sub-clones.

FIG. 6A shows the FVIII-like activity of the anti-FIX/FIXa-antibodies 193/AD3 and 196/AF2 compared to human FVIII, TBS buffer and cell culture medium. After a lag phase, both antibodies gave rise to chromogenic substrate cleavage, as judged by the increasing optical density.

FIG. 6B shows a comparison of the chromogenic activity of factor VIII, 196/AF1, 198/AC1/1 and mouse-IgG.

FIG. 7A shows a comparison of the kinetics of Factor Xa generation by Factor VIII and 196/AF2 with and without the addition of a Factor Xa specific inhibitor.

FIG. 7B shows a comparison of the kinetics of the Factor Xa generation by Factor VIII, mouse-IgG and anti-factor IX/Xa-antibody 198/AM1 with and without the addition of a factor Xa-specific inhibitor, Pefabloc Xa®.

FIG. 8A shows a measurement of the dependence of the factor VIII-like activity of purified anti-factor IX/Xa-antibody 198/AC1/1 in the presence and absence of phospholipids, FIXa/FX and calcium ions.

FIG. 8B shows a measurement of the dependence of FXa generation by anti-FIXa-antibody 196/AF1 in the presence of phospholipids, Ca²⁺ in FIXa/FX.

FIG. 8C shows the generation of FXa by unspecific mouse IgG antibody.

FIG. 9 is a graphical representation of the coagulation times of Factor VIII-deficient plasma in an APTT assay by using various concentrations of anti-factor IX/Xa-antibody 193/AD3.

FIG. 10A shows that in the presence of Factor IXa, antibody 193/AD3 leads to a reduction in the coagulation time of factor VIII-deficient plasma.

FIG. 10B shows a dose-dependent reduction of the clotting time by antibody 193/AD3 in the presence of factor IXa- and factor VIII-inhibitors.

FIG. 11 shows the chromogenic activity of antibodies 198/A1, 198/B1 and 198/AP1 in the presence and absence of human FIXa^b.

FIG. 12 shows the primer sequences (SEQ ID NOS:50–61) for the amplification of the genes of the variable heavy chain of mouse antibody.

FIG. 13 shows the primer sequences (SEQ ID NOS:65–78) for the amplification of the genes of the variable light (kappa) chain of the mouse antibody.

FIG. 14 shows the DNA and derived protein sequence of the scFv from hybridoma cell line 193/AD3 (SEQ.ID.NOS. 81 and 82).

FIG. 15 shows the DNA and derived protein sequence of the scFv from hybridoma cell line 193/K2 (SEQ.ID.NOS. 83 and 84).

FIG. 16 shows the DNA and derived protein sequence of the scFv from hybridoma cell line 198/AB2 (subclone of 198/B1) (SEQ.ID.NOS. 85 and 86).

FIG. 17 shows the DNA and deduced protein sequence of scFv derived from the cell line 198/A1 (SEQ.ID.NOs. 87 and 88).

FIG. 18 demonstrates the chromogenic FVIII-like activity of peptide A1/3 in the presence of 2.9 nM human FIXa. The scrambled version of peptide A1/3, peptide A1/5 does not give rise to any FXa generation.

FIG. 19 demonstrates the dependence of the chromogenic FVIII-like activity of peptide A1/3 on the presence of human FIXa. In the absence of human FIXa, peptide A1/3 does not give rise to any FXa generation. The buffer control, plain imidazole buffer is designated IZ.

FIG. 20 shows that the chirality of Arg-residues does not play a significant role for the chromogenic activity of peptides A1/3-rd and A1/3-Rd-srmb.

FIG. 21 shows that the addition of 2.4 μM peptide B1/7 to the reaction mixture led to a measureable generation of FXa.

FIG. 22 shows that the addition of a FX-specific inhibitor results in a significant reduction in the reaction. If there was no FIXa and FX is added to the reaction mixture, no FXa was synthesized.

FIG. 23 shows vector pBax-IgG1.

FIG. 24 shows the increase of the amidolytic activity of FIXa in the presence of antibody 198/B1 (FIG. 24A) and IgM antibody 198/AF1 (FIG. 24B).

FIG. 25 demonstrates the chromogenic FVIII-like activity of the antibody 198/A1 Fab fragment in the presence of 2.3 nM human FIXa. As a positive control the intact antibody 198/A1 was used as well as 7.5 pM FVIII. The buffer control (IZ) was used as a negative control.

FIG. 26 shows the nucleotide and amino acid sequence of the 198AB2 scFv-alkaline phosphatase fusion protein (ORF of the expression vector pDAP2-198AB2#100, (SEQ.ID.NOs. 89 and 90).

The genes for the VL and the VH domains of antibody 198/AB2 (198/AB2 is an identical subclone of 198/B1) were derived from the corresponding hybridoma cells as described in example 10. The PCR product of the VH-gene was digested SfiI-Asci and the PCR-product of the VL-gene was digested Asci and NotI. VH and VL genes were linked via the Asci site and inserted into SfiI-NotI digested vector pDAP2 (Kerschbaumer R. J. et al, Immuno-technology 2, 145–150, 1996; GeneBank accession No.:U35316). PelB leader: leader sequence of *Erwinia carotovora* Pectate Lyase B, His tag, Histidine tag for metal ion chromatography.

FIG. 27 demonstrates the chromogenic FVIII-like activity of two antibody 198/B1 (subclone AB2) scFv fragment-alkaline phosphatase fusion proteins (198AB2#1 and 198AB2#100) in the presence of 2.3 nM human FIXa. As a positive control 7.5 pM FVIII was used.

FIG. 28 shows the amino acid and nucleotide sequence of pZip198AB2#102 (SEQ.ID.NOs. 91 and 92).

FIG. 29 shows the nucleotide and amino acid sequence of the mAB#8860 scFv-alkaline phosphatase fusion protein (vector pDAP2-8860scFv#11, (SEQ.ID.NOs. 93 and 94). The genes for the VT and the VH domains of antibody #8860 were derived from the corresponding hybridoma cells as described in example 10. The PCR product of the VH-gene was digested SfiI-Asci and the PCR-product of the VL-gene was digested Asci and NotI. VH and VL genes were linked via the Asci site and inserted into SfiI-NotI digested vector pDAP2 (Kerschbaumer R. J. et al, Immuno-technology 2, 145–150, 1996; GeneBank accession No.:U35316).

FIG. 30 shows the nucleotide and amino acid sequence of the mAB #8860 scFv-leucine zipper fusion protein

5

(miniantibody; vector p8860-Zip#1.2, (SEQ.ID.NOS. 95 and 96). The gene of the scFv fragment was derived from mAB #8860 and was swapped from vector pDAP2-8860scFv#11 into SfiI-NotI digested plasmid pZip1 (Kerschbaumer R. J. et al., Analytical Biochemistry 249, 219–227, 1997; GeneBank accession No.: U94951)

FIG. 31 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) miniantibody 198AB-Zip#102 in the presence of 2.3 nM human FIXa. As a positive control 4.5 pM FVIII was used whereas a unrelated miniantibody (8860-Zip#1.2) and plain reaction buffer (IZ) served as negative controls.

FIG. 32 shows a schematic representation of the plasmid pMycHis6 (SEQ ID NOS:107–110).

FIG. 34 shows the nucleotide and amino acid sequence of 198AB2 scFv (linked to the c-myc-tag and the His6tag): ORF of the expression vector pMycHis6-198AB2#102. Vector pMycHis6 was constructed by cleaving vector pCOCK (Engelhardt O. et al, BioTechniques 17, 44-46, 1994) NotI-EcoRI and inserting the following annealed oligonucleotides: (5'-GGCGCAGAACAAAAACTCATCTCAGAA GAGGATCTGAATGGGGCGGCACATCA CCATCACCATCAATAAG-3' (SEQ.ID.No. 103) and 5'-TTATTAGTGTGGTGATGGT GATGTGCC GCCCCATTAGATCCTCTTGAGATGAGTTTG TTCTGC-3'(SEQ.ID.NO. 104)). The resultant vector, named pMycHis6, was cleaved SfiI-NotI and the gene of scFv 198AB2 was swapped into this vector from vector pDAP2-198AB2#100.

FIG. 35 shows the nucleotide and amino acid sequence of the mAB #8860 scFv linked to the c-myc-tag and the His6-tag (vector p8860-M/H#4c, SEQ.ID.NOS. 101 and 102). Plasmid pMycHis6 was cleaved with SfiI and NotI and the DNA sequence coding for the scFv 8860#11 protein was inserted from pDAP2-8860scFv#μ1 (see FIG. 29) yielding plasmid p8860-M/H#4c.

FIG. 36 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) scFv fragment (MycHis-198AB2#102) in the presence of 2.3 nM human FIXa. As a positive control 4.8 pM FVIII was used whereas a unrelated scFv (8860-M/H#4c) and plain reaction buffer (IZ) served as negative controls.

Antibodies and Antibody Derivatives

The present invention also comprises the nucleic acids encoding the inventive antibodies and antibody derivatives, expression vectors, hybridoma cell lines, and methods for producing the same.

Antibodies are immunoglobulin molecules having a specific amino acid sequence which only bind to antigens that induce their synthesis (or its immunogen, respectively) or to antigens (or immunogens) which are very similar to the former. Each immunoglobulin molecule consists of two types of polypeptide chains. Each molecule consists of large, identical heavy chains (H chains) and two light, also identical chains (L chains). The polypeptides are connected by disulfide bridges and non-covalent bonds. In vivo, the heavy and light chains are formed on different ribosomes, assembled in the cell, and secreted as intact immunoglobulins (Roitt I. et al., in: Immunology, second ed., 1989).

6

The inventive antibodies and antibody derivatives and organic compounds derived there from comprise human and animal monoclonal antibodies or fragments thereof, single chain antibodies and fragments thereof and minibodies, 5 bispecific antibodies, diabodies, triabodies, or di-, oligo- or multimers thereof. Also included are peptidomimetics or peptides derived from the antibodies according to the invention, e.g. they comprise one or several CDR regions, preferably the CDR3 region.

10 Further included are human monoclonal antibodies and peptide sequences which, based on a structure activity connection, are produced through an artificial modeling process (Greer J. et al., J. Med. Chem., 1994, Vol. 37, pp. 1035-1054).

15 The term factor IX/IXa activating antibodies and antibody derivatives may also include proteins produced by expression of an altered, immunoglobulin-encoding region in a host cell, e.g. "technically modified antibodies" such as synthetic antibodies, chimeric or humanized antibodies, or

20 mixtures thereof, or antibody fragments which partially or completely lack the constant region, e.g. Fv, Fab, Fab' or F(ab)₂ etc. In these technically modified antibodies, e.g., a part or parts of the light and/or heavy chain may be substituted. Such molecules may, e.g., comprise antibodies consisting of a humanized heavy chain and an unmodified light chain (or chimeric light chain), or vice versa. The terms Fv, Fc, Fd, Fab, Fab' or F(ab)₂ are used as described in the prior art (Harlow E. and Lane D., in "Antibodies, A Laboratory Manual", Cold Spring Harbor Laboratory, 1988).

30 The present invention also comprises the use of Fab fragments or F(ab)₂ fragments which are derived from monoclonal antibodies (mAb), which are directed against factor IX/factor IXa and cause an increase of the procoagulant activity of factor IXa.

35 Preferably, the heterologous framework regions and constant regions are selected from the human immunoglobulin classes and isotypes, such as IgG (subtypes 1 to 4), IgM, IgA and IgE. In the course of the immune response, a class switch of the immuno-globulins may occur, e.g. a switch
 40 from IgM to IgG; therein, the constant regions are exchanged, e.g. from p to y. A class switch may also be caused in a directed manner by means of genetic engineering methods ("directed class switch recombination"), as is known from the prior art (Esser C. and Radbruch A., Annu.
 45 Rev. Immunol., 1990, Vol. 8, pp. 717-735). However, the antibodies and antibody derivatives according to the present invention need not comprise exclusively human sequences of the immunoglobulin proteins.

In one particular embodiment, a humanized antibody 50 comprises complement determining regions (CDRs) from murine monoclonal antibodies which are inserted in the framework regions of selected human antibody sequences. However, human CDR regions can also be used. Preferably, the variable regions in the human light and heavy chains are 55 technically altered by one or more CDR exchanges. It is also possible to use all six CDRs or varying combinations of less than six CDRs.

The humanized antibody according to the present invention preferably has the structure of a human antibody or of a fragment thereof and comprises the combination of characteristics necessary for a therapeutic application, e.g., the treatment of coagulation disorders in patients, preferably factor VIII inhibitor patients.

A chimeric antibody differs from a humanized antibody in that it comprises the entire variable regions including the framework regions of the heavy and light chains of non-human origin in combination with the constant regions of

both chains from human immuno-globulin. A chimeric antibody consisting of murine and human sequences may, for example, be produced. According to the present invention, the antibodies and antibody derivatives may also be single chain antibodies or minibodies (scFv fragments; which, e.g., are linked to proline-rich sequences and oligomerisation domains, e.g. Pluckthun A. and Pack P., Immuno-technology, 1997, Vol. 3, pp. 83–105) or single chain Fv (sfFv) which incorporate the entire antibody binding region in one single polypeptide chain. For instance, single chain antibodies may be formed by linking the V-genes to an oligonucleotide which has been constructed as a linker sequence and connects the C terminus of the first V region with the N terminus of the second V region, e.g. in the arrangement VH-Linker-VL or VL-Linker-V_H; both, V_H and V_L thus may represent the N-terminal domain (Huston JS et al., Int. Rev. Immunol., 1993, Vol. 10, pp. 195–217; Raag R. and Whitlow M., FASEB J., 1995, Vol. 9, pp. 73–80). The protein which can be used as linker sequence may, e.g., have a length of up to 150 Å, preferably up to 80 Å, and more preferably up to 40 Å. Linker sequences containing glycine and serine are particularly preferred for their flexibility, or glutamine and lysine, respectively, for their solubility. The choice of the amino acid is effected according to the criteria of immunogenicity and stability, also depending on whether or not these single chain antibodies are to be suitable for physiological or industrial applications (e.g. immunoaffinity chromatography). The single chain antibodies may also be present as aggregates, e.g. as trimers, oligomers or multimers. The linker sequence may, however, also be missing, and the connection of the V_H and V_L chains may occur directly.

Bispecific antibodies are macromolecular, heterobifunctional cross-linkers having two different binding specificities within one single molecule. In this group belong, e.g., bispecific (bs) IgGs, bs IgM-IgAs, bs IgA-dimers, bs (Fab')₂, bs(scFv)₂, diabodies, and bs bis Fab Fc (Cao Y. and Suresh M. R., Bioconjugate Chem., 1998, Vol. 9, pp. 635–644).

By peptidomimetics, protein components of low molecular weight are understood which imitate the structure of a natural peptide component, or of templates which induce a specific structure formation in an adjacent peptide sequence (Kemp DS, Trends Biotechnol., 1990, pp. 249–255). The peptidomimetics may, e.g., be derived from the CDR3 domains. Methodical mutational analysis of a given peptide sequence, i.e. by alanine or glutamic acid scanning mutational analysis, allows for the identification of peptide residues critical for procoagulant activity. Another possibility to improve the activity of a certain peptide sequence is the use of peptide libraries combined with high throughput screening.

The term antibodies and antibody derivatives may also comprise agents which have been obtained by analysis of data relating to structure-activity relationships. These compounds may also be used as peptidomimetics (Grassy G. et al., Nature Biotechnol., 1998, Vol. 16, pp. 748–752; Greer J. et al., J. Med. Chem., 1994, Vol. 37, pp. 1035–1054).

Examples of hybridoma cells expressing the antibodies or antibody derivatives according to the invention were deposited on 9 Sep. 1999 under the numbers 99090924 (#198/A1), 99090925 (#198/B1) and 99090926 (#198/B1) and on Dec. 16, 1999 under the numbers 99121614 (#193/A0), 99121615 (#196/c4), 99121616 (#198/D1), 99121617 (198/T2), 99121618 (#198/G2), 99121619 (#198/AC1) and 99121620 (#198/U2) according to the Budapest Treaty.

Methods of Production:

The antibodies of the present invention can be prepared by methods known from the prior art, e.g. by conventional

hybridoma techniques, or by means of phage display gene libraries, immunoglobulin chain shuffling or humanizing techniques (Harlow E. and Lane D., in: Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). The production of the inventive antibodies and antibody derivatives may, for instance, be made by conventional hybridoma techniques (Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, Eds. Harlow and Lane, pp. 148–242). According to the present invention, human and also non-human species may be employed therefor, such as cattle, pigs, monkeys, chickens and rodents (mice, rats). Normal, immunocompetent Balb/c mice or FIX-deficient mice may, e.g., be used (factor IX-deficient mice may be obtained from Dr. Darrel Stafford from the University of North Carolina, Chapel Hill). Immunization may, e.g., be effected with factor IX, factor IXaα or completely activated factor IXaβ, or with fragments thereof.

The hybridomas are selected with a view to the fact that the antibodies and antibody derivatives in the supernatants of the hybridoma cells bind to factor IX/factor IXa and cause an increase of the procoagulant activity of factor IXa. The increase in the procoagulant activity may, e.g., be proven by assaying methods as known from the prior art for the measurement of factor VIII-like activity, e.g. chromogenic assays.

Alternatively, the antibodies and antibody derivatives of the invention may also be produced by recombinant production methods. In doing so, the DNA sequence of the antibodies according to the invention can be determined by known techniques, and the entire antibody DNA or parts thereof can be expressed in suitable systems. Recombinant production methods can be used, such as those involving phage display, synthetic and natural libraries, expression of the antibody proteins in known expression systems, or expression in transgenic animals (Jones et al., Nature, 1986, Vol. 321, pp. 522–525; Phage Display of Peptides and Proteins, A Laboratory Manual, 1996, Eds. Kay et al., pp. 127–139; U.S. Pat. No. 4,873,316; Vaughan T. J. et al., Nature Biotechnology, 1998, pp. 535–539; Persic L. et al., Gene, 1997, pp. 9–18; Ames R. S. et al., J. Immunol. Methods, 1995, pp. 177–186).

The expression of recombinantly produced antibodies may be effected by means of conventional expression vectors, such as bacterial vectors, such as pBr322 and its derivatives, pSKF or eukaryotic vectors, such as pMSG and SV40 vectors. Those sequences which encode the antibody may be provided with regulatory sequences which regulate the replication, expression and secretion from the host cell. These regulatory sequences comprise promoters, e.g. CMV or SV40, and signal sequences.

The expression vectors may also comprise selection and amplification markers, such as the dihydrofolate reductase gene (DHFR), hygromycin-B phosphotransferase, thymidine-kinase etc.

The components of the vectors used, such as selection markers, replicons, enhancers etc., may either be commercially obtained or prepared by means of conventional methods. The vectors may be constructed for the expression in various cell cultures, e.g. for mammalian cells such as CHO, COS, fibroblasts, insect cells, yeast or bacteria, such as *E. coli*. Preferably, those cells are used which allow for an optimal glycosylation of the expressed protein. Particularly preferred is the vector pBax (cf. FIG. 17) which is expressed in CHO cells or in SK-Hep.

The production of Fab fragments or F(ab)₂ fragments may be effected according to methods known from the prior art, e.g. by cleaving a mAb with proteolytic enzymes, such as

papain and/or pepsin, or by recombinant methods. These Fab and F(ab)₂ fragments may also be prepared by means of a phage display gene library (Winter et al., 1994, Ann. Rev. Immunol., 12: 433–455).

The antibody derivatives may also be prepared by means of methods known from the prior art, e.g. by molecular modeling, e.g. from Grassy G. et al., Nature Biotechnol., 1998, Vol. 16, pp. 748–752, or Greer J. et al., J. Med. Chem., Vol. 37, pp. 1035–1054, or Rees A. et al., in: "Protein Structure Prediction: A practical approach", ed. Sternberg M. J. E., IRL press, 1996, chapt. 7–10, pp. 141–261.

The purification of the inventive antibodies and antibody derivatives may also be carried out by methods described in the prior art, e.g., by ammonium sulfate precipitation, affinity purification (protein G-Sepharose), ion exchange chromatography, or gel chromatography. The following methods may be used as the test methods to show that the antibodies and antibody derivatives of the present invention bind to factor IX/factor IXa, increase the procoagulant activity of factor IXa or have factor VIII-like activity: the one step coagulation test (Mikaelsson and Oswaldson, Scand. J. Haematol., Suppl., 33, pp. 79–86, 1984) or the chromogenic tests, such as COATEST VIII:C® (Chromogenix) or Immunochrom (IMMUNO). In principle, all the methods used for determining factor VIII activity may be used. As the control blank value for the measurements, e.g., unspecific mouse-IgG antibody may be used.

The present antibodies and antibody derivatives are suitable for therapeutic use in the treatment of coagulation disorders, e.g. in the case of hemophilia A, for factor VIII inhibitor patients etc. Administration may be effected by any method suitable to effectively administer the therapeutic agent to the patient, e.g. by oral, subcutaneous, intramuscular, intravenous or intranasal administration.

Therapeutic agents according to the invention may be produced as preparations which comprise a sufficient amount of antibodies or of antibody derivatives as the active agent in a pharmaceutically acceptable carrier substance. These agents may be present either in liquid or in powdered form. Moreover, the preparations according to the invention may also comprise mixtures of different antibodies, the derivatives thereof and/or organic compounds derived therefrom, as well as mixtures consisting of antibodies and factor 1x and/or factor IXa. Factor IXa may be present as factor IXa α and/or factor IXa β . An example of an aqueous carrier substance is, e.g., saline. The solutions are sterile, sterilisation being effected by conventional methods.

The antibodies or antibody derivatives according to the invention may be present in lyophilized form for storage and be suspended in a suitable solvent before administration. This method has proven generally advantageous for conventional immunoglobulins, and known lyophilisation and reconstitution methods may be applied in this case.

Moreover, the antibodies and antibody derivatives according to the invention may also be used for industrial applications, e.g. for the purification of factor IX/factor IXa by means of affinity chromatography, or as a component of detection methods (e.g. ELISA assays), or as an agent for identification of and interaction with functional domains of a target protein.

The present invention will be described in more detail by way of the following examples and drawing figures, to which, however, it shall not be restricted.

EXAMPLES

Example 1

Immunization of Immunocompetent Mice and Generation of Anti-FIX/IXa Antibody Secreting Hybridoma Cells

Groups of 1–3 normal immunocompetent 5–8 week old Balb/c mice were immunized with 100 µg antigen (100 µl

doses) via the intraperitoneal (i.p.) route. In a typical experiment, mice were inoculated with either recombinant human coagulation factor (F) IX (Benefix™), human activated FIXa α (Enzyme Research Laboratories, Lot: FIXa α 1190L) or human FIXa β (Enzyme Research Laboratories, Lot: HFIXAa β 1332 AL,) adjuvanted with Al(OH)₃ or KFA.

Individual mice were boosted at various times with 100 µg antigen (10011 doses, i.p) and sacrificed two days later. Spleen cells were removed and fused to P3×63-Ag8 6.5.3 myeloma cells essentially as described by Lane et al., 1985 (J. Immunol. Methods, Vol. 81, pp. 223–228). Each fusion experiment was individually numbered, i.e. #193, 195, 196 or 198.

Hybridoma cells were grown in 96 well plates on a macrophage feeder layer (app. 10⁵ cells/ml) and selected in HAT-medium (RPMI-1640 medium supplemented with antibiotics, 10% FCS, Na-pyruvate, L-glutamine, 2-mercaptoethanol and HAT (HAT 100x: 1.0×10⁻²M hypoxanthine in H₂O (136.1 mg/100 ml H₂O), 4.0×10⁻⁵M amidopterin in H₂O (1.76 mg/100 ml H₂O) and 1.6×10⁻³M thymidine in H₂O (38.7 mg/100 ml H₂O)). Medium was first changed after 6 days and thereafter twice a week. After 2–3 weeks HAT-medium was changed to HT-medium (RPMI-1640 supplemented with antibiotics, 10% FCS, Na-pyruvate, L-glutamine, 2-mercaptoethanol and HT) and later on (after additional 1–2 weeks) to normal growth medium (RPMI-1640 medium supplemented with 10% FCS, Na-pyruvate, L-glutamine and 2-mercaptoethanol) (see: HYBRIDOMA TECHNIQUES, EMBO, SKMB Course 1980, Base1).

In another set of experiments FIX deficient C57B16 mice (Lin et al., 1997, Blood, 90: 3962) were used for immunization and subsequent hybridoma production. Since FIX knockout (k.o.) mice do not express endogenous FIX, the anti (a)-FIX antibody spectrum achievable is supposed to be different compared to normal Balb/c mice (due to lack of tolerance).

Example 2

Assaying for FVIII-like Activity in Supernatants of Anti-Fix/FIXa Antibody Secreting Hybridoma Cells

In order to assay the FVIII-like activity of anti-FIXa antibodies secreted by hybridoma cells, the commercially available test-kit COATEST VIII:C/4® (Chromogenix) was employed. The assay was done essentially as described by the manufacturer with the following modifications:

To allow high throughput screening, the assay was down-scaled to microtiter plate format. Briefly, 25 µl aliquots of hybridoma supernatants were transferred to microtiter plate (Costar, #3598) wells and warmed to 37° C. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (1–2581), factor (F) IXa and FX were reconstituted in sterile water and FIXa/FX was mixed with phospholipids according to the supplier's protocol. Per reaction, 50 µl of the phospholipid/FIXa/FX solution were combined with 25 µl CaCl₂ (25 mM) and 50 µl of the substrate/inhibitor cocktail. To start the reaction, 125 µl of the premix were added to the hybridoma supernatant in the microtiter plates and incubated at 37° C. Absorbency at 405 nm and 490 nm of the samples was read at various times (30 min to 12 h) against a reagent blank (MLW, cell culture medium instead of hybridoma supernatant) in a Labsystems iEMS Reader MFTM microtiter plate reader. FVIII-like activity of the samples was calculated by comparing the absorbency of the samples against the absorbency of a diluted FVIII reference standard (IMMUNO AG # 5T4AR00) using GENESIS™ software.

11

The results of a screening for FVIII-like activity in hybridoma cell culture supernatants are shown in FIG. 1. Pre-selected clones derived from fusion experiments #193, #195 and #196 (see above) were examined in a chromogenic FVIII assay as described. Clones 193/M1, 193/N1 and 193/P1 are subclones derived from the master clone 193/C0 (see below). Master clone 195/10 was derived from fusion experiment #195 and clones 196/A0, 196/B0 and 196/C0 were derived from fusion experiment #196. In a typical screening experiment, approximately 1000 clones (in 96 wells) from a single fusion experiment were pre-screened for FVIII-like activity. Subsequently, selected clones were grown on a larger scale (3–5 ml supernatant) and re-analyzed in a chromogenic assay. As a negative control cell culture medium was assayed on each plate (MLW).

Wells either exhibiting high FVIII-like activity or substantial FVIII-like activity were subjected to subcloning procedures. The selection and subcloning process is exemplified for the screening and subcloning of an IgG producing cell line (i.e. 193/C0) but has been done exactly the same way for an IgM (i.e. 196/C0, see below, FIG. 5) producing clone.

The selection process was done by initially plating all hybridoma cell clones derived from a single fusion experiment on ten 96 well plates thereby creating the so called “master plates”. Singular positions (wells) on a master plate usually contained more than one hybridoma cell clone (usually 3 to 15 different clones). Subsequently, the antibody secreted by only several thousand cells was tested. These cells grew under conditions suboptimal for antibody production, which is known to be best in dying cells. So the expected specific anti-FIX antibody concentration in the supernatant may be in the range of 10–12 to 10–14 M. This explains why incubation periods had to be extended compared to standard FVIII assays.

Results of a screening for an IgG mediated FVIII-like activity in hybridoma cell culture supernatants of a master plate are shown in FIG. 2. Supernatants were examined in a chromogenic FVIII assay. Shown are the results derived from the fifth master plate of fusion experiment number #193 (Balb/c mice immunized with FIX α). Absorbance was read after 4 hours of incubation at 37° C. Position ES was identified as exhibiting FVIII like activity significantly higher than the blank (MLW). This cell pool was designated 193/C0 and was further subcloned (FIG. 3). As each well of the master plate contains more than one hybridoma cell clone, cells of a single positive well were expanded and plated at a calculated cell density of 2–0.2 cells/well on a 96 well plate. Again, the supernatants were tested for FVIII-like activity and positive positions were subjected to another round of subcloning. Typically three to four rounds of subcloning were performed with each clone displaying FVIII-like activity to obtain homogenous cell populations. Here the results of the chromogenic assay of the 193/C0 subclones are shown. Absorbance was read after a 4 hour incubation period at 37° C. Positions A6 and D5 exhibited substantial FVIII-like activity and were named 193/M1 and 193/P1, respectively. These two clones were subjected to another round of subcloning. As a negative control plain cell culture medium was assayed on each plate (MLW(H1)).

A comparison of chromogenic FVIII-like activity and FIX-ELISA reactivity of small scale (3 ml) hybridoma cultures is shown in FIG. 4. Before a decision was made whether a master clone (or subclone) was to be further subcloned, clones were grown at a 3–5 ml scale and the supernatants were checked again. This graph shows the FIX specific ELISA results and the FVIII-like chromogenic

12

activity of the master clone 193/C0 and all its subclones which were identified as positives and re-checked. Blanks (absorbency of the chromogenic reagent itself) were subtracted in the case of the ELISA as well as the chromogenic assay readings depicted here. Clone 193/M1 was subcloned and yielded clones 193/V2, 193/M2 and 193/U2. The other clones of the 2nd round came from 193/P1, 193/AB2 and 193/P2 were subcloned. 193/AF3, 193/AB3 and 193/AE3 are subclones of 193/AB2. The other clones of the 3rd round came from 193/P2. Finally 193/AF3 (\rightarrow 193/AF4), AE3 (\rightarrow 193/AE4, 193/AL4, 193/AN4 and 193/AO4) and 193/AD3 (\rightarrow 193/AG4, 193/AH4, 193/AD4, 193/AI4, 193/AK4) were subcloned.

From each fusion experiment, several (5–15) master clones (selected from the master plate) were identified and subjected to subcloning. After 3 rounds of sub-cloning, most of the cell lines were homogenous as demonstrated by ELISA and chromogenic activity analysis (see FIG. 4) as well as by cDNA sequence analysis. A specific master clone and all its subclones produce the same FIX/FIXa binding antibody. However, there are huge differences in the antibody protein sequences of clones derived from different master clones (see Example 11). Most hybridoma cell lines express antibodies from the IgG subclass (i.e. clones #193, #198, like 198/A1, 198/B1, 198/BB1). However, we were also able to select some clones expressing IgM antibodies.

The chromogenic activity of hybridoma supernatant of some important master clones and subclones was determined. Absorbance was measured after a 1 h 30 min and 3 h 30 min incubation period at 37° C. (FIG. 5). In contrast to all the clones from the 193rd fusion, clone 196/C0 and its subclone 196/AP2 produced a FIX/FIXa-specific IgM antibody that gave a strong chromogenic activity even after a short period of incubation.

The following cell lines have been deposited with the European Collection of Cell Cultures (ECACC) in accordance with the Budapest Treaty: 198/B1 (ECACC No. 99090925, deposited Sep. 9, 1999); 198/A1 (ECACC No. 99090924, deposited Sep. 9, 1999); 198/BB1 (ECACC No. 99090926, deposited Dec. 16, 1999); 193/AO (ECACC No. 99121614, deposited Dec. 16, 1999); 196/C4 (ECACC No. 99121615, deposited Dec. 16, 1999); 198/DI (ECACC No. 99121616, deposited Dec. 16, 1999); 198/T2 (ECACC No. 99121617, deposited Dec. 16, 1999); 198/G2 (ECACC No. 99121618, deposited Dec. 16, 1999); 198/AC1 (ECACC No. 99121619, deposited Dec. 16, 1999); and 198/U2 (ECACC No. 99121620, deposited Dec. 16, 1999). The address of the ECACC is Salisbury, Wiltshire SP4 OJG, UK.

To do a more in depth analysis of the biochemical properties of certain antibodies, homogenous hybridoma cell lines expressing different antibodies with FVIII-like activity were expanded and used to express the antibody in question on a larger scale (100–1000 ml). These antibodies were affinity purified (see Example 3) prior to being used in further experiments.

Example 3

Factor IX/FIX $\alpha_{(\alpha,\beta)}$ Binding Properties of Antibodies Exhibiting FIX/FIXa Activating Activity

Factor IX and the two activated forms of FIX, FIX α and FIX β (FIX/FIX $\alpha_{(\alpha,\beta)}$) were diluted in TBS (25 mM Tris HCl, 150 mM NaCl, pH 7.5) to a final concentration of 2 μ g/ml. Nunc Maxisorp ELISA plates were coated with 100 μ l FIX/FIX $\alpha_{(\alpha,\beta)}$ solution according to standard procedures (4° C., overnight) and washed several times with TBST

13

(TBS, 0.1% (v/v) Tween 20), 50 µl hybridoma supernatant was diluted 1:1 with 50 µl TBST/2% BSA and added to the coated ELISA plate. After an incubation period of 2 h at room temperature (RT), plates were washed 4 times with TBST and incubated (2 h, RT) with 100 µl/well of a 1:25000 dilution (in TBST/1% BSA) of an anti-mouse IgG (Fc-specific) peroxidase conjugated antibody (Sigma, #A-0168). Wells were washed 5 times with TBST and finally stained with 100 µl freshly prepared staining solution (10 ml 50M sodium citrate, pH 5 supplemented with 100 µl OPD (60 mg OPD/ml) and 10 µl 30% H₂O₂). The reaction was stopped by the addition of 50 ml H₂S₄ and the optical density recorded at 492 nm and 620 nm in a Labsystems iEMS Reader MF™ microtiter plate reader employing GENESIS™ software.

In certain cases, instead of an anti-mouse IgG ELISA, an anti-mouse IgM ELISA was carried out.

Purification of Mouse-IgG from Hybridoma Cell Culture Supernatants

Hybridoma supernatant (100–500 ml) was supplemented with 200 mM Tris/HCl buffer (pH 7.0) and solid NaCl to give final concentrations of 20 mM Tris and 3M NaCl, respectively. The supernatant was then clarified by centrifugation at 5500×g for 10 minutes. A 1 ml protein G affinity chromatography column (Protein G Sepharose Fast Flow, Amersham-Pharmacia) was washed with 15 ml 20 mM Tris/Cl pH 7.0 and afterwards equilibrated with 10 ml of 20 mM Tris/Cl buffer pH 7.0 containing 3M NaCl. The hybridoma supernatant containing 3M NaCl was then loaded onto the column by gravity. The column was washed with 15 ml of 20 mM Tris/Cl buffer, pH 7.0, containing 3M NaCl. Bound IgG was further eluted with 12 ml glycine/HCl buffer pH 2.8 and 1 ml fractions were collected. 100 µl of 1M Tris pH 9.0 were added to each fraction for neutralization. Fractions containing the IgG were identified by mixing 50>1 with 150 µl of a staining solution (BioRad concentrate, 1:5 diluted with water) in wells of a microplate. Positive fractions were pooled, concentrated to 1 ml in an ultrafiltration concentrator device (Centricon Plus 20, Amicon) according to the manufacturer. The concentrate was diluted with 19 ml TBS (20 mM Tris/Cl buffer pH 7.0 containing 150 mM NaCl) and again concentrated to 1 ml. The diluting/concentrating step was repeated for two more times in order to bring IgG into TBS.

Purification of Mouse-IgM from Hybridoma Cell Supernatants

100–500 ml of hybridoma cell culture supernatant were concentrated to 5–10 ml either with an ultra-filtration concentrator device (Centricon Plus 20, Amicon) according to the manufacturer or by ammonium sulfate precipitation (40% saturation, 0° C.) and redissolving the precipitate with 5–10 ml of TBS. In either case the concentrate was dialyzed against 20 mM Tris Cl buffer pH 7.4 containing 1.25M NaCl and further concentrated to 1 ml in a Centricon Plus 20, (Amicon) ultrafiltration device. IgM was purified from this concentrate with the Immunopure IgM Purification Kit (Pierce) according to the manufacturer. Fractions collected during elution from the maltose binding protein-column were tested for IgM, pooled, concentrated and brought into TBS as described for IgG.

Determination of IgG Concentrations in Purified Preparations

Total IgG content 280 nm-extinction of appropriate dilutions were measured. E280=1.4 corresponds to 1 mg/ml protein.

Factor IXa Specific IgG (Quantitative ELISA)

Wells of a microplate (Nunc Maxisorp) were incubated with 2 µg/ml factor IXa diluted in TBS (25 mM Tris/HCl pH

14

7.5 containing 150 mM NaCl) overnight at 4° C. Wells were washed four times with TBST (25 mM Tris/HCl pH 7.5 containing 150 mM NaCl and 0.1% (v/v) Tween 20). As a standard monoclonal AB the HIX1 anti-FIX (accurate) was used. Standard and samples were diluted in TBST containing 2% (w/v) BSA. The standard dilution series and appropriate dilutions of the samples were incubated on the ELISA-plate for 2 hours at room temperature. Plates were washed 4 times with TBST and incubated (2 h, RT) with 100 µl/well of a 1:25000 dilution (in TBST/1% BSA) of an anti-mouse IgG (Fc-specific) peroxidase conjugated antibody (Sigma, #A-0168) FIXa. Wells were washed 5 times with TBST and finally stained with 100 µl freshly prepared staining solution (10 ml 50 mM sodium citrate, pH 5 supplemented with 100 µl OPD (60 mg OPD/ml) and 10 µl 30% H₂O₂). The reaction was stopped by the addition of 50 ml H₂SO₄ and after 30 minutes the optical density was recorded at 492 nm and 620 nm in a Labsystems iEMS Reader MF™ microtiter plate reader employing GENESIS™ software.

Example 4

Anti-FIX/FIXa Antibodies Exhibiting FVIII-like Activity in a Chromogenic FVIII Assay

Several anti-FIX/FIXa antibody producing hybridoma clones were subcloned up to four times and the resulting monoclonal hybridoma cell line used to produce monoclonal antibody containing supernatant. IgG isotype antibodies derived from these supernatants were purified over affinity columns and dialyzed against TBS (see above). IgM antibodies were used as unpurified supernatant fractions. The following experiments were done with two sets of representative antibodies: 193/AD3 and 198/AC1/I (IgG isotype, the antibody 198/AC1/I is a preparation from the parent 198/AC1 hybridoma clone, i.e. that a (frozen) vial containing 198/AC1 cells is cultivated and antibodies are produced. The supernatant is then used for these experiments.) and 196/AF2 and 196/AF1 (IgM isotype) (FIG. 6A and FIG. 6B). Briefly, 25 µl aliquots of monoclonal antibody containing sample (unpurified hybridoma supernatant or, where indicated, a certain amount of FIX specific antibody) were transferred to microtiter plate wells and warmed to 37° C. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (I-2581), factor (F) IXa and FX were reconstituted in sterile water and FIXa/FX was mixed with phospholipids according to the supplier's protocol. Per reaction, 50 µl of the phospholipid/FIXa/FX solution were combined with 25 µl CaCl₂ (25 mM) and 50 µl of the substrate/inhibitor cocktail. To start the reaction, 125 µl of the premix were added to the monoclonal antibody solution in the microtiter plates and incubated at 37° C. Absorbance at 405 nm and 490 nm of the samples was read at various times (5 min to 6 h) against a reagent blank (cell culture medium instead of hybridoma supernatant) in a Labsystems iEMS Reader MF™ microtiter plate reader using GENESIS™ software.

The time course of FVIII-like activity exhibited by monoclonal antibodies 193/AD3 (IgG isotype) and 196/AF2 (IgM isotype) compared to human FVIII (12 and 16 mU/ml), TBS and to cell culture medium is shown in FIG. 6A. After a lag phase, both antibodies give rise to chromogenic substrate cleavage, as judged by the increasing optical density measurable at 405 nm wavelength.

The time course of FVIII-like activity exhibited by monoclonal antibodies 198/AC1/I (IgG isotype, 10 µg/ml) and 196/AF1 (IgM isotype, unpurified supernatant) compared to human FVIII (16 mU/ml) and 10 µg/ml of mouse IgG is

15

shown in FIG. 6B. After a lag phase, both antibodies give rise to chromogenic substrate cleavage, as judged by the increasing optical density measurable at 405 nm wavelength.

Example 5

FVIII-like Activity Exhibited by Anti-FIX/FIXa-antibodies Generates Factor Xa and is Phospholipid, FIXa/FX and Ca²⁺ Dependent

Factor VIII activity is usually determined with a chromogenic assay and/or an APTT-based clotting assay. Both types of assays rely on FVIIIa/FIXa-mediated factor Xa generation. In the case of a chromogenic FVIII assay, the factor Xa produced will subsequently react with a chromogenic substrate, which can be monitored spectroscopically, e.g., in an ELISA reader. In an APTT based clotting assay free factor Xa will assemble with FVa on a phospholipid surface in the so-called prothrombinase complex and activate prothrombin to thrombin. Thrombin in turn gives rise to fibrin generation and finally to clot formation. Central to the two assay systems is generation of factor Xa by the FVIIIa/FIXa complex.

To demonstrate that the FVIII-like activity exhibited by anti-FIX/FIXa-antibodies indeed generates factor Xa, the following experiment was carried out. Several 25 µl aliquots of unpurified hybridoma supernatant 196/AF2 (IgM isotype) were transferred to microtiter plate wells and warmed to 37° C. As a positive control, 16mU of Recombinate™ were diluted into hybridoma medium (196 HM 007/99) and treated exactly the same way as the hybridoma supernatant. As a negative control, plain hybridoma medium was used. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (I-2581), factor IXa and FX were reconstituted in sterile water and FIXa/FX was mixed with phospholipids according to the supplier's protocol. Pefabloc Xa®, a factor Xa specific proteinase inhibitor (Pentapharm, LTD), was reconstituted with water to a final concentration of 1 mM/l. Per reaction, 5011 of the phospholipid/FIXa/FX solution were combined with 25 µl CaCl₂ (25 mM) and 50 µl of the substrate/thrombin-inhibitor cocktail. To start the reaction, 125 µl of the premix were added to the samples in the microtiter plates and incubated at 37° C. Where indicated, 35 µM Pefabloc Xa® were added. Absorbance at 405 nm and 490 nm was read at various times (every 5 minutes to 6 h) against a reagent blank (cell culture medium) in a Labsystems iEMS Reader MF™ microtiter plate reader employing the GENESIS™ software.

The results of the factor IXa stimulation by the FVIII-like activity exhibited by the IgM anti FIX/FIXa-antibody 196/AF2 in generating factor Xa as judged by the readily measurable cleavage of the chromogenic substrate S-2222 (compare "16 mU FVIIIP" and "196/AF2") is shown in FIG. 7A. Factor Xa activity is effectively blocked by the FXa specific inhibitor "Pefabloc Xa®" (compare "196/AF2" versus "196/AF2 351M Pefabloc Xa®") indicating that indeed FXa was generated.

The same experiment was performed using purified IgG preparations of clone 198/AM1 (FIG. 7B). Purified IgG was diluted in TBS to a final concentration of 0.4 mg/ml and 25 µl (i.e. a total of 10 µg), transferred to microtiter plate wells and warmed to 37° C. As a positive control, 6 mU plasma derived FVIII was used. 10 µg unspecific mouse IgG (Sigma, I-5381) served as a negative control. The assay was performed as described above.

Further experiments show the factor IXa stimulation by the FVIII-like activity exhibited by the IgG anti-FIX/FIXa-

16

antibody 198/AM1 generates factor Xa as judged by the readily measurable cleavage of the chromogenic substrate S-2222 (FIG. 7B). Again factor VIII and antibody 198/AM1 generate FXa which is effectively blocked by the FXa specific inhibitor "Pefabloc Xa®". As a negative control, unspecific mouse IgG (Sigma, 15381) was assayed.

In another set of experiments, the dependence of the FVIII-like activity of either purified anti-FIX/FIXa-antibodies (IgM, FIG. 8A) or of unpurified antibodies (10 derived from cell culture supernatants (IgG, FIG. 8B) on the presence of phospholipids (PL), FIXa/FX and Ca²⁺ was demonstrated. Mouse IgG was used as a control (FIG. 8C). Factor VIII-like activity was assayed essentially as described above. When indicated, either the FIXa/FX mixture, the PL or Ca²⁺ was omitted from the reaction. Absorbency at 405 nm and 490 nm of the samples was read at various times against a reagent blank (buffer instead of purified antibody) in a Labsystems iEMS Reader MF™ microtiter plate reader. The results are shown in FIG. 8A, 15 FIG. 8B and FIG. 8C.

The dependence of the FVIII-like activity of purified anti-FIXa-antibody 198/AC1/1 (IgG isotype, concentration used throughout the assay was 10 µg/ml) on the presence of phospholipids (PL), FIXa/FX and Ca²⁺ is further shown in 20 FIG. 8A. As is easily recognizable, only the complete assay, including antibody, PL, Ca²⁺, and FIXa/FX gives rise to a reasonable FXa generation. The dependence of the FVIII-like activity of cell culture supernatant containing unpurified IgM isotype anti-FIX/FIXa-antibody (196/AF1) on the presence of phospholipids, FIXa/FX and Ca²⁺ is shown in FIG. 25 8B.

Again, as already shown for the purified IgG preparation (FIG. 8A), antibody 198/AC1/1, only the complete assay, including PL, Ca²⁺, FIXa/FX, will give a reasonable amount 30 of FXa generation. To demonstrate the specificity of the reaction, total IgG prepared from normal mouse plasma was assayed under the same conditions as above. The results are shown in FIG. 8C. No FVIII-like activity could be detected. There is, as expected, no activity detectable in the absence of phospholipids, FIXa/FX and Ca²⁺. All experiments were done in a microtiter plate and the OD405 was scanned every 35 5 minutes for 6 h.

Example 6

Certain anti-FIX/FIXa-antibodies are procoagulant in the presence of FIXa

During normal hemostasis, FIX becomes initially activated either by the tissue factor (TF)/factor VIIa pathway or later on by activated factor XI (FXIa). Subsequent to its activation, FIXa associates on the platelet surface in a membrane bound complex with activated FVIII. Factor IXa by itself has little or no enzymatic activity towards FX, but 50 becomes highly active in the presence of FVIIIa. To demonstrate that certain anti-FIX/FIXa antibodies have FVIII-like activity and hence are procoagulant in a FVIII deficient human plasma, the following experiment was carried out. Different amounts of antibody 193/AD3 or mouse IgG (as a control) were used in a standard aPTT based one stage clotting assay. Briefly, 100 µl of antibody-containing samples were incubated with 100 µl of FVIII deficient plasma (DP) and with 100 µl of DAPTTIN (PTT Reagent for determining activated Thromboplastin Time; IMMUNO 55 AG) reagent, in a KC10A clotting analyzer. Where indicated, a total amount of 50 ng activated FIX was included in the reaction mixture. After a 4 minute 60

17

incubation, the reaction was started by the addition of 100 µl CaCl₂ (25 mM). The results are shown in Table 1 and FIG. 9.

µg AB	clotting time (sec)	
	193/AD3 50 ng FIXa	mouse IgG 50 ngFIXa
9	101.6	102.5
4.5	95.6	103.2
2.25	93.1	103.2
1.8	93.7	101.9
1.35	91.4	103.4
0.9	94.4	102.2
0.45	98.1	101.9
0.34	97.1	103.9
0.23	99.3	103.7

Table 1: Clotting times of FVIII deficient plasma in an aPTT based clotting assay employing various amounts of procoagulant (193/AD3) and control antibody (mouse IgG) in the presence of 50 ng activated FIX (0.01UFIX). The molar ratio of antibody in the reaction and activated FIX is 10:1. The molar ratio between antibody and total FIX (FIX and FIXa, assuming that human FVIII deficient plasma contains 1 U (5% g) FIX) varies between 6:1 (9% g antibody in reaction) and 1:6 (0.23% g antibody in reaction). At the optimal shortening of the clotting time, the molar ratio between antibody and total FIX is 1:1. The clotting time without the addition of FIXa is in the range of 120 seconds.

FIG. 9 is a graphical representation of the clotting times of FVIII deficient plasma in an aPTT based clotting assay employing various amounts of procoagulant (193/AD3) and control (mouse IgG) antibody in the presence of 50 ng activated FIX. There is a clear dose-dependent reduction of the clotting time in samples supplemented with antibody 193/AD3. These results imply that antibody 193/AD3 is procoagulant in the presence of FIXa.

Example 7

Anti-FIX/FIXa-antibodies are Procoagulant in the Presence of FVIII Inhibitors and FIXa

A severe complication of the standard FVIII substitution therapy is the development of alloantibodies directed against FVIII, leading to FVIII neutralization and a condition where the patient's blood will not clot.

To demonstrate that certain anti-FIXa-antibodies have FVIII-like activity even in the presence of FVIII inhibitors, the following experiment was carried out. Different amounts of antibody 193/AD3 or, as a control, mouse IgG were used in a standard APTT based one-stage clotting assay. Briefly, 100 µl antibody samples were incubated with either 100 µl of FVIII deficient plasma (FIG. 10A) or FVIII inhibitor plasma (inhibitor potency 400 BU/ml), FIG. 10B) as well as with 100 µl of DAPTTIN reagent, in a KC10A clotting analyzer. In addition, a total amount of 50 ng activated FIXa was included in the reaction mixture. After a 4 minute incubation, the reaction was started by the addition of 100 µl CaCl₂ (25 mM). To ensure equal conditions, the experiments employing FVIII deficient plasma and FVIII inhibitor plasma were done side by side. The results are shown in FIGS. 10A and 10B. As already shown in Example 6, there is a clear dose-dependent reduction of the clotting time in samples supplemented with antibody 193/AD3 in the presence of FVIII inhibitors.

18

Example 8

Anti-FIX/FIXa-antibodies are Procoagulant in the Presence of Defective FVIII and FIXa

To demonstrate that certain anti-FIXa-antibodies have FVIII-like activity in the presence of defective FVIII, the following experiment may be carried out. Increasing amounts of antibody 193/AD3 or, as a control, mouse IgG are used in a standard aPTT-based one stage clotting assay. In this clotting assay, a hemophilia A patient's plasma having very low clotting activity due to the presence of defective FVIII (DF8) is used. Briefly, 100 µl antibody samples are incubated with either 100 µl of DF8 plasma or FVIII deficient plasma as well as with 100 µl of DAPTTIN reagent, in a KC10A clotting analyzer. In addition, a total amount of 50 ng activated FIXa is included in the reaction mixture. After a short incubation, the reaction will be started by the addition of 100 µl CaCl₂ (25 mM). To ensure equal conditions, the experiment employing FVIII deficient plasma and DF8 plasma is done side by side.

Example 9

Anti-FIX/FIXa-antibodies with Procoagulant Activity in the Presence of FIXa Distinguish Between Human and Bovine FIXa

FIX/FIXa specific monoclonal antibodies selected from the 198th fusion experiment were purified from the respective hybridoma supernatant and quantified as described in Example 3. These antibodies were analyzed in a modified one-stage clotting assay (as described in Example 6) and some showed procoagulant activity.

The chromogenic activity of these antibody preparations was measured in the following FXa generation kinetic assay: 10 µg of monoclonal antibody (in 25 µl) were transferred to microtiter plate wells and warmed to 37° C. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (I-2581), factor IXa and FX were reconstituted in sterile water and FIXa/FX (both bovine) were mixed with phospholipids according to the supplier's protocol. Per reaction, 50 µl of the phospholipid/FIXa/FX solution were combined with 25 µl CaCl₂ (25 mM) and 50 µl of the substrate/inhibitor cocktail. To start the reaction, 125 µl of the premix were added to the monoclonal antibody solution in the microtiter plates and incubated at 37° C. Absorbance at 405 nm and 490 nm of the samples was read at various times (5 min to 2 h) against a reagent blank (25 ml TBS instead of monoclonal antibodies) in a Labsystems iEMS Reader MFT™ microtiter plate reader using GENESIS™ software. In parallel, the same reactions were performed except that 50 ng human FIXa were added per reaction. Those antibodies that showed procoagulant activity had no chromogenic activity in the case of bovine FIX, but displayed high activity when human FIXa was present.

FIG. 11 shows the time course of the FVIII-like activity exhibited by the monoclonal antibodies 198/A1, 198/B1 and 198/AP1 with (+) and without (-) addition of 50 ng human FIXa. Non-specific polyclonal mouse IgG was used as a control. 198/A1 and 198/B1 show procoagulant activity (similar as 193/AD3 in example 6) whereas 198/AP1 does not. Antibody 198/BB1 had the same activity pattern (data not shown).

Further monoclonal antibodies selected from the 198th fusion experiment include 198/D1 (ECACC NO. 99121616), 198/T2 (ECACC No. 99121617), 198/G2 (ECACC No. 9912118), 198/U2 (ECACC No. 99121620).

19

Example 10

Structure and Procoagulant Activity of Antibody Derivatives Derived from Anti-FIX/FIXa-antibodies; Subcloning Antibody Variable Domains from Hybridoma Cell Lines 193/AD3, 193/K2, 198/A1 and 198/B1 (Clone AB2)

Cloning procedure: Messenger RNA was prepared from 1×10^6 hybridoma cells of the respective cell line (either 193/AD3, 193/K2, 198/A1 or 198/B1 (clone AB2)) employing the "QickPrep® Micro mRNA Purification Kit" (Pharmacia) according to the manufacturer's instructions. The corresponding cDNA was produced by retro transcription of mRNA using the "Ready-To-Go-You-Prime-First-Strand Beads kit" (Pharmacia) according to the manufacturer's instructions. Heavy and light chain encoding sequences were converted to the corresponding cDNA employing a set of primers. To reverse transcribe heavy chain-specific mRNA (VH), an equimolar mixture of the oligonucleotides MOCG1-2FOR (5' CTC AAT TTT CTT GTC CAC CTT GGT GC 3') (SEQ.ID.NO. 1), MOCG3FOR (5'CTC GAT TCT CTT GAT CAA CTC AGT CT 3') (SEQ.ID.NO. 2) and MOCMFOR (5' TGG AAT GGG CAC ATG CAG ATC TCT 3') (SEQ.ID.NO. 3) was used (RTmix1). In the same reaction tube, light chain-specific cDNA (VL) was synthesized using primer MOCKFOR (5'CTC ATT CCT GTT GAA GCT CTT GAC 3') (SEQ.ID.NO. 4).

The coding sequences for VH were amplified by PCR using the primer-sets depicted in FIG. 12 and the specific cDNA, derived from the reverse transcription mixture (RTmix1) described above, as the template. VK-chain genes were amplified using the primer sets depicted in FIG. 13 and also employing Rtmix1 as a template. The VF-PCR product was cleaved SfiI-Asci and inserted into SfiI-Asci digested vector pDAP2 (GeneBank accession no.: U35316). The pDAP2-VH constructs obtained thereby were named pDAP2-193AD3/VH, pDAP2-198A1/VH, pDAP2-198AB2/VH (derived from antibody 198/B1) and pDAP2-193/K2/VH, respectively. The plasmids were subsequently cleaved with Asci-NotI and the corresponding Asci-NotI digested VK-gene PCR product was inserted. The resultant vectors were designated pDAP2-193/AD3scFv, pDAP2-198/A1scFv, pDAP2-198/AB2scFv (derived from antibody 198/B1) and pDAP2-193/K2scFv and code for the VH-gene and the VL-gene of the monoclonal antibodies 193/AD3, 198/A1, 198/AB2 (derived from antibody 198/B1) and 193/K2. Heavy and light chains are linked by the coding sequence for an artificial, flexible linker ($G_4SGGRASG_4S$) (SEQ ID NO:111); Engelhardt et al., 1994) and enables expression of the scFv variant of the respective antibody.

In FIG. 14, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 193/AD3 are depicted. Nucleotides 1 to 357 code for the heavy chain variable domain, nucleotides 358 to 402 code for the artificial flexible linker and nucleotides 403 to 726 code for the light chain variable region. The protein sequence of the CDR3 region of the heavy chain has the sequence YGNSP-KGFAY (SEQ ID NO:5) and is given in bold letters. The artificial linker sequence ($G_4SGGRASG_4S$; SEQ ID NO:111) is shown.

In FIG. 15, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 193/K2 is shown. Nucleotides 1 to 363 code for the heavy chain variable domain, nucleotides 364 to 408 code for the artificial flexible linker, and nucleotides 409 to 747 code for the

20

light chain variable region. The protein sequence of the CDR3 of the heavy chain has the sequence DGGHGYGSS-FDY (SEQ ID NO:6), and is given in bold letters. The artificial linker sequence ($G_4SGGRASG_4S$; SEQ ID NO:111) is shown.

In FIG. 16, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 198/AB2 (derived from antibody 198/B1) are depicted. Nucleotides 1 to 366 code for the heavy chain variable domain, nucleotides 367 to 411 code for the artificial flexible linker, and nucleotides 412-747 code for the light chain variable region. The protein sequence of the CDR3 region of the heavy chain has the sequence EGGGFTVNWYFDV (SEQ ID NO:7) and is given in bold letters. The artificial linker sequence ($G_4SGGRASG_4S$; SEQ ID NO:111) is also shown.

In FIG. 17, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 198/A1 are depicted. Nucleotides 1 to 366 code for the heavy chain variable domain, nucleotides 367 to 411 code for an artificial flexible linker, and nucleotides 412-747 code for the light chain variable region. The protein sequence of the CDR3 region of the heavy chain has the sequence EGGGYYVN-WYFDV (SEQ ID NO:8) and is given in bold letters. The artificial linker sequence ($G_4SGGRASG_4S$; SEQ ID NO:111) is also shown.

Example 11

Procoagulant Activity of Peptides Derived from CDR3 Regions of Anti-FIX/FIXa-Antibodies

In principle, the antibody molecule can be envisioned as a biological device for the presentation of a combinatorial array of peptide elements in three dimensional space (see Gao et al., 1999, PNAS, 96:6025). Therefore, an antibody (or an antibody derivative, e.g. scFv, Fab, etc.) can be used either as a tool for the detection of functionally important domains of a specific target protein, or on the other hand, for the delineation of amino acid sequences specifically mediating certain interactions, i.e. activating or enhancing the activity of FIXa towards the physiological substrate FX. The latter process has led to the evaluation of a number of heavy chain CDR3 region (CDR3H) derived peptide sequences as FIXa enhancing agents.

Enhancing the procoagulant activity of peptides which exhibit such activity may be accomplished through sequence variation within the peptide regions critical for mediating the FIXa activity enhancement. As a possible step towards peptide sequences with enhanced procoagulant activity, the binding site of an antibody, i.e. 198/A1 or 198/B1, on the FIXa molecule is mapped by employing sequence comparison analyses, competitive binding assays, Western blot analyses and competitive ELISA analyses. Since the crystal structure of FIX is known, molecular modeling is subsequently used to improve the fitting of i.e. 198/B1 derived peptides in the 198/B1 binding site on human FIXa.

On the other hand, methodical mutational analysis of a given peptide sequence such as 198/A1 or 198/B1 CDR3H derived peptide sequences by, e.g., "alanine scanning mutational analysis" allows for the identification of peptide residues critical for procoagulant activity. Another way to improve the activity of a certain peptide sequence is the use of peptide libraries combined with high throughput screening.

The antigen binding site of an antibody is derived from the juxtaposition of the six "complement determining regions (CDR's)" at the N-terminal end of the VL-HL dimer

(or Fv region). The contribution of a single CDR to the antibody specificity for a given antigen may vary considerably, but in general it is thought that the CDR3 region of the heavy chain (CDR3H) is of special influence, i.e. the particular protein sequence of CDR3_H region may be highly important for antigen recognition. The length of CDR3H regions has been reported to vary considerably and is in the range of 4–25 amino acids (Borrebaeck, p. 16).

An example of a methodical mutational analysis of peptide sequences is given below. To improve the solubility/ procoagulant efficacy of peptides derived from the CD3-region of anti FIX/FIXa antibodies, the N-terminal as well as the C-terminal amino acid sequences were changed. In addition, a series of mutated peptides was constructed and analyzed.

The principle of such a study is exemplified by a series of peptides derived from CDR3H region of antibodies 198/A1 and 198/B1. The original peptide A1 (see table 2) is derived from the CDR3H region of antibody 198/A1 and peptide B1 is derived from the CDR3H region of antibody 198/B1, respectively (see example 10, FIGS. 16 and 17). The term “scrambled version” means that a peptide has the same amino acids but in random order.

FVIII assay was developed (see examples 2 and 4). The basic principle is, that without a cofactor, FIXa will have very limited activity towards its natural substrate FX. Only in the presence of a substance having FIXa activation properties, i.e. FVIII or a substance exhibiting FVIII-like activity, a substantial amount of FXa is produced by cleavage of FX through the FIXa/activator complex. The amount of FXa generated is monitored by cleavage of a chromogenic substrate. The principle of the revised chromogenic assay is described for two representative peptides: A1/3 and A1/5 (Table 2). Briefly, 25 µl aliquots of peptide stock solution (in imidazole buffer (IZ) 50 mM imidazole, 100 mM NaCl, pH7.2) were transferred to microtiter plate wells and warmed to 37°C. Chromogenic FXa substrate (S-2222), synthetic thrombin inhibitor (I-2581), bovine FIXa and bovine FX were reconstituted in sterile water and FIXa/FX mixed with phospholipids according to the supplier's protocol. Since the peptides do not react with bovine FIXa, (which comes as a mixture with bovine FX in the Test Kit) 2,9 nM (in most cases 2.3 nM) human FIXa (ERL) were added (see Example 11, FIG. 19). Per reaction, 50 µl of the phospholipid/FIXa/FX solution were combined with 251 CaCl₂ (25 mM) and 50 µl of the substrate/inhibitor cocktail. To start the reaction, 125 µl of the premix were added to the

Peptide	Sequence	Amino-acids	MW (D)	pI	Remark
A1	EGGGYYYVNWYFDV (SEQ ID NO:8)	(13aa)	1569	7.2	Decreased solubility
A1/1	VYGFGWGYEVNDY (SEQ ID NO:10)	(13aa)	1569	7.1	Scrambled version of A1,
A1/2	EEEEGGGGYYVNWYFDEEE (SEQ ID NO:11)	(18aa)	2244	5.8	Acidic pI, soluble,
A1/3	RRREGGGGYYVNWYFDRRR (SEQ ID NO:12)	(18aa)	2407	9.9	Basic pI, soluble,
A1/4	EYGEFYGEVNEYDEFWE (SEQ ID NO:13)	(18aa)	2244	5.8	Scrambled version of A1/2
A1/5	VRYRNRYRWGYRGRFGDE (SEQ ID NO:14)	(18aa)	2407	9.9	Scrambled version of A1/3
A1/3-scr3	RRRGEGYGVYWNGDFYRRR (SEQ ID NO:15)	(18aa)	2407	9.9	Scrambled version of A1/3
A1/3-Rd	RdRdRdEGGGYYYVNWYFDRdRdRd	(18aa)	2407	9.9	Peptide A1/3 but substitute D-Arg for L-Arg
A1/3-Rd-srmb	RdRdRdGEYGVYWNGDFYRdRdRd	(18aa)	2407	9.9	Scrambled version of A1/3-Rd

Table 2

List of a series of antibody 198/A1 derived peptides. Listed are the length of the peptide (aa, amino acids #), the calculated molecular weight (MW, in Dalton (D)) and the statistical isoelectric point (pI). D-Arg is abbreviated as Rd.

In a first series of experiments we improved the solubility of the original CDR3H peptide sequence (A1; EGG-GYYVNWYFDV; SEQ ID NO:8) by removing the C-terminal Val residue and adding several charged residues at the N— as well as the C-terminal end of the peptide. The resulting peptides, A1/2 (acidic pI), A1/3 (basic pI) and their respective scrambled versions A1/4, A1/5 and A1/3scr3 were readily soluble in a variety of buffer systems at physiological pH.

To analyze the FVIII-like (FIXa activating) activity of the peptides, an assay system based on a commercial available

peptide solution in the microtiter plate and incubated at 37°C. Absorbance at 405 nm and 490 nm of the samples was read at various times (5 min to 2 h) against a reagent blank in a Labsystems iEMS Reader MF™ microtiter plate reader using GENESIS™ software.

The result of this experiment are shown in Example 11, FIG. 18. Peptide A1/3 induced a readily measurable FXa generation in the presence of 2.9 nM human FIXa, whereas the scrambled version A1/5 was inactive. In addition, the acidic peptide A1/2 as well as the scrambled versions A1/4 and A1/3-scr3 did not give any significant chromogenic activity when tested under comparable conditions (data not shown). To prove that the peptide A1/3 like the parental antibody 198/A1 does not react with bovine FIXa and FX the experiment shown in FIG. 19 was done. The peptide

A1/3 was incubated as described above with (A1/3 (24 μ M), +hFIXa) and without (A1/3 (24 μ M), w/o hFIXa) 2.3 nM human FIXa (hFIXa). In a control experiment we added plain dilution buffer (IZ) supplemented with 2.3 nM hFIXa to the reaction mixture. As shown in FIG. 19, the reaction takes place only in the presence of human FIXa.

FIG. 18 demonstrates the chromogenic FVIII-like activity of peptide A1/3 in the presence of 2.9 nM human FIXa (hFIXa). The scrambled version of peptide A1/3, peptide A1/5 does not give rise to any FXa generation. FIG. 19 demonstrates the dependence of the chromogenic FVIII-like activity of peptide A1/3 on the presence of human FIXa (hFIXa). In the absence of human FIXa, peptide A1/3 does not give rise to any FXa generation. The buffer control, plain imidazole buffer is designated IZ.

The peptides were also analyzed for their potential to reduce the clotting time in a FVIII deficient plasma. The aPTT based one stage clotting assay was essentially done as described (see example 6). Clotting times (time from starting the reaction to the "clot"-formation were compared either against FVIII, a buffer control (IZ) or a control peptide (scrambled version). The results of two typical clotting experiments done with two different aPTT reagents (DAPTTIN and Pathromtin SL) are shown in table 3A and table 3B.

	peptide conc.	w/o FIXa sec	w/o FIXa sec	average sec	2.2 nM FIXa sec	2.2 nM FIXa sec	average sec
<u>Exp. 1</u>							
IZ	0	107.7	106.8	107	93.1	94.5	94
A1/3	15 μ M	78.2	77.1	78	59.3	59.9	60
	12.5 μ M	80.2	80.6	80	60.2	58.9	60
	7.5 μ M	97.8	97.9	98	73.1	72.7	73
	2.5 μ M	105.2	104.8	105	91.1	91	91
A1/3-scr3	15 μ M	122.5	122	122	106.1	105.5	106
	12.5 μ M	116	117.6	117	103.1	104.5	104
	7.5 μ M	114.2	113.9	114	100.8	100.6	101
	2.5 μ M	107.8	107.4	108	96.3	95.2	96
<u>Exp. 2</u>							
IZ	0	111	109.7	110	94.7	95.5	95
A1/3	12.5 μ M	83.6	85.5	85	56.7	56.7	57
	10 μ M	79.1	78.5	79	63.1	62.5	63
	7.5 μ M	100.1	100.5	100	71.6	73.9	73
	5 μ M	103.4	104.8	104	77	76	77
	2.5 μ M	110.1	108.9	110	88	88.8	88
	1.25 μ M	108.7	109.3	109	90.7	90.8	91

Table 3A. Clotting activity of peptides A1/3 and A1/3-scr (scrambled version of A1/3) in FVIII deficient plasma either in the presence or in the absence (w/o) of 2.2 nM human FIXa. Shown are two independent representative experiments (Exp. 1 and Exp. 2). All clotting experiments have been done in duplicate. Given are the clotting times for the individual experiments and the average clotting time in seconds (sec). Experiments shown in table 3A have been done employing the aPTT reagent DAPTTIN (Baxter Hyland Immuno). Compared to the buffer control (IZ, imidazole buffer) the peptide A1/3 gave rise to a dose dependent reduction in the clotting time. The reduction in the clotting time became much more pronounced by the addition of 2.2 nM activated human FIX to the reaction mix. The scrambled version of peptide A1/3, A1/3-scr3 did not show any reduction of the clotting time. In fact, at concentrations above 2.5 μ M, the scrambled peptide became inhibitory and therefore prolonged the clotting time. Peptides A1/1, A1/2, A1/4 and A1/5 did not give any reduction in the

clotting time indicating that they lack procoagulant activity (data not shown).

	Final conc.	w/o FIXa sec	w/o FIXa sec	average sec	2.2 nM FIXa sec	2.2 nM FIXa sec	average sec
IZ	0	131.8	132.1	132	107.9	108.7	108
FVIII	12.5 mU/ml	68.9	69	69	52.9	53.6	53
	6.25 mU/ml	77.8	77.9	78	58.6	58.9	59
A1/3	15 μ M	152.8	149.3	151	75.4	75.2	75
	10 μ M	135.7	134.6	135	76.2	79.8	78
	5 μ M	152.6	155.6	154	86.6	90.2	88
	1 μ M	138.3	138.8	139	103.7	105.9	105

Table 3B. Clotting activity of peptide A1/3 in FVIII deficient plasma when Pathromtin SL (DADE Behring) is used as an aPTT reagent. The experiments were done in duplicate, either in the presence or in the absence (w/o) of 2.2 nM human FIXa. Given are the clotting times for the individual experiments and the average clotting time in seconds (sec). Factor VIII and imidazole buffer (IZ) were included as positive and negative control respectively.

In contrast to the experiments shown in table 3A the experiments shown in table 3B have been done employing the aPTT reagent Pathromtin SL. In the presence of FIXa, the peptide A1/3 gave rise to a dose dependent reduction in the clotting time whereas in the absence of FIXa no reduction of the clotting time was detectable.

In another series of experiments we set out to improve the plasma stability (protection from, e.g., proteolytic degradation) of peptide A1/3. One approach was to substitute the N- and C-terminal L-Arg residues with D-Arg residues (exemplified by peptides A1/3-rd and A1/3-Rd-srmb). Peptides A1/3-rd and A1/3-Rd-srmb (scrambled version of the peptide) were then analyzed in a chromogenic as well as in the aPTT based clotting assay. These experiments revealed that exchanging the terminal L-Arg residues for D-Arg residues did not change the FVIII-like activity as measured in the chromogenic assay, indicating that chirality of the Arg-residues does not play a major role in chromogenic activity (FIG. 20). In addition, the aPTT based one-stage clotting activity, although somewhat reduced, was still easily detectable (Table 4).

	Peptide conc.	w/o FIXa sec	w/o FIXa sec	average sec	2.2 nM FIXa sec	2.2 nM FIXa sec	average sec
IZ	0	110	109.1	110	96	96	96
A1/3	15 μ M	77.8	78	78	56.1	55.5	56
	12.5 μ M	99.4	100.5	100	65	68	67
	10 μ M	104.4	104.5	104	72	73.2	73
	7.5 μ M	105.2	105.2	105	80.7	80.5	81
	5 μ M	108.4	107.7	108	89.7	88.3	89
	2.5 μ M	107.9	107.6	108	93.6	93.3	93
	1.25 μ M	106.7	107	107	94.4	95	95
A1/3-	15 μ M	96.4	95.4	96	76.1	74.4	75
Rd	12.5 μ M	98	98.6	98	72.3	73.7	73
	10 μ M	93.5	95.8	95	74.2	77.2	76
	7.5 μ M	97.6	98.1	98	80.9	82.2	82
	5 μ M	99.2	99.1	99	86	85.1	86
	2.5 μ M	102.7	103.4	103	94.4	94.7	95
	1.25 μ M	107.5	107.7	108	96.6	96	96
A1/3-	15 μ M	121.9	121.3	122	112.7	112.4	113
Rd	12.5 μ M	117.2	118	118	108.1	107.8	108
	10 μ M	115.8	115.3	116	107.2	107.8	108
	7.5 μ M	114.6	113.6	114	107.6	106.6	107
	5 μ M	113.1	112.4	113	108.5	108.2	108

-continued

Peptide conc.	w/o FIXa sec	w/o FIXa, average sec	2.2 nM FIXa sec	2.2 nM FIXa sec	2.2 nM FIXa average sec	
	111.9	111.9	112	105	104.2	105
2.5 μ M	111.9	111.9	112	105	104.2	105
1.25 μ M	107.2	107.1	107	101.1	105.3	103

Table 4. One stage clotting activity of peptides A1/3, A1/3-Rd and A1/3-Rd-srmb (sequences see table 2). IZ, buffer control.

FIG. 20 demonstrates the unchanged chromogenic activity of peptide A1/3-Rd. Peptides at a final concentration of 12 μ M or the buffer control (IZ) were incubated in the presence of 2.3 nM human FIXa (+). The chromogenic activity of peptide A1/3 and A1/3-Rd was found to be virtually unchanged and gave almost identical results in the chromogenic assay. The scrambled version of peptide A1/3, A1/5 as well as the buffer gave no significant FXa generation.

In the next series of experiments we set out to determine the individual role of any amino acid of the peptide core sequence by substituting each residue for the amino acid Alanine (Table 5).

5

100 mM NaCl, 1% human albumin, pH7.4) to the desired final concentration. The peptides were analyzed for their chromogenic activity as well as for their potential to reduce the clotting time in a FVIII deficient plasma. The one-stage clotting assay was essentially done as described (see example 6). Clotting times (time from starting the reaction to the "clot"-formation were compared either against a buffer control or a control peptide (scrambled version).

Some of the results of the "Alanine scan" are given for the peptides A1/3-2 and A1/3-3. The change of G₃-A₃ as exemplified in the peptide A1/3-2 yields high chromogenic activity and a strong reduction of the one-stage clotting time (34 seconds at a concentration of 12.5 μ M) in the presence of 2.2 nM human FIXa. Peptide A1/3-3 (G₄-A₄) exhibits an optimum of chromogenic activity around a final concentration of 12 μ M with decreased activity at either higher or lower concentrations. The peptide is somewhat inhibitory in a one-stage clotting assay at higher concentrations (12.5 μ M) in the absence of FIXa but becomes strongly active in the presence of 2.2 nM FIXa (31 seconds, 12.5 μ M).

15 In the next series of experiments we set out to determine the individual role of any amino acid of the peptide core sequence by substituting each core residue for the amino acid glutamic acid (E) (see Table 6).

Peptide	Sequence	Amino acid #	MW (D)	pI	Remark
A1/3	RRREGGGGYYVNWYFDRRR (SEQ ID NO:12)	(18aa)	2407	9.9	Basic pI, soluble.
A1/3-13	RRRAGGGGGYYVNWYFDRRR (SEQ ID NO:19)	(18aa)	2349	10.4	E ₁ -A ₁
A1/3-1	RRREAGGGYYVNWYFDRRR (SEQ ID NO:20)	(18aa)	2421	9.9	G ₂ -A ₂
A1/3-2	RRREGAGYYYVNWYFDRRR (SEQ ID NO:21)	(18aa)	2421	9.9	G ₃ -A ₃
A1/3-3	RRREGGGAYYYVNWYFDRRR (SEQ ID NO:22)	(18aa)	2421	9.9	G ₄ -A ₄
A1/3-4	RRREGGGGAYVNWYFDRRR (SEQ ID NO:23)	(18aa)	2315	9.9	Y ₅ -A ₅
A1/3-5	RRREGGGGYAVNWYFDRRR (SEQ ID NO:24)	(18aa)	2315	9.9	Y ₆ -A ₆
A1/3-6	RRREGGGGYYANWYFDRRR (SEQ ID NO:25)	(18aa)	2379	9.9	V ₇ -A ₇
A1/3-7	RRREGGGGYYYVAWYFDRRR (SEQ ID NO:26)	(18aa)	2364	9.9	Y ₈ -A ₈
A1/3-8	RRREGGGGYYYVNAYFDRRR (SEQ ID NO:27)	(18aa)	2292	9.9	W ₉ -A ₉
A1/3-9	RRREGGGGYYYVNWFDRRR (SEQ ID ND:28)	(18aa)	2315	9.9	Y ₁₀ -A ₁₀
A1/3-10	RRREGGGGYYYVNWYADRRR (SEQ ID NO:29)	(18aa)	2331	9.9	F ₁₁ -A ₁₁
A1/3-11	RRREGGGGYYYVNWYFARRR (SEQ ID NO:30)	(18aa)	2363	10.5	D ₁₂ -A ₁₂
A1/3-12srmb	RRRYVYNGWGYZEGARRR (SEQ ID NO:31)	(18aa)	2363	10.4	Scrambled version

55

Table 5. Listed are the peptides designed to elucidate the role of any single amino acid within the peptide core sequence (E₁G₂G₃G₄Y₅Y₆V₇N₈W₉Y₁₀F₁₁D₁₂; SEQ ID NO:112). The subscripted numbers describe the position of the amino acid within the peptide. Alanine, an uncharged small amino acid, was substituted for each amino acid ("Alanine scan"). Also listed are the lengths of the peptides (amino acids #), the calculated molecular weights (MW, in Dalton (D) and the statistical isoelectric points (pI).

Each of the peptides was dissolved individually in imidazole buffer (50 mM imidazole, 100 mM NaCl, pH7.2) and subsequently diluted in clotting buffer (50 mM imidazole,

Peptide	Sequence	Amino-Acids	MW (D)	pI	Remark
A1/3	RRREGGGGYYVNWYFDRRR (SEQ ID NO:12)	(18aa)	2407	9.9	Basic pI, soluble.
A1/3-22	RRREEGGGYYVNWYFDRRR (SEQ ID NO:32)	(18aa)	2479	9.5	G ₂ -E ₂
A1/3-23	RRREGEGLYYVNWYFDRRR (SEQ ID NO:33)	(18aa)	2479	9.5	G ₃ -E ₃

-continued

Peptide	Sequence	Amino-Acids	MW (D)	pI	Remark
A1/3-24	(SEQ ID NO:33) RRREGGEYYVNWFDRRR	(18aa)	2479	9.5	G ₄ -E ₄
A1/3-26	(SEQ ID NO:34) RRREGGGEYVNWFDRRR	(18aa)	2373	9.4	Y ₅ -E ₅
A1/3-27	(SEQ ID NO:35) RRREGGGYEVNWFDRRR	(18aa)	2373	9.4	Y ₆ -E ₆
A1/3-28	(SEQ ID NO:36) RRREGGGYYYENWFDRRR	(18aa)	2437	9.5	V ₇ -E ₇
A1/3-29	(SEQ ID NO:37) RRREGGGYYYYVEVWFDRRR	(18aa)	2422	9.5	N ₈ -E ₈
A1/3-30	(SEQ ID NO:38) RRREGGGYYYYVNEYFDRRR	(18aa)	2350	9.5	W ₉ -E ₉
A1/3-31	(SEQ ID NO:39) RRREGGGYYYYVNWEFDRRR	(18aa)	2373	9.4	Y ₁₀ -E ₁₀
A1/3-32	(SEQ ID NO:40) RRREGGGYYYYVNWFYEDRRR	(18aa)	2389	9.5	F ₁₁ -E ₁₁
A1/3-33	(SEQ ID NO:41) RRREGGGYYYYVNWFYFERRR	(18aa)	2421	9.9	D ₁₂ -E ₁₂
A1/3-34scrmb	(SEQ ID NO:42) RRRGEYGEYWNGDFYRRR	(18aa)	2437	9.5	Scrambled version

Table 6. Listed are the peptides designed to elucidate the role of any single amino acid within the peptide core sequence (E₁G₂G₃G₄Y₄Y₅Y₆V₇N₈W₉Y₁₀F₁₁D₁₂; SEQ ID NO:112). The subscripted numbers describe the position of the amino acid within the peptide. Glutamic acid, a negatively charged large amino acid, was substituted for each amino acid of the core sequence ("Glutamic acid scan"). Also listed are the lengths of the peptide (amino acids #), the calculated molecular weights (MW, in Dalton (D) and the statistical isoelectric points (pI).

Each of the peptides was solved individually in imidazole buffer (50 mM imidazole, 100 mM NaCl, pH7.2) and subsequently diluted in clotting buffer (50 mM imidazole, 100 mM NaCl, 1% human albumin, pH7.4) to the desired final concentration. The peptides derived from the "Glutamic acid scan" series were analyzed for their chromogenic FVIII-like activity as well as for their potential to reduce the clotting time in a FVIII deficient plasma. The one-stage clotting assay was essentially done as described (see example 6).

The peptide A1/3-24 showed some interesting properties. The molecule exhibited high chromogenic FVIII-like activity at concentrations between 6.5 μM-12 μM but lost activity at higher concentrations (up to 24 μM). The peptide had no procoagulant activity in the absence of human FIXa but was strongly active in the presence of 2.2 nM hFIXa.

In a second series of experiments we set out to improve the procoagulant activity of the antibody-198/B1 CDR3H derived peptide sequence B1. In a first step we improved the solubility of the original peptide sequence (B1; EGGGFTVNWFYFDV; SEQ ID NO:7) by removing the C-terminal Val residue and adding several charged residues at the N- as well as the —C-terminal end of the peptide. The resulting peptides B1/4, B1/6 (acidic pI), B1/7 (basic pI) and their scrambled versions B1/5, B1/7scr3 are readily soluble in a variety of buffer systems at physiological pH.

Peptide	Sequence	Amino-acids	MW (D)	pI	Remark
B1	EGGGFTVNWFYFDV	(13aa)	1491	6.0	Decreased solubility
B1/4	REGGGFTVNWFYFDR	(14aa)	1704	7.9	Soluble,
B1/5	FGVGYRGETRNFDW	(14aa)	1704	8.0	Scrambled version, soluble
B1/6	EEEEGGGFTVNWFDEEE	(18aa)	2166	5.0	Acidic pI soluble
B1/7	RRREGGGFTVNWFYFDRRR	(18aa)	2329	9.9	Basic pI soluble
B1/7 scr3	RRRGFGVGYGETNFDWRRR	(18aa)	2329	9.9	Basic pI, soluble, scrambled version

Table 7 is a list of a series of antibody 198/B1 derived peptides. Listed are the length of the peptide (aa, amino acids #), the calculated molecular weight (MW, in Dalton (D) and the statistical isoelectric point (pI).

Peptides B1/4 and B1/5 were soluble in 50 mM Tris, 100 mM NaCl, pH=6.5. Both peptides were analyzed in a chromogenic FVIII assay. Peptide B1/4 but not the scrambled version B1/5 was found to have some chromogenic activity (data not shown).

Subsequently peptides B1/6, B1/7 and B1/7scr3 were analyzed. Each of the peptides was solved individually in 50 mM imidazole, 100 mM NaCl, pH7.2 and subsequently diluted either in clotting buffer (50 mM imidazole, 100 mM NaCl, 1% human albumin, pH7.4) or in imidazole buffer to the desired final concentration. The peptides were analyzed for their chromogenic activity as well as for their potential to reduce the clotting time in a FVIII deficient plasma (table 8 & 9). The one stage clotting assay was essentially done as described (see example 6). Clotting times (time from starting the reaction to the "clot"-formation were compared either against a buffer control or a control peptide (scrambled version).

The FIXa activating activity (FVIII cofactor-like activity) from peptide B1/7 was first measured in the chromogenic assay described above.

As shown in FIG. 21, the addition of 2.4 μM peptide B1/7 to the reaction mixture led to a well measurable generation of FXa. In contrast, the addition of 35 μM Pefabloc Xa, a specific inhibitor of FXa protease activity, resulted in a significant reduction of the chromogenic substrate cleavage reaction (FIG. 22) thereby proving that there was indeed a peptide-FIXa mediated FXa generation. If there was no addition of FIXa and FX to the reaction mixture, no FXa was synthesized (FIG. 22). Peptide B1/6 and the control peptides B1/5 and B1/7scr3 exhibited no activity (data not shown).

FIG. 21 demonstrates the chromogenic activity of peptide B1/7. The peptide at a final concentration of 2.4 μM or the buffer control (IZ) were incubated in the presence of 2.3 nM human FIXa.

In FIG. 22 peptide B1/7 at a final concentration of 2.4 μM or the buffer control (IZ) were incubated in the presence of 2.3 nM human FIXa (as indicated either as "+2.3 nM hFIXa" or "+") The chromogenic activity of peptide B1/7 was found to be dependent on the presence of FIXa and FX since no reaction is detectable when FIXa and FX are left out of the reaction (w/o FIXa/FX). To prove that the peptide B1/7 mediates indeed FXa generation, the FXa specific protease inhibitor Pefabloc Xa was added to the reaction mix (35 μM Pefabloc Xa). In a second set of experiments, the procoagu-

29

lant effect of peptides B1/6, B1/7 and B1/7scr3 were tested in a aPTT based one-step coagulation assay. The experiments were done essentially as described in Example 6. The results are shown in tables 8 and 9.

Pep-tide	12.5 μ M (-)	1.25 μ M (-)	0.125 μ M (-)	12.5 nM (-)	Buffer (-)	remarks
B1/6	115	110	111	111	110	
B1/7	157	112	109	110	110	
B1/7	115	105	106	105	107	
scr3						

Table 8: FVIII deficient plasma was incubated either with peptides B1/6, B1/7scr3 or B1/7 in the absence of activated human FIX. As a negative control, plain buffer was added to the deficient plasma. The clotting times for the various combinations are given. Under these conditions, peptide B1/7 at its highest concentration (12.5 μ M) becomes inhibitory to the coagulation process as indicated by the extended clotting time of 157 seconds.

Pep-tide	12.5 μ M (+)	1.25 μ M (+)	0.125 μ M (+)	12.5 nM (+)	Buffer (+)	remarks
B1/6	103	100	101	100	100	
B1/7	83	92	99	99	100	
B1/7	102	94	94	94	94	
scr3						

Table 9: FVIII deficient plasma was incubated either with peptides B1/6, B1/7scr3 or B1/7 in the presence of activated human FIX. As a negative control, plain buffer was added to the deficient plasma. The clotting times for the various combinations are given. In the presence of FIXa, peptide B1/7 becomes procoagulant as indicated by the reduced clotting time (83 seconds compared to 102 seconds for the scrambled peptide and 100 seconds for the buffer control).

Example 12

Procoagulant Activity of Peptide Derivatives Obtained from CDR3 Regions of Anti-FIX/FIXa- Antibodies in FVIII Inhibitor Plasma

To assay for the procoagulant activity of peptide A1/3 in FVIII inhibitor plasma the following experiment was carried out. We performed a standard aPTT based one stage clotting assay, but instead of FVIII deficient plasma we employed FVIII inhibitor plasma. The inhibitory potency of the plasma was 8.1 Bethesda Units per ml.

TABLE 10

	Peptide conc.	w/o FIXa sec	w/o FIXa sec	Average sec	FIXa sec	FIXa sec	average sec
IZ	0	104.9	103.6	104	94.2	94.1	94
A1/3	12.5 μ M	85.8	85.3	86	61	60.2	61
	10 μ M	88.4	87.9	88	61.3	61.8	62
	7.5 μ M	93.7	92.7	93	68.8	70.9	70
	5 μ M	101.5	101.1	101	81	82	82
	2.5 μ M	106.1	105.3	106	90.2	90.5	90
	1.25 μ M	104.5	104.3	104	91.3	91.4	91

Table 10: Various amounts of peptide A1/3 (12.5 μ M-1.25 μ M) were added to FVIII inhibitor plasma (either in the

presence (FIXa) of 2.2 nM FIXa or in the absence (w/o FIXa). As a negative control, plain buffer was added to the plasma (IZ). Experiments were done in duplicate and the average (aver.) was calculated. The clotting times (in seconds) for the various combinations are given. It is easily appreciable that the peptide A1/3 reduces (in a dose dependent manner) the clotting time of FVIII inhibitor plasma in the presence of FIXa but, although albeit to a much lesser extent, also in the absence of FIXa.

30
Example 13

Conversion of the 196/C4 IgM into IgG1

Since some IgM antibodies demonstrate high FVIII-like activity in chromogenic assays, attempts were made to convert such IgM antibodies into IgG antibodies (though antibody derivatives such as Fab, F(ab)₂, scFv, etc. could also be produced). Described in detail below is the rescue of the IgM variable region genes. Expression vector pBax-IgG1 (FIG. 23) was first constructed from vectors pSI (Promega) and pEF/Bsd (Invitrogen) through multiple cloning steps. B-lymphocytes of a donor are purified from blood and mature mRNA purified from these cells using the "micro-mRNA purification-kit" (Pharmacia). The cDNA of a human kappa chain and a human gamma 1 chain are prepared employing the "you-primefirst-strand-cDNA-kit" (Pharmacia) using specific primers.

The coding sequence of a human kappa light chain constant domain is amplified from the cDNA by PCR using specific primers.

The gene of a human gamma 1 chain constant region (CH1-hinge-CH2—CH3) is amplified from the cDNA by PCR using specific primers.

The PCR product of the light chain constant domain is digested with XbaI and NheI and inserted into digested pSI. The resultant vector is cleaved with EcoRI and XbaI and annealed oligonucleotides are inserted, resulting in vector pSI-Ckappa. The annealed oligonucleotides provide for the leader and the SacI-XbaI sites for insertion of the kappa chain variable region. The PCR product of the human gamma 1 chain constant region is digested with SpeI and BamHI and inserted into digested pSI. The resultant vector is cleaved with SpeI and NotI and annealed oligonucleotides are inserted resulting in vector pSI-Cgamma. The annealed oligonucleotides provide for the leader and the XhoI-BstEI sites for insertion of the heavy chain variable region. Vector pEF/Bsd is digested NheI and SfiI, blunt ended by Klenow treatment and the whole expression cassette of pSI-Ckappa, excised with BglII and BamHI, is inserted (after Klenow treatment). The resultant vector is digested with EcoRI and HindIII and treated with Klenow. The whole expression cassette of pSI-Cgamma is excised with BglII and BamHI and is inserted (after Klenow treatment). The resultant vector is named pBax-IgG1.

The light chain variable region can be inserted in between the SacI-XbaI sites, yielding the complete coding-sequence of a kappa light chain. The heavy chain variable region can be cloned in between the XhoI-BstEI sites, resulting in a complete IgG1 heavy chain gene. Both open reading frames are expressed under the control of the SV40-promoter and harbour the coding sequence of a signal peptide at the 5' end of the genes for secretion of the heavy and light chains into the endoplasmatic reticulum. Transfection into COS cells allows the expression of an IgG1 with the same binding properties as the parental IgM.

Construction of the plasmid pBax-196/C4 is further accomplished by amplifying the VH of the 196/C4 scFv

(subcloned as described in Experiment 10) by PCR using specific primers. The PCR product is digested with XbaI and BstEII and inserted into XbaI and BstEII digested pBax IgG1. The VL of the 196/C4 scFv is amplified by PCR using specific primers. The PCR product is digested with SacI and XbaI and inserted into SacI and XbaI-digested pBax IgG1-VH. The resultant vector (pBax-196/C4) is transfected into COS cells by electroporation, and hybrid IgG1 molecules (murine variable region and human constant region) with the same specificity as the parental IgM is expressed.

Example 14

Activation of FIXa Amydolytic Activity by Anti-FIXa Antibodies

Briefly, 20±1 factor IXa (containing 20 mU FIXa (Stago)) were incubated at 37° C., with 200 µl of reaction buffer (50 mM Tris HCl pH7.4, 100 mM NaCl, 5 mM CaCl₂ and 40% Ethyleneglycol), 25 µl of FIXa substrate (CH₃SO₂-D-CHG-Gly-Arg-pNA, AcOH, 10M/ml, Pentapharm LTD) in the absence or presence of various amounts of anti-FIX antibodies 198/B1 (IgG isotype) or 196/AF1 (IgM isotype). Specific cleavage of FIXa substrate was monitored at 405 nm in an ELISA reader.

The presence of the anti-FIX antibodies enhanced the amydolytic activity of FIXa at least 2 fold. FIG. 24 shows the increase of the amidolytic activity of FIXa in the presence of antibody 198/B1 (FIG. 24A) and antibody 198/AF1 (FIG. 24B).

Example 15

FVIII-like Activity Exhibited by Fab Fragments Derived from Anti FIX/FIXa-antibodies

Fab fragments of anti-FIX/FIXa antibodies were prepared and purified according to standard protocols. Briefly, 1 ml antibody 198/A1(4 mg/ml in 50 mM imidazole, 100 mM NaCl, pH7.4) was incubated overnight with 87 µl fragmentation buffer (1M Na Acetate, 10 mM EDTA 67.5 mg/ml L-cysteine) and 0.25 mg papain (immobilized on agarose beads), at 37° C. The preparation was filtered to remove the papain. L-histidine was added (final concentration 50 mM) and afterwards the pH was adjusted to 7.0. Finally, solid NaCl is added to give a final concentration of 1M.

Subsequently, the 198/A1 Fab fragment was purified by binding to protein L: we used ImmunoPure Immobilized PROTEIN L Plus (Pierce) in a PHARMACIA XK 16/20 Column (gel-volume: 2 ml) Buffers for chromatography were: 1) equilibration-buffer: 50 mM L-histidine pH 7.0; 1M NaCl; 0,1% (w/v) NaN₃; 2) wash-buffer: 50 mM L-Histidine pH 7.0; 0.1 (w/v) NaN₃; 3) elution-buffer: 100 mM glycine pH 2.5; 0.1% (w/v) NaN₃; and 4) neutralization buffer: 2M Tris/Cl pH 8.0;

Chromatography was essentially done by following steps 1 to 7 described in table 11. In order to neutralize the low pH of the elution buffer "Fraction-tubes" were pre-loaded with 0.2 ml 2M Tris pH 8.0.

TABLE 11-continued

	STEP	BUFFER	Flow rate	Vol.	CV	Fractions
5	3. sample-load	sample	1.0 ml/min	x ml	x	flow-through
	4. wash 1	equi-buffer	1.0 ml/min	20 ml	10	flow-through
	5. wash 2	wash-buffer	1.0 ml/min	10 ml	5	flow-through
	10 6. elution	elution-buffer	1.0 ml/min	15 ml	7.5	1,0 ml fractions
	7. neutralization	wash-buffer	2.0 ml/min	10 ml	5	waste

Table 11

The final 198/A1 Fab preparation was dialyzed against 50 mM imidazole, 100 mM NaCl, pH7.4 and analyzed in a chromogenic FVIII assay as described above (FIG. 25). Compared to an intact antibody, the 198/A1 Fab fragment has somewhat less activity; however, the Fab fragment still gives rise to FIX dependent FXa generation.

FIG. 25 demonstrates the chromogenic FVIII-like activity of the antibody 198/A1 Fab fragment in the presence of 2.3 nM human FIXa. As a positive control we used the intact antibody 198/A1 as well as 7.5 pM FVIII. Buffer control (IZ) instead of 198/A1 Fab fragment or FVIII was used as a negative control.

Example 16

FVIII-like Activity Exhibited by Fusion Proteins Between scFv Fragments of Anti-FIX/FIXa Antibodies and *E. coli* Alkaline Phosphatase

The single chain Fv fragment (see example 10) of antibody 198/B1 (subclone AB2) was fused to the N-terminus of *E. coli* alkaline phosphatase employing the pDAP2 vector system (Kerschbaumer et al., 1996). Two identical clones were isolated and designated pDAP2-198AB2#1 and pDAP2-198AB2#100 (FIG. 26). The resulting fusion proteins were expressed in *E. coli*, purified by metal affinity chromatography (Kerschbaumer et al., 1997) and analysed in a standard chromogenic assay (FIG. 27).

FIG. 27 demonstrates the chromogenic FVIII-like activity of two antibody 198/B1 (subclone AB2) scFv fragment-alkaline phosphatase fusion proteins (198AB2#1 and 198AB2#100) in the presence of 2.3 nM human FIXa. As a positive control we used 7.5 pM FVIII.

Example 17

FVIII-like Activity Exhibited by a Bivalent Miniantibody

In order to obtain a bivalent miniantibody, the scFv fragment of antibody 198/B1 (subclone AB2) was fused to a amphipatic helical structure employing the pZip1 vector system (Kerschbaumer et al. (Analytical Biochemistry 249, 219–227, 1997). Briefly, the gene of the 198/B1 scFv fragment was isolated from the plasmid pDAP-198AB2#100 (example 16) by digestion with SfiI and NotI. The DNA fragment was gel purified and inserted in the SfiI/NotI digested vector pZip1. The resulting plasmid was sequenced and designated pZip-198AB2#102 (FIG. 28). In parallel, we constructed a miniantibody version from an irrelevant monoclonal antibody termed #8860. In a first step, the single chain Fv fragment of antibody #8860 was assembled in the vector pDAP2. The cloning was done essentially as described in example 10. The construct was

TABLE 11

STEP	BUFFER	Flow rate	Vol.	CV	Fractions
1. column-wash	elution-buffer	2.0 ml/min	10 ml	5	waste
2. equilibration	equi-buffer	2.0 ml/min	10 ml	5	waste

33

named pDAP2-8860scFv#11 (FIG. 29). Subcloning of the scFv fragment contained within pDAP2-8860scFv#11 into plasmid pZip1 (see above) yielded the miniantibody construct p8860-Zip#1.2 (FIG. 30). Since antibody #8860 does not react with FIX/FIXa (as judged by Western Blot and ELISA analysis) it represents an appropriate negative control. Subsequently, the miniantibody proteins were expressed in *E. coli* and purified from bacterial supernatants by binding to Protein L according to the following protocol: For affinity chromatography we used ImmunoPure Immobilized PROTEIN L Plus (Pierce) in a PHARMACIA XK 16/20 Columns having a gel-volume of 4 ml Buffers employed were: 1) equilibration-buffer: 5 mM L-Histidine pH 7.0, 1M NaCl, 0.1% (w/v) NaN₃, wash-buffer: 50 mM L-histidine pH 7.0, 0.1% (w/v) NaN₃; elution-buffer: 100 mM glycine pH 2.5, 0.1% (w/v) NaN₃; and neutralization buffer: 2M Tris/Cl pH 8.0.

Samples were prepared as follows: The bacterial culture supernatant was obtained by centrifugation of the bacterial expression culture (11,000×g, 4° C., 10 minutes). 470 g of ammonium-sulphate was added to 1 liter of supernatant and the solution stirred on ice for 1 hour to precipitate the protein. The precipitate was pelleted at 14,000×g for 35 minutes at 2° C. and re-dissolved in 100 ml 20 mM Tris pH 7.0. Subsequently the concentrate was dialyzed against 20 mM Tris pH 7.0, L-histidine was added to a final concentration of 50 mM and the pH was adjusted to 7.0. Finally, solid NaCl was added to give a final concentrations of 1M. Before loading on the column, a sample was first centrifuged at 16,000×g for 15 min at room temperature and then filtered through a 0.45 µm sterile filter.

Chromatography was essentially done by following steps 1 to 7 described in table 12. In order to neutralize the low pH of the elution buffer "Fraction-tubes" were pre-loaded with 0.2 ml 2M Tris pH 8.0.

STEP	BUFFER	Flow rate	Vol.	CV	Fractions
1. column-wash	elution-buffer	2.0 ml/min	20 ml	5	waste
2. equilibration	equi-buffer	2.0 ml/min	20 ml	5	waste
3. sample-load	sample	1.0 ml/min	x ml	x	flow-through
4. wash 1	equi-buffer	1.0 ml/min	40 ml	10	flow-through
5. wash 2	wash-buffer	1.0 ml/min	20 ml	5	flow-through
6. elution	elution-buffer	1.0 ml/min	30 ml	7.5	1.0 ml fractions-waste
7. neutralization	wash-buffer	2.0 ml/min	20 ml	5	waste

Table 12. The final 198/B1 (subclone AB2) miniantibody preparation (designated 198AB-Zip#102) and the negative control 8860-Zip#1.2 were dialyzed against 50 mM imidazole, 100 mM NaCl, pH7.4 and analyzed in a chromogenic FVIII assay as described above (FIG. 31).

As can be seen in FIG. 31, the miniantibody construct 198AB-Zip#102 gives rise to substantial FXa generation (compare to FVIII) whereas the negative control miniantibody 8860-Zip#1.2 does not.

FIG. 31 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) miniantibody 198AB-Zip#102 in the presence of 2.3 nM human FIXa. As a positive control we used 4.8 pM FVIII whereas an unrelated miniantibody (8860-Zip#1.2) and plain reaction buffer (IZ) served as negative controls.

Example 18

FVIII-like Activity Exhibited by Anti-FIXa/FIX Antibody scFv Fragments

The single chain Fv fragment of antibody 198/B1 (subclone AB2) as well as the scfv fragment of antibody

34

#8860 were expressed employing the pMycHis6 vector system. Vector pMycHis6 (FIGS. 32 & 33) was constructed by cleaving vector pCOCK (Engelhardt et al., 1994, Biotechniques, 17: 44-46) with NotI and EcoRI and insertion of the following oligonucleotides: mychis6-co: 5' ggc-cgcagaacaaaactcatctcagaaggatcatccatcacatcacatcaccatcactaataag 3' (SEQ. ID.NO.

10 gtgcccccattcagatccctt tctgagatgagttttgttcgc 3' (SEQ.ID.NO. 80) FIG. 32 shows a schematic representation of the plasmid pMycHis6. The c-myc-tag sequence is used to detect the scFv fragment in an ELISA or a Western Blot analysis (Evan et al., Mol.Cell.Biol., 1985, 5(12), pp. 3610-6). The His6-tag sequence was included to facilitate the purification of scFv fragments by metal ion chromatography (Hochuli et al., 1988, Biotechnology, 6: 1321-1325). The plasmid contains the lacZ gene promoter (PlacZ) the PelB-leader sequence (see legend FIG. 26) an *E. coli* origin of replication (colElori) and a M13 phage origin of replication (M13ori). To allow for specific selection, the plasmid also carries the gene for the enzyme β-lactamase (AmpR) mediating resistance against the antibiotic ampicillin.

15 The gene of the 198/B1 (clone AB2)-scFv was rescued from plasmid pDAP2-198AB2#100 (example 16) by digestion with SfiI and NotI and inserted into SfiI/NotI cleaved pMycHis6. The resultant plasmid was designated pMycHis-198AB2#102. FIG. 34 shows the nucleotide and amino acid

20 sequence of 198AB2 scFv (linked to the c-myc-tag and the His6tag):the resulting ORF of the expression vector is named pMycHisG-198AB2#102. Vector pMycHis6 was constructed by cleaving vector pCOCK (Engelhardt O. et al, BioTechniques 17, 44-46, 1994) NotI-EcoRI and inserting the following annealed oligonucleotides: (5'-GGCGCAGAACAAAAACTCATCTCAGAA-GAGGATCTGAATGGGG 35 GCGGCACATCACCATACCACATCACTAATAAG-3' (SEQ.ID.No. 103) and 5'-TTATTAGTGTGATGGTGATGGT GATGTGCGGCCCATTCAGATCCTCTCTGAGATGA GTTTTGTTCTGC-3'(SEQ.ID.NO. 104)). The resultant vector, named pMycHis6, was cleaved SfiI-NotI and the gene of scFv 198AB2 was swapped into this vector from 40 45 vector pDAP2-198AB2#100.

In analogy to the 198AB2 construct, the #8860 scFv fragment was cloned from a plasmid designated pDAP2-8860scFv clone 11. The pure scFv protein of #8860 was designated 8860-M/H#4c (plasmid p8860-M/H#4c, FIG. 35). The scFv proteins were expressed in *E. coli* and affinity purified from bacterial supernatants on Protein L columns (see example 17). The final MycHis-198AB2#102 and 50 55 8860-M/H#4c preparations were dialyzed against 50 mM imidazole, 100 mM NaCl, pH7.4 and analyzed in a chromogenic FVIII assay as described above (FIG. 36).

As can be seen in FIG. 36, the scfv construct MycHis-198AB2#102 gave rise to a substantial FXa generation whereas the negative controls 8860-M/H#4c and plain reaction buffer (IZ) did not.

60 65 FIG. 36 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) scFv fragment (MycHis-198AB2#102) in the presence of 2.3 nM human FIXa. As a positive control we used 4.8 pM FVIII whereas a unrelated scfv (8860-M/H#4c) and plain reaction buffer (IZ) served as negative controls.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 112

<210> SEQ ID NO 1
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer oligonucleotide MOCG1-2FOR

<400> SEQUENCE: 1

ctcaattttc ttgtccacct tggtgc 26

<210> SEQ ID NO 2
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer oligonucleotide MOCG3FOR

<400> SEQUENCE: 2

ctcgatttca ttgatcaact cagtct 26

<210> SEQ ID NO 3
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer oligonucleotide MOCMFOR

<400> SEQUENCE: 3

tggaatgggc acatgcagat ctct 24

<210> SEQ ID NO 4
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:primer MOCKFOR

<400> SEQUENCE: 4

ctcatttcctg ttgaagctct tgac 24

<210> SEQ ID NO 5
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell line 193/AD3 heavy chain CDR3 region

<400> SEQUENCE: 5

Tyr Gly Asn Ser Pro Lys Gly Phe Ala Tyr
1 5 10

<210> SEQ ID NO 6
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell line 193/K2 heavy chain CDR3 region

-continued

<400> SEQUENCE: 6

Asp Gly Gly His Gly Tyr Gly Ser Ser Phe Asp Tyr
1 5 10

<210> SEQ ID NO 7
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma
cell line 193/AB2 (derived from antibody 198/B1) heavy chain CDR3
region, peptide B1

<400> SEQUENCE: 7

Glu Gly Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Val
1 5 10

<210> SEQ ID NO 8
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma
cell line 198/A1 heavy chain CDR3 region, peptide A1

<400> SEQUENCE: 8

Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Val
1 5 10

<210> SEQ ID NO 9

<400> SEQUENCE: 9

000

<210> SEQ ID NO 10
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutated peptide A1/1 scrambled versioon of A1

<400> SEQUENCE: 10

Val Tyr Gly Phe Gly Trp Gly Tyr Glu Val Asn Asp Tyr
1 5 10

<210> SEQ ID NO 11
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutated peptide A1/2

<400> SEQUENCE: 11

Glu Glu Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Glu
1 5 10 15

Glu Glu

<210> SEQ ID NO 12
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutated peptide A1/3

-continued

<400> SEQUENCE: 12

```
Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
 1           5          10          15
```

Arg Arg

<210> SEQ ID NO 13

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutated peptide A1/4 scrambled version of A1/2

<400> SEQUENCE: 13

```
Glu Tyr Gly Glu Gly Tyr Gly Glu Val Asn Glu Tyr Asp Glu Phe Glu
 1           5          10          15
```

Trp Glu

<210> SEQ ID NO 14

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutated peptide A1/5 scrambled version of A1/3

<400> SEQUENCE: 14

```
Val Arg Tyr Arg Asn Arg Tyr Arg Trp Gly Tyr Arg Gly Arg Phe Gly
 1           5          10          15
```

Asp Glu

<210> SEQ ID NO 15

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutated peptide A1/3-scr3 scrambled version of A1/3

<400> SEQUENCE: 15

```
Arg Arg Arg Gly Glu Tyr Gly Val Tyr Trp Asn Gly Asp Phe Tyr Arg
 1           5          10          15
```

Arg Arg

<210> SEQ ID NO 16

<400> SEQUENCE: 16

000

<210> SEQ ID NO 17

<400> SEQUENCE: 17

000

<210> SEQ ID NO 18

<400> SEQUENCE: 18

000

<210> SEQ ID NO 19

-continued

```

<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-13 Alanine scan E-1-A-1

<400> SEQUENCE: 19

```

Arg	Arg	Arg	Ala
1	5	10	15

Arg Arg

```

<210> SEQ ID NO 20
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-1 Alanine scan G-2-A-2

<400> SEQUENCE: 20

```

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

```

<210> SEQ ID NO 21
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-2 Alanine scan G-3-A-3

<400> SEQUENCE: 21

```

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

```

<210> SEQ ID NO 22
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-3 Alanine scan G-4-A-4

<400> SEQUENCE: 22

```

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

```

<210> SEQ ID NO 23
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-4 Alanine scan Y-5-A-5

<400> SEQUENCE: 23

```

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

-continued

```

<210> SEQ ID NO 24
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-5 Alanine scan Y-6-A-6

<400> SEQUENCE: 24

```

Arg	Arg	Arg	Glu	Gly	Gly	Tyr	Ala	Val	Asn	Trp	Tyr	Phe	Asp	Arg
1			5			10						15		

Arg Arg

```

<210> SEQ ID NO 25
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-6 Alanine scan V-7-A-7

<400> SEQUENCE: 25

```

Arg	Arg	Arg	Glu	Gly	Gly	Tyr	Tyr	Ala	Asn	Trp	Tyr	Phe	Asp	Arg
1			5			10						15		

Arg Arg

```

<210> SEQ ID NO 26
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-7 Alanine scan N-8-A-8

<400> SEQUENCE: 26

```

Arg	Arg	Arg	Glu	Gly	Gly	Tyr	Tyr	Val	Ala	Trp	Tyr	Phe	Asp	Arg
1			5			10						15		

Arg Arg

```

<210> SEQ ID NO 27
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-8 Alanine scan W-9-A-9

<400> SEQUENCE: 27

```

Arg	Arg	Arg	Glu	Gly	Gly	Tyr	Tyr	Val	Asn	Ala	Tyr	Phe	Asp	Arg
1			5			10						15		

Arg Arg

```

<210> SEQ ID NO 28
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-9 Alanine scan Y-10-A-10

<400> SEQUENCE: 28

```

Arg	Arg	Arg	Glu	Gly	Gly	Tyr	Tyr	Val	Asn	Trp	Ala	Phe	Asp	Arg
1			5			10						15		

Arg Arg

-continued

```

<210> SEQ ID NO 29
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-10 Alanine scan F-11-A-11

```

<400> SEQUENCE: 29

Arg	Arg	Arg	Glu	Gly	Gly	Tyr	Tyr	Val	Asn	Trp	Tyr	Ala	Asp	Arg
1			5			10			15					

Arg Arg

```

<210> SEQ ID NO 30
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-11 Alanine scan D-12-A-12

```

<400> SEQUENCE: 30

Arg	Arg	Arg	Glu	Gly	Gly	Tyr	Tyr	Val	Asn	Trp	Tyr	Phe	Ala	Arg
1			5			10			15					

Arg Arg

```

<210> SEQ ID NO 31
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-12srmb scrambled version

```

<400> SEQUENCE: 31

Arg	Arg	Tyr	Val	Tyr	Asn	Gly	Trp	Gly	Tyr	Phe	Glu	Gly	Ala	Arg
1			5			10			15					

Arg Arg

```

<210> SEQ ID NO 32
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-22 Glutamic acid scan G-2-E-2

```

<400> SEQUENCE: 32

Arg	Arg	Glu	Glu	Gly	Gly	Tyr	Tyr	Val	Asn	Trp	Tyr	Phe	Asp	Arg
1			5			10			15					

Arg Arg

```

<210> SEQ ID NO 33
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-23 Glutamic acid scan G-3-E-3

```

<400> SEQUENCE: 33

Arg	Arg	Glu	Glu	Gly	Gly	Tyr	Tyr	Val	Asn	Trp	Tyr	Phe	Asp	Arg
1			5			10			15					

Arg Arg

-continued

```

<210> SEQ ID NO 34
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-24 Glutamic acid scan G-4-E-4

<400> SEQUENCE: 34

```

Arg Arg Arg Glu Gly Gly Glu Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

```

<210> SEQ ID NO 35
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-26 Glutamic acid scan Y-5-E-5

<400> SEQUENCE: 35

```

Arg Arg Arg Glu Gly Gly Glu Tyr Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

```

<210> SEQ ID NO 36
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-27 Glutamic acid scan Y-6-E-6

<400> SEQUENCE: 36

```

Arg Arg Arg Glu Gly Gly Tyr Glu Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

```

<210> SEQ ID NO 37
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-28 Glutamic acid scan V-7-E-7

<400> SEQUENCE: 37

```

Arg Arg Arg Glu Gly Gly Tyr Tyr Glu Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

```

<210> SEQ ID NO 38
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-29 Glutamic acid scan N-8-E-8

<400> SEQUENCE: 38

```

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Glu Trp Tyr Phe Asp Arg
 1 5 10 15

-continued

Arg Arg

<210> SEQ ID NO 39
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutant peptide A1/3-30 Glutamic acid scan W-9-E-9

<400> SEQUENCE: 39

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

<210> SEQ ID NO 40
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutant peptide A1/3-31 Glutamic acid scan Y-10-E-10

<400> SEQUENCE: 40

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

<210> SEQ ID NO 41
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutant peptide A1/3-32 Glutamic acid scan F-11-E-11

<400> SEQUENCE: 41

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

<210> SEQ ID NO 42
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutant peptide A1/3-33 Glutamic acid scan D12-E-12

<400> SEQUENCE: 42

Arg	Arg	Arg	Glu
1	5	10	15

Arg Arg

<210> SEQ ID NO 43
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/A1 derived mutant peptide A1/3-34srmb scrambled version

<400> SEQUENCE: 43

Arg	Arg	Arg	Gly
1	5	10	15

-continued

Arg Arg

<210> SEQ ID NO 44

<400> SEQUENCE: 44

000

<210> SEQ ID NO 45

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/4

<400> SEQUENCE: 45

Arg Glu Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Arg
1 5 10

<210> SEQ ID NO 46

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/5 scrambled version

<400> SEQUENCE: 46

Phe Gly Val Gly Tyr Arg Gly Glu Thr Arg Asn Phe Asp Trp
1 5 10

<210> SEQ ID NO 47

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/6

<400> SEQUENCE: 47

Glu Glu Glu Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Glu
1 5 10 15

Glu Glu

<210> SEQ ID NO 48

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/7

<400> SEQUENCE: 48

Arg Arg Arg Glu Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Arg
1 5 10 15

Arg Arg

<210> SEQ ID NO 49

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/7scr3 scrambled version

-continued

<400> SEQUENCE: 49

```
Arg Arg Arg Phe Gly Val Gly Tyr Gly Glu Thr Asn Phe Asp Trp Arg
 1           5          10          15
```

Arg Arg

```
<210> SEQ_ID NO 50
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
      back primer VH1BACK-Sfi
```

<400> SEQUENCE: 50

```
catgccatga ctcgcggccc agccggccat ggccsaggt marctgcags agtcwgg      57
```

```
<210> SEQ_ID NO 51
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
      back primer VH1BACKSfi
```

<400> SEQUENCE: 51

```
gtcctcgcaa ctgcggccca gccggccatg gccgagggtgc agcttcagga gtcagg      56
```

```
<210> SEQ_ID NO 52
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
      back primer VH2BACKSfi
```

<400> SEQUENCE: 52

```
gtcctcgcaa ctgcggccca gccggccatg gccgatgtgc agcttcagga gtcagg      56
```

```
<210> SEQ_ID NO 53
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
      back primer VH3BACKSfi
```

<400> SEQUENCE: 53

```
gtcctcgcaa ctgcggccca gccggccatg gcccagggtgc agctgaagsa gtcagg      56
```

```
<210> SEQ_ID NO 54
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
      back primer VH4/6BACKSfi
```

<400> SEQUENCE: 54

```
gtcctcgcaa ctgcggccca gccggccatg gcccagggtyc agctgcarca rtctgg      56
```

```
<210> SEQ_ID NO 55
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
```

-continued

```

back primer VH5/9BACKSfi

<400> SEQUENCE: 55

gtcctcgcaa ctgcggccca gccggccatg gcccaggtyc arctgcagca gyctgg      56

<210> SEQ ID NO 56
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
    back primer VH7BACKSfi

<400> SEQUENCE: 56

gtcctcgcaa ctgcggccca gccggccatg gccgargtga agctggtgga rtctgg      56

<210> SEQ ID NO 57
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
    back primer VH8BACKSfi

<400> SEQUENCE: 57

gtcctcgcaa ctgcggccca gccggccatg gccgaggttc agtttcagca gtctgg      56

<210> SEQ ID NO 58
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
    back primer VH10BACKSfi

<400> SEQUENCE: 58

gtcctcgcaa ctgcggccca gccggccatg gccgaagtgc agctgktgga gwctgg      56

<210> SEQ ID NO 59
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
    back primer VH11BACKSfi

<400> SEQUENCE: 59

gtcctcgcaa ctgcggccca gccggccatg gcccagatcc agttgtcgtca gtctgg      56

<210> SEQ ID NO 60
<211> LENGTH: 68
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
    forward primer VH1FOR2LiAsc

<400> SEQUENCE: 60

accgccagag gcgcgcac ctgaaccgcc tccacctgag gagacggtga ccgtggtccc      60
ttggcccc      68

<210> SEQ ID NO 61
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

```

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH1FORLiAsc

<400> SEQUENCE: 61

accgccagag gcgcgcccac ctgaaccgcc tccacctgag gagacggtga ccgtggtccc 60

<210> SEQ ID NO 62

<211> LENGTH: 60

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH2FORLiAsc

<400> SEQUENCE: 62

accgccagag gcgcgcccac ctgaaccgcc tccacctgag gagactgtga gagtggtgcc 60

<210> SEQ ID NO 63

<211> LENGTH: 60

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH3FORLiAsc

<400> SEQUENCE: 63

accgccagag gcgcgcccac ctgaaccgcc tccacctgca gagacagtga ccagagtccc 60

<210> SEQ ID NO 64

<211> LENGTH: 60

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH4FORLiAsc

<400> SEQUENCE: 64

accgccagag gcgcgcccac ctgaaccgcc tccacctgag gagacggtga ctgaggttcc 60

<210> SEQ ID NO 65

<211> LENGTH: 60

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK2BACK-LiAscI

<400> SEQUENCE: 65

ggttcagatg ggcgccctc tggcggtggc ggatcgac ttgagctcac ccagtctcca 60

<210> SEQ ID NO 66

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK1BACKLi Asc

<400> SEQUENCE: 66

ggttcagatg ggcgccctc tggcggtggc ggatcgac ttgtgatgwc acagtctcc 59

<210> SEQ ID NO 67

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse

-continued

V-kappa back primer VK2BACKLi Asc

<400> SEQUENCE: 67

ggttcagatg ggccgcgcctc tggcggtggc ggatcggatg ttktgtatgac ccaaactcc 59

<210> SEQ ID NO 68

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK3BACKLi Asc

<400> SEQUENCE: 68

ggttcagatg ggccgcgcctc tggcggtggc ggatcggata ttgtgtatrac bcaggcwg 59

<210> SEQ ID NO 69

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK4BACKLi Asc

<400> SEQUENCE: 69

ggttcagatg ggccgcgcctc tggcggtggc ggatcggaca ttgtgctgac mcartctcc 59

<210> SEQ ID NO 70

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK5BACKLi Asc

<400> SEQUENCE: 70

ggttcagatg ggccgcgcctc tggcggtggc ggatcgsaaa wtgtkctcac ccagtctcc 59

<210> SEQ ID NO 71

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK6BACKLi Asc

<400> SEQUENCE: 71

ggttcagatg ggccgcgcctc tggcggtggc ggatcggaya tyvvgatgac mcagwctcc 59

<210> SEQ ID NO 72

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK7BACKLi Asc

<400> SEQUENCE: 72

ggttcagatg ggccgcgcctc tggcggtggc ggatcgcaaa ttgttctcac ccagtctcc 59

<210> SEQ ID NO 73

<211> LENGTH: 59

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK8BACKLi Asc

-continued

<400> SEQUENCE: 73

ggttcagatg ggccgcgc tggcggtggc ggatcgcat tattcagg gcttgggg 59

<210> SEQ ID NO 74
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK1NOT10

<400> SEQUENCE: 74

gagtcatattct gcggccgccc gtttgatttc cagcttggcc cc 42

<210> SEQ ID NO 75
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK2NOT10

<400> SEQUENCE: 75

gagtcatattct gcggccgccc gttttatttc cagcttggcc cc 42

<210> SEQ ID NO 76
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK3NOT10

<400> SEQUENCE: 76

gagtcatattct gcggccgccc gttttatttc cagcttggcc cc 42

<210> SEQ ID NO 77
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK4NOT10

<400> SEQUENCE: 77

gagtcatattct gcggccgccc gttttatttc caactttggcc cc 42

<210> SEQ ID NO 78
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK5NOT10

<400> SEQUENCE: 78

gagtcatattct gcggccgccc gtttcagctc cagcttggcc cc 42

<210> SEQ ID NO 79
<211> LENGTH: 74
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
oligonucleotide mychis6-co

-continued

<400> SEQUENCE: 79

ggccgcagaa caaaaactca ttcagaaga ggatctgaat gggcgac atcaccatca	60
ccatcactaa taag	74

<210> SEQ ID NO 80

<211> LENGTH: 74
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
oligonucleotide mychis-ic

<400> SEQUENCE: 80

aattcttatt agtcatggtg atggatgtg cccggccat tcagatcctc ttctgagatg	60
agttttttgtt ctgc	74

<210> SEQ ID NO 81

<211> LENGTH: 726
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
hybridoma cell line 193/AD3

<400> SEQUENCE: 81

gaggtgaagc tggggaggc tggacctgag ctgaagaagc ctggagagac agtcaagatc	60
tccctgcaagg cttctggta tatcttcaca aactatggaa tgaactgggt gaagcaggct	120
ccagggaaagg gtttaaagtg gatgggctgg ataaacacct acactggaga gccaacatat	180
gctgtatgact tcaagggacg gtttgccttc tctttggaaa cctctgcacg cactgcctat	240
ttgcagatca acaaccta aatgaggac acggctacat atttctgtgc attatatgg	300
aactccccata aggggtttgc ttactggggc caagggactc tggtcactgt ctctgcagg	360
ggaggcgggtt caggtggcg cgccctcggc ggtggcgat cggatattca gatgacacag	420
tctcccaaataat ccctgcttgt atcagcaggaa gacagggtt ccataaacctg caaggccagt	480
cagagtgtga gtaatgtatg agcttggta caacagaagc cggggcagtc tcctaaacta	540
ctgtatgtact atgcattccaa tcgctacact ggagtccctg atcgcttcac tggcagtgg	600
tatggacgg atttcactt caccatcagg actgtgcagg ctgaagacct ggcagtttat	660
ttctgtcaggc aggattatgg ctctccccc acgttcggag ggggcaccaa gctggaaatt	720
aaacgg	726

<210> SEQ ID NO 82

<211> LENGTH: 242
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
hybridoma cell line 193/AD3

<400> SEQUENCE: 82

Glu Val Lys Leu Val Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu	
1 5 10 15	

Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr	
20 25 30	

Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met	
35 40 45	

Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe

-continued

50	55	60		
Lys	Gly	Arg	Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr	
65		70	75	80
Leu	Gln	Ile	Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys	
		85	90	95
Ala	Leu	Tyr	Gly Asn Ser Pro Lys Gly Phe Ala Tyr Trp Gly Gln Gly	
	100		105	110
Thr	Leu	Val	Thr Val Ser Ala Gly Gly Gly Ser Gly Gly Arg Ala	
	115		120	125
Ser	Gly	Gly	Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Lys Phe	
	130		135	140
Leu	Leu	Val	Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser	
145		150	155	160
Gln	Ser	Val	Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln	
	165		170	175
Ser	Pro	Lys	Leu Leu Met Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val	
	180		185	190
Pro	Asp	Arg	Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr	
	195		200	205
Ile	Ser	Thr	Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln	
	210		215	220
Asp	Tyr	Gly	Ser Pro Pro Thr Phe Gly Gly Thr Lys Leu Glu Ile	
225		230	235	240
Lys Arg				

<210> SEQ ID NO 83
 <211> LENGTH: 747
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
 hybridoma cell line 193/K2

<400> SEQUENCE: 83

gaagtgcagc	tgggggaggc	ctagtgaagc	ctggagggtc	cctgaaactc	60
tcctgtgcag	cctctggatt	cactttcagt	acctataccca	tgtcttgggt	120
ccggagaaga	ggctggagtg	ggtcgcaacc	attagtagtg	gtggtagtta	180
ccagacagtg	tgagggcccg	attcaccatc	tccagagaca	atgccaagaa	240
ctgcaaatga	gcagtctgaa	gtctgaggac	acagccatgt	attactgtac	300
ggacacgggt	acggtagtag	cttgactac	tggggccaag	gcaccactct	360
tcaggtggag	gcgggttcagg	tgggcgcgc	tctggcggtg	gcggatcgca	420
acccagtctc	cactctccct	gcctgtcagt	cttggagatc	aagcctccat	480
tctagtcaga	gcattgtaca	tagtaatgga	aacacctatt	tagaatggta	540
ccaggccagt	ctccaaagct	cctgatctac	aaagttcca	accgatttc	600
gacaaattca	gtggcagtgg	atcagggaca	gatttcacac	tcaagatcag	660
gctgaggatc	tgggagttta	ttactgcttt	caaggttac	atgttccgtg	720
ggaggcacca	agctggaaat	caaacgg			747

<210> SEQ ID NO 84
 <211> LENGTH: 249
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from hybridoma cell line 193/K2

<400> SEQUENCE: 84

Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly
1															
														10	15

Ser	Leu	Lys	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Thr	Tyr	
														20	25	30

Thr	Met	Ser	Trp	Val	Arg	Gln	Thr	Pro	Glu	Lys	Arg	Leu	Glu	Trp	Val	
														35	40	45

Ala	Thr	Ile	Ser	Ser	Gly	Gly	Ser	Tyr	Thr	Tyr	Tyr	Pro	Asp	Ser	Val	
														50	55	60

Arg	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr		
														65	70	75	80

Leu	Gln	Met	Ser	Ser	Leu	Lys	Ser	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys	
														85	90	95

Thr	Arg	Asp	Gly	Gly	His	Gly	Tyr	Gly	Ser	Ser	Phe	Asp	Tyr	Trp	Gly	
														100	105	110

Gln	Gly	Thr	Thr	Leu	Thr	Val	Ser	Ser	Gly	Gly	Gly	Ser	Gly	Gly		
														115	120	125

Arg	Ala	Ser	Gly	Gly	Gly	Ser	Gln	Ile	Val	Leu	Thr	Gln	Ser	Pro		
														130	135	140

Leu	Ser	Leu	Pro	Val	Ser	Leu	Gly	Asp	Gln	Ala	Ser	Ile	Ser	Cys	Arg		
														145	150	155	160

Ser	Ser	Gln	Ser	Ile	Val	His	Ser	Asn	Gly	Asn	Thr	Tyr	Leu	Glu	Trp	
														165	170	175

Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Ser	Pro	Lys	Leu	Leu	Ile	Tyr	Lys	Val	
														180	185	190

Ser	Asn	Arg	Phe	Ser	Gly	Val	Pro	Asp	Lys	Phe	Ser	Gly	Ser			
														195	200	205

Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Leu	
														210	215	220

Gly	Val	Tyr	Tyr	Cys	Phe	Gln	Gly	Ser	His	Val	Pro	Trp	Thr	Phe	Gly		
														225	230	235	240

Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg

<210> SEQ ID NO 85

<211> LENGTH: 747

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from hybridoma cell line 198/AB2 (subclone of 198/B1)

<400> SEQUENCE: 85

gaggtgcagc	tccaggagtc	agggggaggc	ttagtgaagc	ctggagggtc	cctgaaactc	60
tcctgtgcag	cctctggatt	cactttcagt	agctataccca	tgtcttgggt	tcgcccact	120
ccggagaaga	ggctggagtg	ggtcgcaacc	attagtagtg	gtggtagttc	cacctactat	180
ccagacagtg	tgaaggggccg	attcaccatc	tccagagaca	atgccaagaa	caccctgtac	240
ctgcaaatga	gcagtctgag	gtctgaggac	acagccatgt	attactgtac	aagagagggg	300
ggtggtttca	cctgtcaactg	gtacttcgat	gtctggggcg	cagggactct	ggtcactgtc	360
tctgcagggtg	gaggcgggttc	aggtggggcgc	gcctctggcg	gtggcggatc	ggaaaatgtg	420

-continued

ctcacccagt	ctccagcttc	tttggctgtg	tctctaggc	agagggccac	cataatcctgc	480
agagccagt	aaagtgttga	tagttatggc	tataatttta	tgcactgta	tcagcagata	540
ccaggacagc	cacccaaact	cctcatctat	cgtgcaccca	accttagagtc	tgggatccct	600
gccaggttca	gtggcagtgg	gtctaggaca	gacttcaccc	tcaccattaa	tcctgtggag	660
gctgatgatg	ttgcaaccta	ttactgtcag	caaagtaatg	aggatccgct	cacgttcggt	720
actgggacca	gactggaaat	aaaacgg				747

<210> SEQ ID NO 86
<211> LENGTH: 249
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from hybridoma cell line 198/AB2 (subclone of 198/B1)

<400> SEQUENCE: 86

Glu	Val	Gln	Leu	Gln	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly
1				5				10				15			
Ser	Leu	Lys	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
	20				25					30					
Thr	Met	Ser	Trp	Val	Arg	Gln	Thr	Pro	Glu	Lys	Arg	Leu	Glu	Trp	Val
	35				40					45					
Ala	Thr	Ile	Ser	Ser	Gly	Gly	Ser	Ser	Thr	Tyr	Tyr	Pro	Asp	Ser	Val
	50				55				60						
Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Thr	Leu	Tyr
	65				70				75				80		
Leu	Gln	Met	Ser	Ser	Leu	Arg	Ser	Glu	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
	85					90					95				
Thr	Arg	Glu	Gly	Gly	Phe	Thr	Val	Asn	Trp	Tyr	Phe	Asp	Val	Trp	
	100				105					110					
Gly	Ala	Gly	Thr	Leu	Val	Thr	Val	Ser	Ala	Gly	Gly	Gly	Ser	Gly	
	115				120				125						
Gly	Arg	Ala	Ser	Gly	Gly	Gly	Ser	Glu	Asn	Val	Leu	Thr	Gln	Ser	
	130				135				140						
Pro	Ala	Ser	Leu	Ala	Val	Ser	Leu	Gly	Gln	Arg	Ala	Thr	Ile	Ser	Cys
	145				150				155			160			
Arg	Ala	Ser	Glu	Ser	Val	Asp	Ser	Tyr	Gly	Tyr	Asn	Phe	Met	His	Trp
	165					170			175						
Tyr	Gln	Gln	Ile	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Arg	Ala
	180				185				190						
Ser	Asn	Leu	Glu	Ser	Gly	Ile	Pro	Ala	Arg	Phe	Ser	Gly	Ser		
	195				200				205						
Arg	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Asn	Pro	Val	Glu	Ala	Asp	Asp	Val
	210				215				220						
Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Ser	Asn	Glu	Asp	Pro	Leu	Thr	Phe	Gly
	225				230				235			240			
Thr	Gly	Thr	Arg	Leu	Glu	Ile	Lys	Arg							
	245														

<210> SEQ ID NO 87
<211> LENGTH: 747
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv derived from hybridoma cell line 198/A1

-continued

```
<220> FEATURE: 
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(747)
<223> OTHER INFORMATION: n = g, a, c or t

<400> SEQUENCE: 87

gagggtgcagc ttcaaggagtc agggggaggc ttatgtaaagc ctggggggtc cctgaaaactc 60
tcctgtgcag cctctggatt catttttagt agttataccca tgtcttggt tcgccagact 120
ccggagaaga ggctggagtg ggtcgcaacc attagtagtg gtggtagttc cacctactat 180
ccagacagtg tgaagggcgc attaccatc tccagagaca atgccaagaa caccctgtac 240
ctgcaaataatg gcagtctgaa gtcgtggagac acagccatgt atcactgtac aagagaggg 300
ggtgtgttatt acgtcaactg gtacttcgat gtctgggcgc caggcaccac tctcacagtc 360
tcctcagggtg gaggcggttc aggtggcgc gcctctggcg gtggcggtac ggacatttag 420
ctcacncagt ctccagcttc tttggctgtg tctctagggc agagggccac catatcctgc 480
agagccagt aaagtgttga tagttatggc aagagttta tgcactggta ccagcagaaa 540
ccagggcgcg cacccaaact cctcatctat cgtgcaccca acctagaatc tggatccct 600
gccaggggtca gtggcagttgg gtctaggaca gacttcccc tcaccattaa tcctgtggag 660
gtctgtatgttgcnaaccta ttactgtcag caaatgtatc aggtatccc cacgttcgggt 720
gtctgggacca gactqaaaat aaaacgg 747
```

<210> SEQ ID NO 88
<211> LENGTH: 249
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv derived from hybridoma cell line 198/A1

<400> SEQUENCE: 88
 Glu Val Gln Leu Gln Glu Ser Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr
 20 25 30
 Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
 35 40 45
 Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr Tyr Tyr Pro Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr His Cys
 85 90 95
 Thr Arg Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Val Trp
 100 105 110
 Gly Ala Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Ser Gly
 115 120 125
 Gly Arg Ala Ser Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser
 130 135 140
 Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys
 145 150 155 160
 Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Lys Ser Phe Met His Trp
 165 170 175
 Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala
 180 185 190

-continued

Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser
195 200 205

Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val
210 215 220

Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly
225 230 235 240

Ala Gly Thr Arg Leu Glu Ile Lys Arg
245

```

<210> SEQ_ID NO 89
<211> LENGTH: 2199
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:198A2
      scFv-alkaline phosphatase fusion protein (ORF of expression
      vector pDAP2-198AB2#100)
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (228)
<223> OTHER INFORMATION: n = g, a, c or t

```

<400> SEQUENCE: 89

atgaaatacc	tattgcctac	ggcagccgcgt	ggattgttat	tactcgccgc	ccagccggcc	60
atggcggagg	tgaagctgggt	ggagtctggg	ggaggccttag	tgaagcctgg	agggtccctg	120
aaactctcct	gtgcagccctc	tggattcaact	ttcagtagct	ataccatgtc	ttgggttcgc	180
cagactccgg	agaagaggct	ggagtggttc	gcaaccattha	gtagtggngg	tagtccacc	240
tactatccag	acagtgtgaa	gggccgattc	accatctcca	gagacaatgc	caagaacacc	300
ctgtacctgc	aatgagcacag	tctgaggctc	gaggacacag	ccatgttatta	ctgtacaaga	360
gagggggggtg	gtttcaccgt	caactggta	ttcgatgtct	ggggcgcagg	aacctcagtc	420
accgtctcct	caggtggagg	cggttcaggt	gggcgcgcct	ctggcggtgg	cgatcggac	480
attgtgctga	cacagtctcc	agcttctttg	gctgtgtctc	tagggcagag	ggccaccata	540
tcctgcagag	ccagtgaaag	tgttgatagt	tatggctata	attttatgca	ctggatcatcg	600
cagataccag	gacagccacc	caaactcctc	atctatcg	catccaaacct	agagtctgg	660
atcccgtccca	ggttcagtgg	cagtgggtct	aggacagact	tcaccctcac	cattaatcct	720
gtggaggctg	atgatgttgc	aaccttattac	tgtcagcaaa	gtaatgagga	tccgctcacg	780
ttcgggtactg	ggaccagact	gaaataaaa	cgggcggcccg	cagcccgccgc	accagaaaatg	840
cctgttctgg	aaaaccgggc	tgctcagggc	gatattactg	cacccggccg	tgctcggcgt	900
ttaacgggtg	atcagactgc	cgctctgcgt	gattctctta	gcfataaaacc	tgcaaaaaat	960
attatttgc	tgattggcga	tggatgggg	gactcgaaaa	ttactgccc	acgtaattat	1020
gccgaagggtg	cgggcggcgtt	ttttaaagggt	atagatgcct	taccgcttac	cgggcaatac	1080
actcaactatg	cgtgaataaa	aaaaaccggc	aaaccggact	acgtcaccga	ctcgggtgca	1140
tcagcaaccg	cctggtaaac	cggtgtcaaa	acctataacg	gcccgcgtgg	cgtcgtat	1200
cacgaaaaag	atcaccaac	gattctggaa	atggcaaaag	ccgcaggct	ggcggaccgt	1260
aacgtttcta	ccgcagagtt	gcaggatgcc	acgccccgt	cgctgggtgc	acatgtgacc	1320
tcgcgcaaat	gctacggtcc	gagcgcgacc	agtaaaaat	gtccggtaa	cgctctggaa	1380
aaaggcggaa	aaggatcgat	taccgaacag	ctgcttaacg	ctcgtccga	cgttacgctt	1440
ggcggcggcg	caaaaacctt	tgctgaaacg	gcaaccgcgt	gtgaatggca	ggaaaaaacg	1500

-continued

```

ctgcgtgaac aggcacaggc gcgtggttat cagttggtaa gcgatgctgc ctcactgaat    1560
tcggtgacgg aagcgaatca gcaaaaacc cttgtggcc tggggctgtga cggcaatata    1620
ccagtgcgtt ggcttaggacc gaaagcaacg taccatggca atatcgatata gccccgagtc    1680
acctgtacgc caaatccgca acgtaatgac agtgttaccaa ccctggcgca gatgaccgac    1740
aaagccattt aattgtttag taaaaatggaa aaaggcttt tcctgcaagt tgaagggtgc    1800
tcaatcgata aacaggatca tgctgcaat ccttggggc aaattggcgaa gacgggtcgat    1860
ctcgatgaag ccgtacaacg ggcgctggaa ttcgctaaaa aggagggtaa cacgctggtc    1920
atagtcaccc ctgtacacgc ccacgcccacg cagattgttgc cgccggatac caaagctccg    1980
ggcctcaccc aggcgctaaa taccaaagat ggcgcagtgaa tggtgtatgaa ttacggaaac    2040
tccgaagagg attcacaaga acataccggc agtcagttgc gtattggggc gtatggcccg    2100
catgccgcca atgttgggg actgaccgac cagaccgatc tcttctacac catgaaagcc    2160
gctctggggg atatcgacca ccatcaccat caccattaa                                2199

```

```

<210> SEQ_ID NO 90
<211> LENGTH: 732
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:198A2
      scFv-alkaline phosphatase fusion protein (ORF of expression
      vector pDAP2-198AB2#100)

```

```
<400> SEQUENCE: 90
```

```

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
   1           5           10          15

Ala Gln Pro Ala Met Ala Glu Val Lys Leu Val Glu Ser Gly Gly Gly
   20          25          30

Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
   35          40          45

Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu
   50          55          60

Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr
   65          70          75          80

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
   85          90          95

Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp
  100         105          110

Thr Ala Met Tyr Tyr Cys Thr Arg Glu Gly Gly Phe Thr Val Asn
  115         120          125

Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Ser Val Thr Val Ser Ser
  130         135          140

Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Ser Asp
  145         150          155          160

Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln
  165         170          175

Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly
  180         185          190

Tyr Asn Phe Met His Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys
  195         200          205

Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg
  210         215          220

Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro

```

-continued

225	230	235	240
Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu			
245	250	255	
Asp Pro Leu Thr Phe Gly Thr Gly Thr Arg Leu Glu Ile Lys Arg Ala			
260	265	270	
Ala Ala Ala Arg Ala Pro Glu Met Pro Val Leu Glu Asn Arg Ala Ala			
275	280	285	
Gln Gly Asp Ile Thr Ala Pro Gly Gly Ala Arg Arg Leu Thr Gly Asp			
290	295	300	
Gln Thr Ala Ala Leu Arg Asp Ser Leu Ser Asp Lys Pro Ala Lys Asn			
305	310	315	320
Ile Ile Leu Leu Ile Gly Asp Gly Met Gly Asp Ser Glu Ile Thr Ala			
325	330	335	
Ala Arg Asn Tyr Ala Glu Gly Ala Gly Phe Phe Lys Gly Ile Asp			
340	345	350	
Ala Leu Pro Leu Thr Gly Gln Tyr Thr His Tyr Ala Leu Asn Lys Lys			
355	360	365	
Thr Gly Lys Pro Asp Tyr Val Thr Asp Ser Ala Ala Ser Ala Thr Ala			
370	375	380	
Trp Ser Thr Gly Val Lys Thr Tyr Asn Gly Ala Leu Gly Val Asp Ile			
385	390	395	400
His Glu Lys Asp His Pro Thr Ile Leu Glu Met Ala Lys Ala Ala Gly			
405	410	415	
Leu Ala Thr Gly Asn Val Ser Thr Ala Glu Leu Gln Asp Ala Thr Pro			
420	425	430	
Ala Ala Leu Val Ala His Val Thr Ser Arg Lys Cys Tyr Gly Pro Ser			
435	440	445	
Ala Thr Ser Glu Lys Cys Pro Gly Asn Ala Leu Glu Lys Gly Lys			
450	455	460	
Gly Ser Ile Thr Glu Gln Leu Leu Asn Ala Arg Ala Asp Val Thr Leu			
465	470	475	480
Gly Gly Gly Ala Lys Thr Phe Ala Glu Thr Ala Thr Ala Gly Glu Trp			
485	490	495	
Gln Gly Lys Thr Leu Arg Glu Gln Ala Gln Ala Arg Gly Tyr Gln Leu			
500	505	510	
Val Ser Asp Ala Ala Ser Leu Asn Ser Val Thr Glu Ala Asn Gln Gln			
515	520	525	
Lys Pro Leu Leu Gly Leu Phe Ala Asp Gly Asn Met Pro Val Arg Trp			
530	535	540	
Leu Gly Pro Lys Ala Thr Tyr His Gly Asn Ile Asp Lys Pro Ala Val			
545	550	555	560
Thr Cys Thr Pro Asn Pro Gln Arg Asn Asp Ser Val Pro Thr Leu Ala			
565	570	575	
Gln Met Thr Asp Lys Ala Ile Glu Leu Leu Ser Lys Asn Glu Lys Gly			
580	585	590	
Phe Phe Leu Gln Val Glu Gly Ala Ser Ile Asp Lys Gln Asp His Ala			
595	600	605	
Ala Asn Pro Cys Gly Gln Ile Gly Glu Thr Val Asp Leu Asp Glu Ala			
610	615	620	
Val Gln Arg Ala Leu Glu Phe Ala Lys Lys Glu Gly Asn Thr Leu Val			
625	630	635	640
Ile Val Thr Ala Asp His Ala His Ala Ser Gln Ile Val Ala Pro Asp			
645	650	655	

-continued

Thr Lys Ala Pro Gly Leu Thr Gln Ala Leu Asn Thr Lys Asp Gly Ala
660 665 670

Val Met Val Met Ser Tyr Gly Asn Ser Glu Glu Asp Ser Gln Glu His
675 680 685

Thr Gly Ser Gln Leu Arg Ile Ala Ala Tyr Gly Pro His Ala Ala Asn
690 695 700

Val Val Gly Leu Thr Asp Gln Thr Asp Leu Phe Tyr Thr Met Lys Ala
705 710 715 720

Ala Leu Gly Asp Ile Ala His His His His His His
725 730

<210> SEQ ID NO 91
<211> LENGTH: 978
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:plasmid
pZip-198AB2#102
<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(978)
<223> OTHER INFORMATION: n = g, a, c or t

<400> SEQUENCE: 91

atgaaatacc	tattgcctac	ggcagccgct	ggattgttat	tactcgccgc	ccagccggcc	60
atggcggagg	tgaagcttgt	ggagtctggg	ggaggcttag	tgaagcttgg	agggtccctg	120
aaactctctt	gtgcagcctc	tggattcaact	tgcagtagct	ataccatgtc	ttgggttcgc	180
cagactccgg	agaagaggct	ggagtgggtc	gcaaccattha	gtagtggngg	tagttccacc	240
tactatccag	acagtgtgaa	ggcccgattc	accatctcca	gagacaatgc	caagaacacc	300
ctgtacctgc	aatagagcag	tctgaggctt	gaggacacag	ccatgttatta	ctgtacaaga	360
gaggggggtg	gtttcacccgt	caactggtaac	tgcgtatgtct	ggggcgccagg	aacctcagtc	420
accgtctcct	cagggtggagg	cggttcagggt	gggcgcgcct	ctggcggtgg	cggatcggac	480
attgtgctga	cacagtntcc	agtttcttttg	gctgtgtctc	tagggcagag	ggccaccata	540
tcntgcagag	ccagtgaaag	tgttgatagt	tatggctata	attttatgca	ctggtatcag	600
cagataccag	gacagccacc	caaactccctc	atctatcgtg	catccaaacct	agagtctggg	660
atccctgcca	ggttcagtgg	cagtgggtct	aggacagact	tcaccctcac	cattaatcct	720
gtggaggctg	atgatgttgc	aaccttattac	tgtcagcaaa	gtaatgagga	tccgctcacg	780
ttcggtactg	ggaccagact	ggaaataaaaa	cgggcggccg	caccgaagcc	ttccactccg	840
cccggtctt	cccgtatgaa	acagctggaa	gacaaagtag	aggagctct	tagcaagaac	900
taccatctag	aaaacgaggt	agctcgtctg	aaaaagcttg	tttgtgaacg	tgggtggcac	960
catcaccatc	accattaa					978

<210> SEQ ID NO 92
<211> LENGTH: 325
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:plasmid
pZip-198AB2#102
<220> FEATURE:
<221> NAME/KEY: MOD_RES
<222> LOCATION: (166)
<223> OTHER INFORMATION: Xaa = Cys, Tyr, Ser or Phe

<400> SEQUENCE: 92

-continued

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Glu Val Lys Leu Val Glu Ser Gly Gly Gly
 20 25 30
 Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
 35 40 45
 Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu
 50 55 60
 Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr
 65 70 75 80
 Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
 85 90 95
 Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp
 100 105 110
 Thr Ala Met Tyr Tyr Cys Thr Arg Glu Gly Gly Phe Thr Val Asn
 115 120 125
 Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Ser Val Thr Val Ser Ser
 130 135 140
 Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Ser Asp
 145 150 155 160
 Ile Val Leu Thr Gln Xaa Pro Ala Ser Leu Ala Val Ser Leu Gly Gln
 165 170 175
 Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly
 180 185 190
 Tyr Asn Phe Met His Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys
 195 200 205
 Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg
 210 215 220
 Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro
 225 230 235 240
 Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu
 245 250 255
 Asp Pro Leu Thr Phe Gly Thr Gly Thr Arg Leu Glu Ile Lys Arg Ala
 260 265 270
 Ala Ala Pro Lys Pro Ser Thr Pro Pro Gly Ser Ser Arg Met Lys Gln
 275 280 285
 Leu Glu Asp Lys Val Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu
 290 295 300
 Asn Glu Val Ala Arg Leu Lys Lys Leu Val Gly Glu Arg Gly Gly His
 305 310 315 320
 His His His His
 325

<210> SEQ ID NO 93
 <211> LENGTH: 2190
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mAB#8860
 scFv-alkaline phosphatase fusion protein (vector construct
 pDAP2-8860scFv#11)

<400> SEQUENCE: 93
 atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgccgc ccagccggcc 60
 atggccgagg ttcagcttca gcagtctggc cctgagctgg tgaagccccgg ggcctcaagt 120

-continued

aagatttcct gcaaagcttc tggctacgca ttca	cttggatgaa ctgggtgaag	180
cagaggcctg gacagggtct tgagtggatt ggacggattt atcctggaaa tggagatact		240
aactacaatg ggaagttcaa gggcaaggcc acactgactg cagacaatc ctccagcaca		300
gcctacatgc agctcagcag cctgacctct gtggactctg cggtctatctt ctgtcgagat		360
gttaacgtat attactatgc tatggactac tggggtaaag gaacctcagt caccgtctcc		420
tcaggtggag gcggttcagg tgggcgcgcc tctggcggtg gcggatcgca aattgttctc		480
acccagtctc ctgcttcctt agctgtatct ctggggcaga gggccaccat ctcatcgagg		540
gccagcaaaa gtgtcagtagt atctggctat agttatatgc actggtagcca acagaaacca		600
ggacagccac ccaaactctt catctatctt gcatccaacc tagaatctgg ggtccctgcc		660
aggttcagtg gcagtgggtc tgggacagac ttcaccctca acatccatcc tgtggaggag		720
gaggatgctg caacatttta ctgtcagcac agtagggagc ttcctcgac gttcggttga		780
ggcaccaagc tggaaatcaa acgggcggcc gcagccccggg caccgaaaat gcctgttctg		840
aaaaaccggg ctgctcaggcg cgatattact gcacccggcg gtgctcgcc tttaacgggt		900
gatcagactg ccgctctcg tattttctt agcgataaac ctgaaaaaaaaa tattttttt		960
ctgattggcg atggatggg ggactcggaa attactgcg cacgtattaat tgccgaaagg		1020
gcgggcggct ttttaaagg tataatgcc ttaccgctt ccggcaataa cactactat		1080
gcgtgaata aaaaaaccgg caaacccggac tacgtcacccg actcggtcgtc atcagaacc		1140
gcctggtaa ccgggtgtcaa aacctataac ggccgcgttgc gcgtcgatata tcacgaaaaa		1200
gatcacccaa cgattcttggaa aatggcaaaa gcccgggtc tggcgaccgg taacgtttct		1260
accgcagagt tgcaggatgc cacgcggcgt gcgcgtgggg cacatgtgac ctcgcgc当地		1320
tgctacggtc cgagcgcgcac cagtgaaaaa tggccgggttgc acgctcttggaaaaggcg		1380
aaaggatcga ttaccgaaca gctgcttaac gctcgtcgcc acgttacgct tggcgccggc		1440
gcaaaaaaaaactt ttgctgaaac ggcaaccgc ggtgaatggc agggaaaaac gctgcgtgaa		1500
caggcacagg cgcgtggta tca		1560
gaagcgaatc agcaaaaaaaaacc cctgcgttgc ctgtttgtgc acggcaataat gccagtgcgc		1620
tggctaggac cgaaagcaac gtaccatggc aatatcgata agcccgactt caccgttacg		1680
ccaaatccgc aacgtaatga cagtgatcca accctggccg agatgaccga caaaggcatt		1740
gaattgttga gtaaaaaatga gaaaggctt ttccctgcaag ttgaagggtgc gtcaatcgat		1800
aaacaggatc atgctgcgaa tccttgggg caaattggcg agacggtcgaa tctcgatgaa		1860
gccgtacaac gggcgcttggaa attcgctaa aaggagggttgc acacgctgttgc atatgttacc		1920
gctgtatcacg cccacgcgcag ccagattgtt gcgcggata ccaaagctcc gggccttacc		1980
caggcgctaa ataccaaaga tggcgctgttgc atgggtatgaa gttacggggaa ctccgaaagag		2040
gattcacaag aacataccgg cagtcgttgc cgtattgggg cgtatggccc gcatgcgc当地		2100
aatgttggttt gactgaccga ccagaccgtt ctcttctaca ccatgaaagc cgctctgggg		2160
gatatcgac accatcacca tcaccattaa		2190

<210> SEQ ID NO 94
<211> LENGTH: 729
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mAB#8860
scFv-alkaline phosphatase fusion protein (vector construct)

-continued

pDAP2-8860scFv#11)

<400> SEQUENCE: 94

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1 5 10 15

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Gln Gln Ser Gly Pro Glu
 20 25 30

Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
 35 40 45

Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly
 50 55 60

Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asn Gly Asp Thr
 65 70 75 80

Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
 85 90 95

Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Val Asp
 100 105 110

Ser Ala Val Tyr Phe Cys Ala Asp Gly Asn Val Tyr Tyr Tyr Ala Met
 115 120 125

Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly
 130 135 140

Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Ser Gln Ile Val Leu
 145 150 155 160

Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr
 165 170 175

Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
 180 185 190

Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
 195 200 205

Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly
 210 215 220

Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu
 225 230 235 240

Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Arg
 245 250 255

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala Ala
 260 265 270

Arg Ala Pro Glu Met Pro Val Leu Glu Asn Arg Ala Ala Gln Gly Asp
 275 280 285

Ile Thr Ala Pro Gly Gly Ala Arg Arg Leu Thr Gly Asp Gln Thr Ala
 290 295 300

Ala Leu Arg Asp Ser Leu Ser Asp Lys Pro Ala Lys Asn Ile Ile Leu
 305 310 315 320

Leu Ile Gly Asp Gly Met Gly Asp Ser Glu Ile Thr Ala Ala Arg Asn
 325 330 335

Tyr Ala Glu Gly Ala Gly Gly Phe Phe Lys Gly Ile Asp Ala Leu Pro
 340 345 350

Leu Thr Gly Gln Tyr Thr His Tyr Ala Leu Asn Lys Lys Thr Gly Lys
 355 360 365

Pro Asp Tyr Val Thr Asp Ser Ala Ala Ser Ala Thr Ala Trp Ser Thr
 370 375 380

Gly Val Lys Thr Tyr Asn Gly Ala Leu Gly Val Asp Ile His Glu Lys
 385 390 395 400

-continued

Asp His Pro Thr Ile Leu Glu Met Ala Lys Ala Ala Gly Leu Ala Thr			
405	410	415	
Gly Asn Val Ser Thr Ala Glu Leu Gln Asp Ala Thr Pro Ala Ala Leu			
420	425	430	
Val Ala His Val Thr Ser Arg Lys Cys Tyr Gly Pro Ser Ala Thr Ser			
435	440	445	
Glu Lys Cys Pro Gly Asn Ala Leu Glu Lys Gly Gly Lys Gly Ser Ile			
450	455	460	
Thr Glu Gln Leu Leu Asn Ala Arg Ala Asp Val Thr Leu Gly Gly			
465	470	475	480
Ala Lys Thr Phe Ala Glu Thr Ala Thr Ala Gly Glu Trp Gln Gly Lys			
485	490	495	
Thr Leu Arg Glu Gln Ala Gln Ala Arg Gly Tyr Gln Leu Val Ser Asp			
500	505	510	
Ala Ala Ser Leu Asn Ser Val Thr Glu Ala Asn Gln Gln Lys Pro Leu			
515	520	525	
Leu Gly Leu Phe Ala Asp Gly Asn Met Pro Val Arg Trp Leu Gly Pro			
530	535	540	
Lys Ala Thr Tyr His Gly Asn Ile Asp Lys Pro Ala Val Thr Cys Thr			
545	550	555	560
Pro Asn Pro Gln Arg Asn Asp Ser Val Pro Thr Leu Ala Gln Met Thr			
565	570	575	
Asp Lys Ala Ile Glu Leu Leu Ser Lys Asn Glu Lys Gly Phe Phe Leu			
580	585	590	
Gln Val Glu Gly Ala Ser Ile Asp Lys Gln Asp His Ala Ala Asn Pro			
595	600	605	
Cys Gly Gln Ile Gly Glu Thr Val Asp Leu Asp Glu Ala Val Gln Arg			
610	615	620	
Ala Leu Glu Phe Ala Lys Lys Glu Gly Asn Thr Leu Val Ile Val Thr			
625	630	635	640
Ala Asp His Ala His Ala Ser Gln Ile Val Ala Pro Asp Thr Lys Ala			
645	650	655	
Pro Gly Leu Thr Gln Ala Leu Asn Thr Lys Asp Gly Ala Val Met Val			
660	665	670	
Met Ser Tyr Gly Asn Ser Glu Glu Asp Ser Gln Glu His Thr Gly Ser			
675	680	685	
Gln Leu Arg Ile Ala Ala Tyr Gly Pro His Ala Ala Asn Val Val Gly			
690	695	700	
Leu Thr Asp Gln Thr Asp Leu Phe Tyr Thr Met Lys Ala Ala Leu Gly			
705	710	715	720
Asp Ile Ala His His His His His His			
725			

```

<210> SEQ ID NO 95
<211> LENGTH: 969
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
      scFv-leucine zipper fusion protein (miniantibody vector construct
      p8860-Zip#1.2)

```

```

<400> SEQUENCE: 95
atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgccgc ccagccggcc      60
atggcggagg ttcagcttca gcagtctgga cctgagctgg tgaagcccg ggcctcaagtg    120

```

-continued

```

aagatttcct gcaaagcttc tggctacgca tttagtgcgt cttggatgaa ctgggtgaag 180
cagaggcctg gacagggtct tgagtggatt ggacggattt atcctggaaa tggagatact 240
aactacaatg ggaagttcaa gggcaaggcc acactgactg cagacaaatc ctccagcaca 300
gcctacatgc agctcagcag cctgacatct gtggactctg cggtcttattt ctgtcgat 360
gtaacgtat attactatgc tatggactac tgggttcaag gaacctcagt caccgtctcc 420
tcaggtggag gcgggttcagg tggcgccgc tctggcggtg gcggatcgca aattgttctc 480
acccagtctc ctgcttcctt agtgcgtatct ctggggcaga gggccaccat ctcatcgagg 540
gccagcaaaa gtgtcagttac atctggctat agttatatgc actggatcca acagaaacca 600
ggacagccac ccaaactcct catctatctt gcatccaacc tagaatctgg ggtccctgcc 660
aggttcagtg gcagtgggtc tgggacagac ttccaccctca acatccatcc tgtggaggag 720
gaggatgctg caaccttata ctgtcagcac agtagggagc ttccctggac gttcgggtgga 780
ggcaccaagc tggaaatcaa acgggcggcc gcaccgaaagc cttccactcc gcccgggtct 840
tcccgttatga aacagctgga agacaaagta gaggagctcc ttagcaagaa ctaccatcta 900
gaaaacgagg tagctcgatctt gaaaaagctt gtttgtgaac gtgggttca ccatcaccat 960
caccattaa                                         969

```

```

<210> SEQ_ID NO 96
<211> LENGTH: 322
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
    scFv-leucine zipper fusion protein (miniantibody vector construct
    p8860-Zip#1.2)

```

```
<400> SEQUENCE: 96
```

```

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
   1           5           10          15

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Gln Gln Ser Gly Pro Glu
   20          25           30

Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
   35          40           45

Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly
   50          55           60

Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asn Gly Asp Thr
   65          70           75           80

Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
   85          90           95

Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Val Asp
  100         105          110

Ser Ala Val Tyr Phe Cys Ala Asp Gly Asn Val Tyr Tyr Ala Met
  115         120          125

Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly
  130         135          140

Gly Ser Gly Gly Arg Ala Ser Gly Gly Ser Gln Ile Val Leu
  145         150          155          160

Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr
  165         170          175

Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
  180         185          190

Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile

```

-continued

195	200	205
-----	-----	-----

Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly	210	215	220
---	-----	-----	-----

Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu	225	230	235	240
---	-----	-----	-----	-----

Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Arg	245	250	255
---	-----	-----	-----

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala Pro	260	265	270
---	-----	-----	-----

Lys Pro Ser Thr Pro Pro Gly Ser Ser Arg Met Lys Gln Leu Glu Asp	275	280	285
---	-----	-----	-----

Lys Val Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val	290	295	300
---	-----	-----	-----

Ala Arg Leu Lys Lys Leu Val Gly Glu Arg Gly Gly His His His His	305	310	315	320
---	-----	-----	-----	-----

His His

<210> SEQ_ID NO 97

<211> LENGTH: 270

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:part of plasmid pMycHis6 differing from vector pCOCK

<400> SEQUENCE: 97

cagggaaacag ctaggaccat gattacgcca agcttccatg aaaattctat ttcaaggaga	60
--	----

cagtcatataat gaaatacaccta ttgcctacgg cagccgctgg attgttatta ctgcggccc	120
--	-----

agccggccat ggcccaggtg cagctgcagg cgccgcctgca ggtcgacctc gagatcaaac	180
--	-----

gggcggccgc agaacaaaaaa ctcatctcaag aagaggatct gaatggggcg gcacatcacc	240
---	-----

atcaccatca ctaataagaa ttcactggcc	270
----------------------------------	-----

<210> SEQ_ID NO 98

<211> LENGTH: 61

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:part of plasmid pMycHis6 differing from vector pCOCK

<400> SEQUENCE: 98

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala	1	5	10	15
---	---	---	----	----

Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Ala Arg Leu Gln Val	20	25	30
---	----	----	----

Asp Leu Glu Ile Lys Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu	35	40	45
---	----	----	----

Glu Asp Leu Asn Gly Ala Ala His His His His His His	50	55	60
---	----	----	----

<210> SEQ_ID NO 99

<211> LENGTH: 888

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:198AB2 scFv linked to c-myc-tag and His6 tag (ORF of expression vector pMycHis6-198AB2#102)

<220> FEATURE:

-continued

<221> NAME/KEY: modified_base

<222> LOCATION: (228)

<223> OTHER INFORMATION: n = g, a, c or t

<400> SEQUENCE: 99

```

atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgccgc ccagccggcc      60
atggccgagg tgaagctggg ggagtctggg ggaggcttag tgaagcttgg agggtccctg      120
aaactctcct gtgcagcctc tggattcaact ttcaagttagt ataccatgtc ttgggttcgc      180
cagactccgg agaagaggct ggagtgggtc gcaaccattha gtatggngg tagttccacc      240
tactatccag acagtgtgaa gggccgattc accatctcca gagacaatgc caagaacacc      300
ctgtacctgc aaatgagcag tctgaggctt gaggacacag ccatgttatta ctgtacaaga      360
gaggggggtg gtttcaccgt caactggtaa ttcgatgtct ggggcgcagg aacctcaagt      420
accgtctcct caggtggagg cggttcagggt gggcgcgcct ctggcgggtgg cggatcggac      480
attgtgctga cacagtctcc agtttcttg gctgtgtctc tagggcagag ggccaccata      540
tcctgcagag ccagtgaaag tggtgatagt tatggctata attttatgca ctggatcag      600
cagataccag gacagccacc caaaactcctc atctatcgta catccaaacct agagtctgg      660
atcccctgcca gtttcagtgg cagtgggtctt aggacagact tcaccctcac cattaaatct      720
gtggaggctg atgatgttgc aacattttac tgtcagcaaa gtaatgagga tccgctcacg      780
ttcggtaactg ggaccagact ggaataaaaa cgggcggcccg cagaacaaaa actcatctca      840
gaagaggatc tgaatggggc ggcacatcac catcaccatc actaataa                      888

```

<210> SEQ_ID NO 100

<211> LENGTH: 294

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:198AB2 scFv
linked to c-myc-tag and His6 tag (ORF of expression vector
pMycHis6-198AB2#102)

<400> SEQUENCE: 100

Met	Lys	Tyr	Leu	Leu	Pro	Thr	Ala	Ala	Ala	Gly	Leu	Leu	Leu	Ala
1			5				10				15			

Ala	Gln	Pro	Ala	Met	Ala	Glu	Val	Lys	Leu	Val	Glu	Ser	Gly	Gly
			20			25				30				

Leu	Val	Lys	Pro	Gly	Gly	Ser	Leu	Lys	Leu	Ser	Cys	Ala	Ala	Ser	Gly
		35				40				45					

Phe	Thr	Phe	Ser	Ser	Tyr	Thr	Met	Ser	Trp	Val	Arg	Gln	Thr	Pro	Glu
		50			55				60						

Lys	Arg	Leu	Glu	Trp	Val	Ala	Thr	Ile	Ser	Ser	Gly	Gly	Ser	Ser	Thr
65				70			75				80				

Tyr	Tyr	Pro	Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn
			85			90		95							

Ala	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	Met	Ser	Ser	Leu	Arg	Ser	Glu	Asp
100				105				110							

Thr	Ala	Met	Tyr	Tyr	Cys	Thr	Arg	Glu	Gly	Gly	Phe	Thr	Val	Asn
115				120			125							

Trp	Tyr	Phe	Asp	Val	Trp	Gly	Ala	Gly	Thr	Ser	Val	Thr	Val	Ser
130				135				140						

Gly	Gly	Gly	Ser	Gly	Gly	Arg	Ala	Ser	Gly	Gly	Gly	Ser	Asp
145				150			155			160			

Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Ala	Val	Ser	Leu	Gly	Gln
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

-continued

165	170	175	
Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly			
180	185	190	
Tyr Asn Phe Met His Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys			
195	200	205	
Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg			
210	215	220	
Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro			
225	230	235	240
Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu			
245	250	255	
Asp Pro Leu Thr Phe Gly Thr Gly Thr Arg Leu Glu Ile Lys Arg Ala			
260	265	270	
Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala			
275	280	285	
His His His His His			
290			

<210> SEQ ID NO 101
 <211> LENGTH: 876
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
 scFv linked to c-myc-tag and His6-tag designated 8860-M/H#4c
 (plasmid vector p8860-M/H#4c)

<400> SEQUENCE: 101

atgaaatacc tattgcctac ggcaagccgct ggattgttat tactcgccgc ccagccggcc	60
atggccgagg ttcatgttca gcagtctgga cctgagctgg tgaagcccg ggccctcaatg	120
aagatttcct gcaaaggcttc tggctacgc ttcatgtact ctggatgaa ctgggtgaag	180
cagaggcctg gacagggtct tgagtggatt ggacggattt atcctggaaa tggagatact	240
aactacaatg ggaagttcaa gggcaaggcc acactgactg cagacaaatc ctccagcaca	300
gcctacatgc agctcagcag cctgaccctt gtggactctg cggctatattt ctgtgcagat	360
gttaacgtat attactatgc tatggactac tgggtcaag gaacctcagt caccgtctcc	420
tcaggtggag gcggttcagg tgggcgegcc tctggcggtg gcggatcgc aattgttctc	480
acccagtctc ctgcttcctt agctgtatct ctggggcaga gggccaccat ctcatgcagg	540
gccagcaaaa gtgtcagtagt acatggctat agttatatgc actggatcca acagaaacca	600
ggacagccac ccaaactctt catctatctt gcatccaacc tagaatctgg ggtccctgcc	660
aggttcagtg gcagtgggtc tgggacagac ttccaccccta acatccatcc tgtggaggag	720
gaggatgctg caacctatta ctgtcagcac agtagggagc ttccctggac gttcgggtgaa	780
ggcaccaagc tggaaatcaa acggcgggcc gcagaacaaa aactcatctc agaagaggat	840
ctgaatgggg cggcacatca ccatcaccat cactaa	876

<210> SEQ ID NO 102
 <211> LENGTH: 291
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
 scFv linked to c-myc-tag and His6-tag designated 8860-M/H#4c
 (plasmid vector p8860-M/H#4c)

<400> SEQUENCE: 102

-continued

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Gln Gln Ser Gly Pro Glu
 20 25 30
 Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
 35 40 45
 Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly
 50 55 60
 Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asn Gly Asp Thr
 65 70 75 80
 Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
 85 90 95
 Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Val Asp
 100 105 110
 Ser Ala Val Tyr Phe Cys Ala Asp Gly Asn Val Tyr Tyr Ala Met
 115 120 125
 Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly
 130 135 140
 Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Ser Gln Ile Val Leu
 145 150 155 160
 Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr
 165 170 175
 Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
 180 185 190
 Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
 195 200 205
 Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly
 210 215 220
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu
 225 230 235 240
 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Arg
 245 250 255
 Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala Glu
 260 265 270
 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala His His His
 275 280 285
 His His His
 290

<210> SEQ ID NO 103
 <211> LENGTH: 74
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:annealed
 oligonucleotide

<400> SEQUENCE: 103

```
ggccgcagaa caaaaactca tctcagaaga gcatctgaat ggggcggcac atcaccatca     60
ccatcaactaa taag                                                                    74
```

<210> SEQ ID NO 104
 <211> LENGTH: 69
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence:annealed oligonucleotide

<400> SEQUENCE: 104

ttttagtgtga tggtgatggatgtgcgcg cccattcaga tcctcttctg agatgagttt	60
ttgtttctgc	69

<210> SEQ ID NO 105

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:CDR3 peptide

<220> FEATURE:

<221> NAME/KEY: MOD_RES

<222> LOCATION: (1)..(16)

<223> OTHER INFORMATION: Xaa = any amino acid

<400> SEQUENCE: 105

Cys Xaa Xaa Tyr Gly Asn Ser Pro Lys Gly Phe Ala Tyr Xaa Xaa Cys			
1	5	10	15

<210> SEQ ID NO 106

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:CDR3 peptide

<400> SEQUENCE: 106

Phe Arg Asn Arg Gly Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp			
1	5	10	15

<210> SEQ ID NO 107

<211> LENGTH: 30

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:portion of plasmid pMycHist6 with pelB-leader, polylinker and c-myc tag

<400> SEQUENCE: 107

Leu Ala Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Ala Arg Leu			
1	5	10	15

Gln Val Asp Leu Glu Ile Lys Arg Ala Ala Ala Glu Gln Lys		
20	25	30

<210> SEQ ID NO 108

<211> LENGTH: 90

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:portion of plasmid pMycHist6 with pelB-leader, polylinker and c-myc tag

<400> SEQUENCE: 108

ctcgcgcccc agccggccat ggcccagggtg cagctgcagg cgccgcctgca ggtcgaccc	60
gagatcaaac gggcgccgc agaacaaaaa	90

<210> SEQ ID NO 109

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:c-myc-tag

-continued

<400> SEQUENCE: 109

```

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly
 1           5           10

```

```

<210> SEQ ID NO 110
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:His6-tag

```

<400> SEQUENCE: 110

```

His His His His His His
 1           5

```

```

<210> SEQ ID NO 111
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:flexible
linker

```

<400> SEQUENCE: 111

```

Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Ser
 1           5           10           15

```

```

<210> SEQ ID NO 112
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:A1 peptide
core sequence

```

<400> SEQUENCE: 112

```

Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp
 1           5           10

```

What is claimed is:

1. An isolated antibody or antibody fragment thereof that binds Factor IX or Factor IXa and increases the procoagulant activity of Factor IXa.

2. The antibody or antibody fragment according to claim 1 that increases the procoagulant activity of Factor IXa in the presence of Factor VIII inhibitors.

3. The antibody or antibody fragment according to claim 1 wherein the antibody is an IgG, IgM, IgA or IgE antibody.

4. The antibody or antibody fragment according to claim 1, wherein said antibody or antibody fragment is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a bispecific antibody, a diabody, and di-, oligo- or multimers thereof.

5. A CDR3 peptide of the antibody or antibody fragment according to claim 1 consisting of an amino acid sequence selected from the group consisting of:

Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr (SEQ ID NO:5); and

Asp-Gly-Gly-His-Gly-Tyr-Gly-Ser-Ser-Phe-Asp-Tyr (SEQ ID NO:6).

6. The antibody or antibody fragment according to claim 1, wherein the variable region of said antibody or antibody fragment comprises amino acids 1-119 and amino acids 135-242 as listed in SEQ ID NO:82.

7. The antibody or antibody fragment according to claim 6 that additionally comprises an artificial linker sequence.

8. The antibody or antibody fragment according to claim 45 1, wherein the variable region of said antibody or antibody fragment comprises amino acids 1-121 and amino acids 137-249 as listed in SEQ ID NO:84.

9. The antibody or antibody fragment according to claim 8 that additionally comprises an artificial linker sequence.

10. The antibody or antibody fragment according to claim 50 1, wherein the variable region of said antibody or antibody fragment comprises amino acids 1-122 and amino acids 138-249 as listed in SEQ ID NO:86.

11. The antibody or antibody fragment according to claim 10 that additionally comprises an artificial linker sequence.

12. A hybridoma cell line secreting an antibody that binds Factor LX or Factor IXa and increases the procoagulant activity of Factor IXa.

13. The hybridoma cell line according to claim 12 that is selected from the group consisting of cell lines having ECACC deposit numbers 99090924, 99090925, 99090926, 99121614, 99121615, 99121616, 99121617, 99121618, 99121619 and 99121620.

14. An antibody that is secreted by a hybridoma cell line according to claim 12.

15. A preparation comprising an antibody or antibody fragment according to claim 1 and a pharmaceutically acceptable carrier.

103

16. The preparation according to claim **15**, additionally comprising Factor IX α and/or Factor IX β .

17. A method of obtaining an antibody that interacts with Factor IX or Factor IXa and increases the procoagulant activity of Factor IXa, comprising the steps of:

immunizing an immunocompetent mouse with an antigen selected from the group consisting of FIX, FIX α , FIX β or fragments thereof,

isolating spleen cells of the immunized mouse,

producing hybridoma cells,

screening the hybridoma cell supernatants for an increase in the procoagulant activity of Factor IXa, isolating and purifying the antibody from a supernatant from the

104

hybridoma cells which exhibit an increase in the procoagulant activity of Factor IXa.

18. The antibody or antibody fragment according to claim **4**, wherein the antibody fragment is a single chain antibody.

19. The antibody or antibody fragment according to claim **4**, wherein the antibody is a humanized antibody.

20. The antibody or antibody fragment according to claim **2** wherein the antibody is selected from the group consisting of an IgG, IgM, IgA or IgE antibody.

21. The antibody or antibody fragment of claim **1**, wherein the antibody fragment comprises a CDR3 peptide.

22. The antibody or antibody fragment of claim **1**, wherein the antibody fragment is a CDR3 peptide.

* * * * *